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Abstract
STEM CELL MATRIX AND CARTILAGE REGENERATION
Jingting Li
Cartilage defects caused by injuries of the knee affect about 900,000 Americans annually,
resulting in more than 200,000 surgical procedures. Cartilage repair remains a major challenge
due to its limited healing capacity. Current cell-based therapy using autologous chondrocyte
implantation has been developed for decades and promising results have been observed in clinic.
However, the shortage of autologous chondrocytes and their uncertain long-term effectiveness
have led researchers to find alternative solutions. Stem cells from various tissues have been
shown to be potential sources of chondrocytes. Among them, synovium-derived stem cells
(SDSCs) have been suggested as tissue-specific stem cells for chondrogenesis. However, a
major obstacle challenging the cartilage tissue engineering is cell senescence, which is due
mainly to extensive ex vivo passaging and elderly donors. A reconstructed ex vivo
microenvironment that can maintain or enhance stemness is urgently needed for facilitating largescale tissue engineering. To facilitate ex vivo expansion, the conventional methods for stem cell
expansion were extensively investigated. We first compared the influence of low- and highseeding density on human SDSC stemness during ex vivo expansion. Low-density seeding
expansion yielded SDSCs with enhanced proliferative and multi-differentiation capacities
compared to high-density seeding though it was not highly efficient. Downregulation of ERK1/2
and JNK and upregulation of p38 might be attributed to the retained “stemness” under low-density
expansion. We next compared the impact of hypoxia, fibroblast growth factor-2 (FGF-2)
supplementation and a novel approach of SDSC-deposited decellularized extracellular matrix
(DECM) on SDSC stemness. DECM expansion enhanced greater SDSC proliferation while
retaining stem cell characteristics, compared to FGF-2 supplementation alone. The combination
of hypoxia, FGF-2 and DECM contributed to the highest cell number in SDSC expansion,
indicating their synergistic effects. Although the chondrogenic index was comparable between
DECM expansion and FGF-2 supplementation, which were much higher than expansion on
plastic flask alone, the observations that FGF-2 induced hypertrophic marker genes suggested
the superiority of DECM in enhancing SDSC self-renewal while retaining stemness. Other
potential cell sources for depositing DECM were also evaluated. We found that, besides SDSCs,
adipose- or urine-derived stem cells and dermal fibroblasts could also deposit the DECM, which
could enhance SDSC self-renewal and chondrogenic potential without concomitantly enhancing
adipogenic and osteogenic potentials. These findings suggest that, given an optimal DECM
substrate, the chondrogenic potential within the tissue-specific SDSC could be substantially

i

enhanced. We further characterized human fetal synovial fibroblasts as fetal SDSCs as they
possessed the multi-lineage differentiation capacities and mesenchymal stem cell surface marker
expression. Fetal SDSC-derived DECM expansion not only increased cell number and enhanced
chondrogenic potential; it also lowered SDSC senescence marker expression while enhancing
MSC marker expression compared to expansion on plastic flasks alone. As cell senescence is a
limiting factor for tissue regeneration, we then investigated whether the DECM derived from fetal
SDSCs referred to as a young stem cell microenvironment could be used for rejuvenating adult
SDSC. We found that fetal SDSC-derived DECM (FE) was superior to adult SDSC-deposited
DECM (AE) in promoting SDSC proliferation and chondrogenic potential. Further investigation
revealed that unique proteins in FE might be responsible for the rejuvenation effect and
advantageous proteins in AE might contribute to differentiation more than proliferation. Compared
to AE, the lower elasticity of FE yielded expanded SDSCs with lower elasticity, which could be
responsible for the enhancement of chondrogenic differentiation. MAPK and noncanonical Wnt
signals were also actively involved in DECM-mediated SDSC rejuvenation. The young and
healthy microenvironment provided by fetal SDSCs could serve as a “fountain of youth” for adult
SDSC rejuvenation. Finally, we tested whether the DECM expansion system would also be
beneficial to the chondrocyte-like nucleus pulposus cell (NPC) rejuvenation from human herniated
discs and whether fetal DECM was superior to adult DECM. Although both SDSC and NPC
deposited DECMs (SECM and NECM) significantly enhanced NPC proliferation, only NECM
expanded NPCs manifested the increased redifferentiation capacities after chondrogenic
induction. NECM was better than SECM in functioning as an expansion system in vitro by
promoting NPC proliferation and redifferentiation. In conclusion, we have demonstrated that the
DECM deposited by human primary cells or stem cells serves as an ex vivo expansion system for
maintaining self-renewal and differentiation potential, which could greatly benefit the future
generation of cell-based therapy for cartilage and intervertebral disc regeneration.
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SPECIFIC AIMS

	
  
Cartilage defects caused by injuries to the knee affect about 900,000 Americans annually,
1

resulting in more than 200,000 surgical procedures. Cartilage repair remains a major challenge
due to its limited healing capacity. Current cell-based therapy using autologous chondrocyte
implantation (ACI) has been developed for decades and promising results have been observed in
clinic.

2;3

However, the shortage of autologous chondrocytes and their uncertain long-term

effectiveness have led researchers to find alternative solutions. Stem cells from various tissues
have been shown to be potential sources of chondrocytes. Among them, the synovium-derived
stem cell (SDSC) has been suggested as a the tissue-specific stem cell for chondrogenesis.

4

However, a major obstacle challenging the cartilage tissue engineering is cell senescence, which
5

is due mainly to extensive ex vivo passaging and elderly donors. A reconstructed ex vivo
microenvironment that can maintain or enhance stemness is urgently needed for facilitating largescale tissue engineering.
Recently many studies have suggested that decellularized tissue matrix provides a threedimensional structure with biochemical and biomechanical cues to facilitate tissue and organ
regeneration. Previous work have demonstrated that porcine SDSC derived stem cell matrix
could be decellularized (DECM) and serve as a substrate that can significantly enhance cell
6

proliferation and facilitate chondrogenesis. However, it remains unclear if this DECM system
could be successfully translated into human primary cells.
Based on these exciting data and our preliminary novel data along with the urgent clinical need
for cartilage regeneration, we hypothesized that (i) DECM as a novel expansion system is
superior to conventional methods in maintaining SDSC stemness and facilitatating
chondrogenesis; (ii) Young DECM derived from fetal SDSCs can rejuvenate adult stem
cells and restore their self-renewal and chondrogenic differentiation potentials; and (iii)
Young DECM expansion system could also be applied to rejuvenate chondrocyte-like
nucleus pulposus cells (NPCs) from herniated discs toward higher proliferation and
redifferentiation potentials.
Our long-term goal was to develop an efficient in vitro expansion system with proliferation and
chondrogenic differentiation rejuvenating capacities, which can provide a large quantity of high
quality cells for cartilage engineering. The potential impact of this study is that the optimization of
ex vivo stem cell protocols with decellularized extracellular matrix for maintaining stemness and
facilitating chondrogenesis will provide high quality and a large quantity of cells for ACI. The

xiii

understanding of the rejuvenation mechanism by matrixes will advance the knowledge of
cartilage regeneration and benefit the development of better treatment for cartilage defect.
The objectives of this dissertation were to: (1) investigate the effect of conventional methods
(seeding density, low oxygen, growth factor) and the novel DECM expansion system on SDSCs
for facilitating chondrogenesis and explore the potential cell sources of DECM; (2) characterize
the rejuvenating effect of fetal SDSCs deposited young DECM on adult SDSCs and its potential
mechanisms; (3) apply the young DECM expansion system to the rejuvenation of primary NPC
from herniated human discs. The central hypothesis was that DECM deposited by human
primary cells or stem cells can serve as ex vivo expansion system for cartilage regeneration. The
following three specific aims and correspondent hypothesis are described as below.
Specific Aims:
Specific aim 1: Demonstrate that DECM is superior to conventional methods as an
expansion system in maintaining SDSC stemness and facilitating chondrogenesis.
1.1 Investigate the effect of seeding density, hypoxia, fibroblast growth factor-2 (FGF-2) and
DECM on SDSC expansion and chondrogenic differentiation.
Hypothesis 1.1: We hypothesized that low density seeding can enhance SDSC self-renewal and
chondrogenic differentiation. Hypoxia, FGF-2 and DECM deposited by SDSCs in combination or
alone can increase the proliferative and chondrogenic differentiation potentials in SDSCs.
1.2 Investigate whether DECM derived from sources including SDSCs, dermal fibroblasts,
adipose and urine-derived stem cell can reprogram SDSCs.
Hypothesis 1.2: We hypothesized that DECMs derived from SDSCs, dermal fibroblasts, adipose
and urine-derived stem cells can reprogram SDSCs toward more proliferation and stemness,
especially chondrogenesis.
Specific aim 2: Characterize the rejuvenation effect of young DECM on adult SDSCs
towards proliferation and chondrogenesis.
2.1 Characterize fetal synovium fibroblasts as fetal SDSCs and investigate its deposited DECM.

xiv

Hypothesis 2.1: We hypothesized that fetal synovium fibroblasts contain fetal SDSCs due to the
capacity to express MSC markers and undergo multi-lineage differentiation.
2.2 Examine the rejuvenation effect from young DECM on adult SDSCs by comparing SDSCs
expanded on either young or old DECM through evaluating their self-renewal and chondrogenic
differentiation potentials.
Hypothesis 2.2: We hypothesized that young DECM deposited by fetal SDSCs can rejuvenate
adult SDSCs towards proliferation and chondrogenesis.
Specific aim 3: Investigate the rejuvenation effect of primary NPCs from herniated human
discs using young or adult DECMs deposited by SDSCs and NPCs.
3.1 Investigate whether human fetal or adult SDSC deposited DECM can rejuvenate NPCs from
herniated intervertebral discs.
Hypothesis 3.1: We hypothesized that DECM derived from fetal or adult SDSCs can enhance
proliferative and/or chondrogenic potentials.
3.2 Investigate whether human fetal or adult NPC derived DECM can enhance NPC proliferation
and redifferentiation potentials.
Hypothesis 3.2: We hypothesized that DECM derived from fetal or adult NPCs can enhance
proliferative and/or chondrogenic potentials.
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CHAPTER

1:LITERATURE

REVIEW

1.1 Current Status of Cartilage Defect and Intervertebral Disc Degeneration
1.1.1 Cartilage Biology and Intervertebral Disc Biology
Articular cartilage is a unique, hypocellular, and avascular tissue, made mostly of extracellular
collagens and proteoglycans (PGs). It allows for a smooth gliding of articulating surfaces of a joint
in order to withstand high loads during a lifetime. The structural integrity of the articular cartilage
is essential to perform physical activity throughout life.
Different types of cartilage tissue are present throughout the body at various sites. According to
the histological classification, there are hyaline, elastic, and fibrocartilage depending on their
1

molecular composition. Hyaline articular cartilage is formed by the chondrocytes (~5% of the
cartilage wet weight and <10% of the cartilage tissue volume) surrounded by an intricate network
of extracellular matrix (ECM). The cartilage matrix is rich in PGs (~10%) (mostly aggrecan, but
also decorin, biglycan, and fibromodulin) and collagen fibrils (~15%) (mostly type-II collagen, but
also type-IX, -XI, -VI, and -XIV collagens) and a number of additional molecules for stabilization
(link protein, cartilage oligomeric matrix protein, fibronectin, tenascin).

2-4

Normal hyaline articular

cartilage contains about 70-80% water mainly bound to PGs, but a proportion of which can move
freely for joint lubrication and for nutrition of the chondrocytes. Adult hyaline articular cartilage is
avascular and aneural tissue that does not possess a lymphatic drainage. The chondrocytes thus
derive oxygen and nutrition from the synovial fluid by diffusion.
The cartilage (~2-5 mm thick) is structurally divided in three zones (Figure 1.1), each with a
unique cell morphology and collagen fibers that depend on the expression of specific molecules.
The superficial/tangential zone (~10-20%) contains flattened chondrocytes (at the highest density
and expressing lubricin essential for lubrication) and fibers parallel to the surface. The
intermediate/ transitional zone (~40-60%) is formed of round-shaped cells and oblique, less
organized fibers. The deep/basal zone (~30%) (Including the calcified zone) also contains roundshaped cells (at the lowest density) and fibers, both in vertical columns perpendicular to the
surface. The specific organization of articular cartilage and the embedded chondrocytes result
from complex developmental processes in which the joints are formed during embryogenesis.

5

This process is called endochondral ossification (Figure 1.2), and can be divided into four steps:
chondrogenesis from early mesenchymal condensations, chondrocyte differentiation and
hypertrophy, mineralization of the matrix and invasion of bone cells, and finally, the definitive
formation of bone. Chondrogenesis is the first step in endochondral ossification and is based on

1

strongly regulated events that comprise condensation of mesenchymal chondroprogenitor cells,
differentiation into chondrocytes, and the patterning of chondrofying tissues into skeletal
structures. The composition of ECM changes during the differentiation of mesenchymal cells into
chondrocytes. The expression of collagen I decreases, chondrocytes start producing collagen II,
IX, and XI as well as aggrecan, link protein, and Gla protein. This composition of cartilage is
largely retained in adult articular cartilage. In those parts of the embryonic cartilage in which
cartilage is replaced by bone, chondrocytes differentiation further and become hypertrophic
expressing collagen X. The invasion of blood vessels from the perichondrium indicated the
vascularization of cartilage and the beginning of bone formation.

5;6

The ECM gets mineralized in

part by hypertrophic chondrocytes, and through the coordinated action of mineralizing osteoblasts
and bone resorbing osteoclasts that migrate into the remodeling cartilage.
The chondrocytes exist at low oxygen tension, especially those in the deep/basal zone. In normal
adult cartilage, the chondrocytes do not show proliferative activity and the network of type-II
collagen fibers is extremely stable, with a half-life of several years, and also the turnover of
2

aggrecan is not excessive (months to years), making cartilage a very consistent tissue. This
results in a limited ability of cartilage to self-heal after trauma and degenerative disease.

7

Nevertheless, the adult chondrocytes are capable of adjusting the metabolic (structural and
functional) cartilage homeostasis by regulating the balance of ECM components (synthesis
versus degradation) depending on the (complex) presence and influence of various factors
including the composition of the matrix itself, mechanical loads, local hormones, growth factors
(transforming growth factor beta - TGF-β, insulin-like growth factor I - IGF-I, the bone
morphogenetic proteins 2 and 7 - BMP-2, -7), and cytokines (interleukin 1 - IL-1, tumor necrosis
factor alpha - TNF-α), disease (osteoarthritis - OA) or injury, and aging.

2;8

The chondrocytes

respond for instance to mechanical forces by interactions between their cell surface integrins and
the components of the matrix or to local factors (hormones, growth factors, cytokines) by
interactions with specific cell surface receptors. As a consequence, these cells can either secrete
matrix molecules or the enzymes that degrade them (matrix metalloproteinase’s - MMPs,
aggrecanases) by undergoing phenotypic changes.

2;9-11

Intervertebral disc (IVD) stabilizes the spine by anchoring adjacent vertebral bodies to each other;
at the same time allowing movement between vertebrae, which gives the spine its flexibility, and
they absorb and distribute loads applied to the spine. With increasing age they undergo striking
changes in volume, shape, structure, and composition that decrease motion and alter the
mechanical properties of the spine. Like other connective tissues, discs consist of a sparse
population of cells and an abundant ECM formed by an elaborate framework of macromolecules

2

filled with water. The cells synthesize the macromolecules and then maintain and repair the
framework created from these molecules. The integrity and mechanical properties of the IVD
depend on the macormolecules and their interactions with water. Due to lack of blood supply in
the mature disc, the cells rely on the ability of nutrients and wastes to move through the matrix.
Transport of these molecules through the matrix depends on the composition and organization of
the macromolecular framework, and the matrix water content, which is largely determined by the
PG concentration.

12

The IVD is part of an anatomic unit that includes the nucleus pulposus (NP) located centrally, the
annulus fibrosus (AF) located peripherally, and the cartilaginous end-plates (CEP) with their
associated capillary beds both cranially and caudally. The healthy AF comprises concentric layers
of predominantly type I collagen fibrils, which serve as a boundary containing the inner NP. The
healthy NP tissue is characterized by high PG and water content within a loose collagen network.
It has a sparse, heterogeneous population of cells responsible for maintaining the matrix. The
negatively charged ECM retains between 66-86% water,

13

which permits distribution of and

resistance to spinal loads while sustaining disc height.
Interestingly, articular cartilage in synovial joints bears a lot of resemblance to NP (Figure 1.3).
But the NP is not a viable option due to a lack of precursors, high susceptibility to degeneration,
and various other pathologies. In contrast, synovial lining has a highly robust adult stem cell
population that exhibits a great capacity for both cartilage and NP repair and may be suitable for
NP regeneration. A recent comprehensive review also suggested the potential of using synovium
derived stem cells (SDSCs) as a source for NP regeneration.

14

1.1.2 Degenerative Joint and Disc Disease
OA is the most common and highly prevalent degenerative joint diseases in which articular
cartilage integrity is compromised. It affects more than 20% of American adults and 10% of men
older than 60 develop OA. It is highly associated with age and characterized by a change in
chondrocyte behavior that leads to elevated production of proteolytic enzymes, such as MMP13,
and consequently to cartilage damage and loss of joint function. The current understanding about
OA is that it is a disease of the entire joint and not only a pathological degradation of articular
cartilage. Inflammation of synovial membrane causes release of chondrotoxic proteins leading to
cartilage destruction. Typical OA is characterized by areas of poorly delineated defects.
Untreated cartilage defects resulting from trauma or osteochondritis dissecans tend to predispose
patients to the development of OA. Current treatments are focused on symptomatic relief but they
lack efficacy to control the progression of this disease, which is a leading cause of disability. The
pharmacological interventions that address chronic pain are insufficient, and no proven structure-

3

9

modifying therapy is available. With the progress of defining the molecular mechanisms involved
in the initiation and progression of OA, the effective disease-modifying drugs is being developing.
Cell-based therapy and novel approaches using mesenchymal stem cells (MSCs) as an
alternative cell source to chondrocytes are currently on trial.

15;16

Patients suffering from

degenerative diseases such as OA are the main group that will benefit from successful cartilage
regeneration.

17

Rheumatoid arthritis (RA) is an autoimmune disease that results in a chronic, systematic
inflammatory disorder that affects many tissues and organs, but principally attacks flexible joints.
During RA pathogenesis, proinflammatory cytokines present in the rheumatoid synovial fluid
activated MMP secretion by chondrocytes, synoviocytes and increase pericellular degradation of
these cells. Cartilage degeneration is the result of the action of MMP. To date, the goal of
treatment in RA is to reduce joint inflammation and pain, maximize joint function, and prevent joint
destruction and deformity.
Degenerative disc disease is the degeneration of one or more IVD of the spine, also called
degenerative disc disorder. It is a disease of aging and can cause severe chronic pain and greatly
affects the quality of one’s life. Current treatments are predominantly conservative or, less
commonly, surgical; in many cases there is no clear diagnosis and therapy is considered
inadequate.
Aging is the accumulation of changes in a person over time. It affects every organ to a different
degree. Aged chondrocytes are less responsive to mechanical and inflammatory stimulus. Their
protein secretion has been altered, as evidenced by decreased anabolic activity and increased
production of proinflammatory cytokines and matrix-degrading enzymes. The above changes
make cartilage more susceptible to damage and can lead to the early onset of OA and other
degenerative diseases. Age also has an influence on cell properties when using autologous
chondrocytes.

18

1.1.3 Cartilage Defects and Disc Degeneration
Age-related degeneration of articular cartilage and IVD is the most common causes of pain and
disability in middle-aged and older people.

19;20

OA, trauma, and metabolic disorders of the

subchondral bone, such as osteonecrosis or osteochondritis dissecans are the primary causes of
cartilage defects accompanied with degeneration.

21

Cartilage is vulnerable to traumatic injury;

due to its avascular nature, inability to access MSCs, and the irreversible aging process, the
ability of cartilage to self-heal is disappointing. In 1000 knee arthroscopies, 61% of the knee joints
had cartilage defects; 44% of them were due to OA, 28% were due to focal cartilage defects, and

4

2% were due to osteochondritis dissecans.

22

Patients with symptomatic cartilage defects often

report pain, swelling, joint locking, stiffness, and clicking. Symptoms may cause significant
functional impairment, often limiting one’s ability to work, play sports, and perform activities of
daily living.
Symptomatic disc degeneration is thought to be a significant contributor to low back pain (LBP),
23

which is estimated to trigger between 2.8% and 5%

24

of health-care visits in the United States.

The overall cost of LBP exceeds $100 billion/year in the United States alone, when considering
both direct costs and indirect costs, such as lost wages and productivity.

25

The lumbar spine disc

degeneration begins earlier in life than degeneration of any other connective tissue in the human
body, often by the second decade.

19;26-28

As degeneration progresses, the IVD becomes less able

to efficiently absorb physiological loads, resulting in load transfer to adjacent vertebral bodies
leading to end plate changes, osteophyte formation, and trabecular microfractures.
Degenerative fissures in the lamellae of the AF coalesce

30

29

leads to a lack of structural integrity,

which may allow heriniation of the central NP material.
During development, the immature NP arises from the embryonic notochord and remains
populated with notochordal cells (NCs).

31

These large, highly-vacuolated, and metabolically active

cells produce a high PG content matrix in addition to providing regulatory cues for surrounding
cells.

32-34

With age and degeneration, NP undergoes extensive changes in terms of matrix

composition and cell population. Initial signs of degeneration present around the first decade of
life along with a decline in NCs,

26

though it is still unclear whether the decline is due to the

continued differentiation of NCs into chondrocyte-like NPs or due to the programmed death
(apoptosis) of the resident cells with invasion by cells from CEP or AFs, both of which together
with NP consist IVD.

35-37

Degeneration of NP results in a transition from the gelatinous healthy

tissue to a more fibrous structure that is unable to provide mobility to the spine and allows
complex motion. The consequent altered transmission of spinal loads can ultimately lead to disc
failure.

1.2 Current Treatments for Cartilage Defect and Disc Degeneration

	
  
1.2.1 Conservative Treatments and Autologous Chondrocyte Implantation
The first step in the management of articular cartilage lesion is always conservative treatment,
which typically begins with the use of medications or nutritional supplements including
acetaminophen, nonsteroidal anti-inflammatory drugs, and glucosamine and chondroitin sulfate.
These medications may help decrease the symptoms of articular cartilage lesion, but they are
generally of limited benefit to relatively young and active patients. Although physical therapy

5

helps optimize extremity strength and flexibility, it is not highly effective in reducing the symptoms
associated with cartilage defect.
Current surgical methods of managing chondral defects include palliative treatment with
arthroscopic debridement and lavage, reparative treatment with marrow-stimulation and
restorative treatment, including osteochondroal grafting, total joint arthroplasty and autologous
chondrocyte implantation (ACI). The first generation of ACI was introduced in 1987 and published
in 1994.

38

The procedure involves harvesting autologous chondrocytes from non-weight bearing

aspects of the knee. Chondrocytes are then isolated by collagenase digestion and expanded in
vitro. During a second surgery, the cartilage defect is debrided up to the healthy edges and
covered with an autologous periosteal patch, taken from the medial tibia. Finally, the suspension
of healthy autologous cultured chondrocytes is directly injected into the chondral defect under the
periosteal patch. Despite significant improvements and positive clinical reports, the adoption of
periosteal based ACI (ACI-P) has been limited partly owing to post-operative complications such
as cell leaking and periosteal-related hypertrophy.
The second generation of ACI is known as collagen-covered ACI (ACI-C) and is characterized by
the application of a bioabsorbable collagen membrane in place of the periosteal flap. The
chondrocytes are cultured with collagen membrane for several weeks; the membrane is then cut
to the correct size and shape of the cartilage defect. Despite ACI-C showing similar clinical
improvements and fewer complications, cutting and repeated manipulation of the seeded
membrane may result in the loss of critical chondrocytes. A modified ACI-C technique has been
developed in which expanded chondrocytes are applied to the collagen membrane after it has
been cut to size, reducing the risk of viable cell loss while retaining the ease and speed of the
technique. However, ACI-C still suffers from technical problems such as insufficient mechanical
stability, uncertain cell distribution within the defect, and the necessity of an intact cartilage
shoulder surrounding the defect.
The third generation of ACI is tissue-engineered matrices seeded with autologous chondrocytes;
it is called matrix associated/induced ACI (MACI). Cultured autologous chondrocytes are directly
seeded onto biodegradable collagen type I/III membrane or allowed to penetrate into a threedimensional (3D) scaffold or fleece prior to intra-articular implantation. The cell carrier based
MACI technique procedure was recently reviewed by Brittberg.

39

Several commercially available

products have been developed and marketed in Europe, such as MACI®, Hyalograft® C,
Novocart® 3D, and BioSeed®-C etc.

40

The widely adopted MACI® used in routine orthopaedic

practice is the only third-generation cell carrier that is currently being evaluated in a randomized,
controlled trial to meet European regulations for marketing approval and potentially those of other
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countries. MACI minimizes donor site morbidity by avoiding the harvest and implantation of a
periosteal flap. The 3D cultures that MACI can provide also solve the problem of chondrocyte
dedifferentiation during expansion and serve as a barrier to fibroblast invasion.
1.2.2 Current Therapeutic Strategies for Nucleus Pulposus Regeneration
Conservative treatments of acute and/or chronic LBP, such as bed rest, anti-inflammatory
medications, and physical therapy, have been proved ineffectual. The most popular surgical
options are still discectomy followed by fusion. Despite the many reports of good to excellent
outcomes with this method, long-term adverse biomechanical consequences to adjacent
functional spinal unit need to be concerned.

41

Regenerative strategies over the past decades have advanced significantly, but a number of
hurdles remain before a clinical treatment can be widely accepted. Autologous transplantation
techniques are among the earliest tissue engineering strategies and recently have demonstrated
promise for long-term articular cartilage repair in humans.

42

Due to a number of similarities

between cartilage and the NP tissue, the autologous paradigm has been extended to disc repair.
After promising results in canine models,

43

the Euro Disc randomized trial found that, two years

after surgery, patients maintained increased pain reduction and decreased loss of tissue
hydration.

44

However, the results of this strategy may be limited due the reliance on a population

of cells with a deteriorated capacity due to the degenerative process. Procurement of cells is also
difficult, in part due to the high incidence of apoptosis,

45

which reduces an already sparse cell

population. This issue is further complicated by the extensive passaging procedure required to
obtain sufficient numbers of cells for in vivo implantation. When passaged in monolayer, NP cells
(NPCs) are known to proliferate slowly

46

and undergo increasing dedifferentiation.

47-49

Cells from

degenerated NP also become increasingly senescent which makes them minimally responsive to
growth factor or cytokine stimulation; the cells display increased catabolic metabolism
characterized by the increased production of matrix degrading enzymes.

50-53

1.3 Current Efforts and Challenges of Cartilage Tissue Engineering

	
  
1.3.1 Cell Sources and Biomaterials for Cartilage Engineering
Without doubt, autologous chondrocytes are the idea cell source for repairing cartilage.
Unfortunately, the use of autologous chondrocytes is fraught with unsolved challenges, such as
the loss of chondrocyte markers and dedifferentiation in culture during expansion, potential cell
leakage, uneven cell distribution in 3D space, potential donor site morbidity (complications of
donor site healing), shortage of chondrocytes due to limited cell number from biopsy, short
lifespan of chondrocytes, lack of uniformity of in vitro expanded chondrocytes from laboratory to

7

laboratory, and low cell quality from aged patients.
Two broad types of stem cells in mammals include embryonic stem cells (ESCs), which are
isolated from the inner cell mass of blastocysts and adult stem cells, which are found in various
tissues. ESCs possess the capability to self-renewal and to differentiate into all types of cells.
However, its application in humans are restricted by ethical issues. Adult stem cells were first
discovered in bone marrow and other accessible sources such as adipose, blood, skin, and urine.
The most frequently investigated adult stem cells for cartilage tissue engineering is bone marrow,
adipose, synovium-derived stem cells (SDSC). The tissue-specificity of SDSC as a stem cell for
cartilage regeneration has been recently reviewed.

54

Other candidate cell sources are also promising. Fetal stem cells located in the organs of fetuses,
are not immortal but highly proliferative and multipotent. Recently, induced pluripotent stem cells
(iPSCs) have been developed by reprogramming human somatic cells, providing a more
abundant and ethical-feasible source of progenitor cells that also possess the capacity of
generating all types of human cells.

55

However, the low efficiency of reprogramming terminally

differentiated cells into iPSCs has remained a major obstacle that prevents the wide application of
this technology in practical use. (Table 1.1)
Cell type

Advantages

Disadvantages

Autologous

Native phenotype

Small initial cell number

chondrocyte

Minimal risk of immunological

De-differentiation on expansion

problem
Allogeneic

Larger cell number

Limited donor availability

chondrocyte

Off-the-shelf solution

Risk of disease transmission

Fetal

Strong potential to produce large

Limited donor availability

mesenchymal

numbers

Risk of diease transmission

stem cell

Off-the-shelf solution

Potential ethical considerations

Adult

Potential to produce large numbers

Potential for hypertrophy

mesenchymal

Various harvest sites

Heterogeneous population of

stem cell

Additional paracrine signaling

cells

potential

Stable and reproducible
differentiation still problematic

Induced

Large source of patient specific cells

Stable and reproducible

pluripotent stem

Multiple cell types can be produced

differentiation still problematic

cells
Embryonic stem

Potential for teratoma
Off-the-shelf solution

Stable and reproducible
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cells

Multiple cell types can be produced

differentiation still problematic
Potential for teratoma
Ethical considerations

Table 1.1 Advantages and disadvantages of various cell sources.

Scaffolds made of natural biomaterials, such as collagen and hyaluronic acid, can maintain the
expression of aggrecan and type-II collagen in chondrocytes. For instance, collagen has been
intensively studied as a natural polymer with respect to cartilage tissue engineering.
Chondrocytes cultured within collagen gels preserve their phenotype and glycosaminoglycan
(GAG) production for as long as six weeks in culture.

56

Matrices and membranes derived from

collagen also stimulate chondrocytes to produce new collagen.

57

Hyaluronan, a highly

concentrated component in the ECM of articular cartilage, is also a good candidate for
biodegradable and biocompatible scaffold material. Chondrocytes cultured with chemical crosslinking hyaluronan scaffold express more chondrogenic markers, type-II collagen, aggrecan, and
less type-I collagen.

58

Other natural polymers derived from ECM used in cartilage engineering as

3D culture systems include fibrin glue, alginate, agarose, chitosan, chondroitin sulfate, gelatin,
and silk fibroin.

59

1.3.2 Challenges of Cell Senescence in Cartilage Engineering
Adult stem cell based therapies present great potentials for cartilage regeneration. However, cell
senescence remains a big challenge for large scale ex vivo expansion and maintenance of MSC
stemness. It is known that intrinsic and extrinsic factors are involved in the process of cell
senescence. The intrinsic mechanism is called the Hayflick limit.

60

Most somatic cell types reach

cell-cycle arrest after a characteristic number of population doublings, which is also referred to as
“cellular or replicative senescence”. In humans, cell-cycle arrest is typically reached after 20 to
100 cell population doublings. It prevents cells from immortalization and suppresses oncogenesis.
However, it also limits the goal of large-scale ex vivo cell expansion as required for cartilage
regeneration and tissue engineering applications. Although it is possible to overcome the Hayflick
limit by genetically modifying cells, for instance, transfecting human articular chondrocytes with
the human telomerase gene,

61

such manipulations are regarded as potentially dangerous in the

context of tissue engineering. On the other hand, extrinsic factor-associated senescence, also
called stress-induced senescence, is considered more premature, as it can halt cell growth before
the Hayflick limit is reached. Theoretically, through modifying the culture conditions and
minimizing the stress in ex vivo culture, growth potentials can be regained. Recent concepts
about cell senescence are similar to a stress-responsive, adaptive phenotype that develops
through multiple stages during the development of degenerative diseases, which can spread from
cell to cell and occur at any point in life.

62

In other words, senescence could be an alternative cell

9

fate that develops in response to injury or metabolic dysfunction and might occur in nondividing
as well as dividing cells.

63

Below is a brief review of the cell number limitations and loss of

phenotype during ex vivo expansion, donor-site morbidity, and age-related decline in
chondrogenic capacities; all these elements lead to cell senescence during cartilage tissue
engineering. Critical obstacles for researchers and clinical therapists will also be presented
(Figure 1.4).
1.3.2.1 Ex vivo expansion
Chondrocyte senescence developing during ex vivo expansion is commonly characterized by
accumulation of reactive oxygen species (ROS) and advanced glycation end products, increased
expression of senescence-associated β-galactosidase (SA-β-gal), nuclear and mitochondrial DNA
damage, and decreased mitochondrial function. Average articular chondrocyte telomere erosion
rate in vivo is about 30bp per year.

64

During an 8–10-fold cellular ex vivo expansion, telomere

length is impaired as long as 900 bp due to loss of the telomerase activity of chondrocytes.

65

Similar to chondrocytes, MSC senescence results in cell proliferation arrest, characterized by flat
shape, circumscribed nuclei, increased lysosome compartment, shortened telomere, and
endogenous SA-β-gal activity.
long-term ex vivo culture.

67

66;67

All the characteristics just mentioned develop during MSC

Bone marrow-derived stem cells (BMSCs) isolated from fresh bone

marrow aspirates underwent senescence with a change in morphology and shape after 38
population doublings and largely lost their ex vivo differentiation capacities at or around the sixth
passage,

68;69

but there is also evidence of adverse changes as early as the first or second

passage.

70;71

Surprisingly, the osteogenic differentiation potential, including alkaline phosphatase

(ALP) expression and bone nodule formation ex vivo, appeared to be retained despite replicative
senescence.

72

Banfi et al. observed loss of osteogenic differentiation along with proliferation

capacities in BMSCs passaged at around 22 cell doublings.

70

Consistent results were obtained

from Muraglia et al., who investigated differentiation in a BMSC population derived from a single
cell.

73

What the cases just mentioned have in common is the initial loss of adipogenic

differentiation capacity. Overall, ex vivo expansion leads to a progressive decrease of proliferative
abilities and differentiation potentials. Similarly, Li et al. found that human placenta-derived MSCs
underwent aging and spontaneous osteogenic differentiation during regular culture expansion,
with down-regulation of human telomerase reverse transcriptase and up-regulation of the
osteogenic gene runt-related transcription factor 2 (RUNX2) and ALP expression. Stem cell selfrenewal associated genes octamer-binding transcription factor 4 (OCT4) and SRY (sex
determining region Y)-box 2 (SOX2) expression declined progressively.

63

In addition, researchers have investigated the effect of seeding density during MSC ex vivo
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expansion. Despite sporadic evidence suggesting that plating density is not critical for maintaining
a multipotent MSC population, time in culture does affect MSC characteristics in general; loss of
adipogenic and chondrogenic differentiation abilities was observed in the higher density group.

74

More studies have shown that high-density plating produced a higher percentage of flattened
human BMSCs with characteristics of cellular senescence and the loss of ability to differentiate,
while low-density plating resulted in a higher proliferation rate as well as more multi-potent
cells.

75-77

The evidence just provided suggests that seeding density could be an influential factor

for developing senescence; low-density seeding could be useful when selecting the homogenous
subpopulations of MSCs with higher proliferation and differentiation potentials.

78;79

1.3.2.2 Donor age
Another parameter that should be considered is aging, as decreased proliferation and the
propensity toward senescence were observed in aged donors. Chondrocytes obtained from aged
individuals (older than 40 years) have a much lower ability to repair cartilage damage than those
obtained from younger patients.

80

Pestka et al. recently revealed the difference in chondrocyte

quality during ex vivo expansion in cells collected from 252 ACI patients.

21

Results suggested that

no specific parameters other than age could be identified as influencing the quality of cells.

21

A

more dramatic change in chondrogenic potentials of human chondrocytes from juveniles (< 13
years old) and adults (13 years and older) is also documented by Adkisson et al..

81

More attention has been paid to multi-potent cells in cartilage tissue engineering. Differences in
MSCs from aged donors have been found in proliferation, cell attachment, and senescence in
both animal and human cells.

82-87

However, there have been conflicting reports about changes in

MSC differentiation potentials attributed to donor age. Several previous studies have shown no
difference attributable to donor age in human BMSC differentiation potential.

88-91

In recent years,

Kretlow et al. observed different chondrogenic capacities of murine BMSCs from animals of
different ages.
BMSCs.

93

92

Zheng et al. demonstrated the impaired chondrogenic differentiation in aged rat

Microarray analysis indicated significant age-related differences in the expression of

genes that influence cartilage ECM formation.

93

Age-related mechanical properties and collagen

content changes were also noted in bovine BMSCs.

94

Inconsistent results were obtained from

human BMSCs as well. Scharstuhl et al. isolated BMSCs from the femoral shafts of 98 patients
and investigated the relationship between chondrogenic differentiation capacities and age or
OA.

91

Surprisingly, no correlation from either factor was observed. However, Payne et al. found

an age-related decline in chondrogenic differentiation in BMSCs even with transforming growth
factor β1 (TGF-β1) stimulation, though only in men.

95

Since 1999, donor age has been identified

as an important factor in periosteum-derived stem cell (PDSC) ex vivo chondrogenic
differentiation.

96

Later, De Bari et al. demonstrated that adult PDSCs could undergo
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chondrogenesis regardless of donor age.

97

1.3.2.3 Trauma and degenerative diseases
Trauma such as joint injuries is most commonly caused by mechanical factors, which promote
human articular chondrocyte senescence by increasing oxidative stress, as characterized by cellcycle arrest, senescent morphology, and increased SA-β-gal activity, possibly through
accelerating telomere shortening.

98

Challenging human MSCs with oxidative stress results in

similar characteristics, but manifests an increased tolerance regarding proliferation.

99

Intracellular

ROS were found to correlate with articular chondroctye senescence through activation of p38
kinase, which further promotes ROS generation, forming a positive feedback loop. Hong et al.
found that ionizing radiation induced chondrocyte senescence by negative post-transcriptional
regulation of SIRT via ROS-dependent p38 kinase activation.

100

Sirtuin 1, a mammalian Sir2

ortholog and nicotine adenine dinucleotide-dependent deacetylase, has reportedly been involved
in cell aging pathways.

101

OA is characterized by degeneration of articular cartilage, limited intraarticular inflammation with
synovitis, and changes in peri-articular and subchondral bone. Murphy et al. observed reduced
chondrogenic differentiation capacities of BMSCs from patients with advanced OA.

102

Han et al.

observed decreased proliferative and chondrogenic potentials of SDSCs collected from OA
patients during ex vivo expansion; microarray analysis suggested late-passage cells
overexpressed cell-cycle prolongation and cell aging-associated genes, while repressing
expression of cell growth-related genes.

103

Additionally, aging changes in the joint tissue

contribute to the development of OA, as cellular senescence results in the development of a
senescent secretory phenotype, and aging changes the matrix with increased formation of
advanced glycation end products that affect the mechanical properties of joint tissues.

1.4 Potential contribution of Decellularized Extracellular Matrix for Cartilage Regeneration
The stem cell niche is a specific site in adult tissues where stem cells reside and undergo selfrenewal and differentiation. It is formed by the supporting cells and ECM that provide a
microenvironment for stem cells and the cytokines and physical signals emanating from the
supporting cells.

104-106

In vivo, the cells are surrounded by an ECM that is responsible for the

multidimensional and long-range ordering of highly organized tissues. The ECM is primarily
composed of various collagens, laminins, and glycoproteins serving as substrates for a myriad of
adhesion molecules including integrins, cadherins, and discoidin domain receptors.

107

Cell-matrix

interaction-induced signaling constitutes a critical determinant of cell behavior, making the ECM
composition a key factor in the stem cell niche. It functions as a reservoir for growth factors and
provides natural and intrinsic cues that direct the remodeling process during cell differentiation.
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108-

111

Due to the highly conserved nature of ECM components between species, decellularized matrix
is applicable in tissue engineering through tissue-processing methods. Recently, decellularized
tissue matrix derived from different tissues or organs such as heart, lung, brain, liver, bladder,
and adipose have been engineered through simple biochemical methods that function as a
natural scaffold to support proliferation and differentiation of the recellularized cells as
summarized in a recent review.

112

Demineralized bone matrix was able to induce ectopic bone

formation due to the existence of the active osteoinductive ingredient BMP.

113

Cartilage-derived

matrix can also induce chondrogenesis of BMSCs and can support neocartilage formation from
chondrocytes without exogenous growth factors.

114;115

Cartilage-derived matrix is advantageous

in serving as a scaffold for cell-based cartilage repair. Chondrocytes can be used to deposit
matrix, which can be decellularized later to from DECM.
Similarly, stem cells, especially tissue-specific stem cells can be applied to deposit the
decellularized stem cell matrix (DSCM). DSCM deposited by porcine SDSCs provides a tissuespecific microenvironment favoring expanded cell chondrogenesis.

116

A rejuvenated effect was

also observed in porcine chondrocytes and NPC after expansion on SDSC derived DSCM.

117;118

Human BMSCs derived DSCM provides a tissue-specific microenvironment favoring expanded
BMSC endochondral bone formation.

119

The combination of a tissue-specific stem cell and DSCM

would help provide large-quantity and high-quality cells to improve cartilage regeneration and
benefit cartilage repair, which will greatly advance the development of the next generation ACI in
the near future.

1.5 Future Directions of Cartilage Engineering

	
  
The need for cartilage defect repair is demanding as the aging population grows. The benefits of
a cell based technique such as ACI that results in hyaline repair tissue with good integration at
the defect is attractive and companies have been investing to support research.

120

However,

modest results from clinical trials show that limitations of ACI, such as poor cell persistence,
viability, post-translation, and cell relocation to non-target sites, still exist.

121

Long-term evaluation

and more in vivo studies are needed. Current development of ACI and the next generation of
cartilage repair largely depend on progress in the cartilage tissue engineering field. One focus in
the next generation of cell-based cartilage tissue engineering and repair is stem cells, especially
tissue-specific stem cells.

122;123

Finding tissue-specific stem cells for cartilage tissue engineering

is not accomplished yet though SDSCs have been proposed as a good candidate.

54

Biomaterials,

which can be applied directly or used as stem cell delivery vehicles, should help elicit and
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enhance beneficial stem cell responses. Other than these, cell senescence also presents a big
challenge in cartilage engineering due to the unmet demand of large quantity of high quality cells
from donor of elder age, degenerative disease or extensive ex vivo expansion. Current efforts in
applying growth factors, antioxidants, and modulating nutrients and oxygen factors have
significantly improved proliferative abilities in both chondrocytes and MSCs. The promoted
chondrogenic differentiation also alleviated progression to cell senescence to a lesser extent.
However, efficiency and concerns about immune rejection as well as transformation of cells could
be worrisome. Fortunately, the creation of the ex vivo microenvironment using DECM, especially
DSCM, has given us hope. Through incubating cells in a more youthful and natural ex vivo niche,
cell senescence could be slowed. Ideally, a tissue-specific DSCM could be reconstructed to
rejuvenate and/or reprogram autologous chondrocytes and stem cells in proliferation and
chondrogenic potential, which may be a future direction for the next generation of cartilage
engineering.
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Figure 1.1

Figure 1.1	
   Section of cartilage detailing the various zones from the upper superficial zone down
to the underlying bone. Differences in cell phenotype can be detected between the superficial,
middle and deep zones. These differences can still be observed during in vitro culture,
demonstrating functional differences between the cells of each zone. Figures are from Johnstone
B, Alini M, Cucchiarini M et al.	
   Tissue engineering for articular cartilage repair--the state of the art.
Eur Cell Mater 2013;25:248-67.
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Figure 1.2

	
  
Figure 1.2 Schematic representation of the chondrogenesis and endochondral ossification. A.
First mesenchymal cells condense to form a dense cell mass. B. Mesenchymal cells proliferate
and differentiate into chondroblasts. C. These cells start secreting cartilage ECM and become
mature chondrocytes. D. Eventually, chondrocytes grow to become hypertrophic, and if the tissue
undergoes endochondral ossification. E. Cartilage is vascularized, ECM is degraded,
hypertrophic chondrocytes become apoptotic, and osteoblasts invade the free space within the
tissue. Figures are from Quintana L, zur Nieden NI, Semino CE. Morphogenetic and regulatory
mechanisms during developmental chondrogenesis: new paradigms for cartilage tissue
engineering. Tissue Eng Part B Rev. 2009;1:29-41.
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Figure 1.3

Figure 1.3 Resemblance between synovial joint and intervertebral disc. Figures are from Shoukry
M, Li J, Pei M. Reconstruction of an in vitro niche for the transition from intervertebral disc
development to nucleus pulposus regeneration. Stem Cells Dev. 2013;8:1162-76.
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Figure 1.4

Figure 1.4 Senescence-associated signal transduction pathways in chondrogenic differentiation.
Figures are from Li J, Pei M. Cell senescence: a challenge in cartilage engineering and
regeneration. Tissue Eng Part B. 2012;4:270-87.
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ABSTRACT
Our hypothesis in this study is that low seeding density expansion could retain human synoviumderived stem cell (hSDSC) “stemness”, defined as higher proliferation and multi-differentiation
capacity; retention of “stemness” probably occurs through the mitogen-activated protein kinase
(MAPK) signaling pathway. hSDSCs were expanded in conventional plastic flasks for two
2

consecutive passages at either low or high density (30 or 3,000 cells/cm ). Expanded cells were
assessed for the effect of seeding density on their morphology, proliferation, apoptosis, stem cell
surface markers, and multi-lineage differentiation capacity (chondrogenic, adipogenic, and
osteogenic differentiation) using flow cytometry, biochemical analysis, histology, immunostaining,
and real-time polymerase chain reaction. The MAPK signaling pathway (Erk1/2, p38, and JNK)
and senescence-associated markers (p21 and caveolin) were also evaluated for their role in cell
density-based monolayer expansion using western blot. Our data suggested that low seeding
density expansion yielded hSDSCs with enhanced proliferation and multi-differentiation capacity
compared to those grown at high seeding density, despite the fact that the cells expanded at both
high and low density had lower osteogenic capacity. Low seeding density also down-regulated
Erk1/2 and JNK expression and up-regulated p38 expression, which might be responsible for the
retained “stemness” in the cells expanded at low density. Low seeding density expansion could
retain hSDSC proliferation and multi-differentiation capacity and protect cells from replicative
senescence.
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INTRODUCTION
Autologous chondrocyte implantation is a biological solution for the treatment of focal cartilage
defects [1]. Due to the limited sources of chondrocytes available from patients themselves and
lack of an effective ex vivo expansion system, researchers turned to mesenchymal stem cells
(MSCs), which reside in adult tissues and possess multi- lineage differentiation potentials. MSCs
have been isolated from various human tissues, such as bone marrow, adipose, periosteum, and
synovium [2, 3]. Further application in clinical treatment is based on efficient ex vivo expansion to
produce large-scale and high-quality human MSCs.
Since MSCs have proliferation potential, optimization of cell seeding density during monolayer
expansion represents a simple and effective method to yield a sufficient number of cells for
clinical use. This approach has been investigated in bone marrow stromal cells (BMSCs) and
adipose stem cells (ASCs). Recent data indicate that altering the monolayer expansion conditions
affects ASCs in their self-renewal rate, multipotency, and lineage-specific differentiation potential.
Estes et al. found that monolayer culture conditions (such as growth factor supplementation, cell
seeding density, etc.) may “prime” cells or predispose them toward a specific phenotype and thus
underscore the importance of early culture conditions in determining the growth and
differentiation potential of ASCs [4]. Time in culture affects BMSC stem cell characteristics [5].
More interestingly, seeding BMSCs at low densities allows for the detection of a distinct
population of rapidly self-renewing cells that have a higher capacity for multi-lineage
differentiation [6, 7].
Recently, synovium-derived stem cells (SDSCs), tissue-specific stem cells for chondrogenic
differentiation [8, 9], have attracted much attention in cartilage engineering and regeneration [10–
14]. Since there is no study on whether seeding density during ex vivo cell expansion favors
SDSC proliferation and differentiation capacity, this study seeks to determine the effects of cell
seeding density on human SDSC (hSDSC) ex vivo expansion and subsequent multi- lineage
differentiation potentials. Considering the roles of the three major mitogen-activated protein
kinase (MAPK) signaling pathways [the extracellular signal-regulated kinase 1/2 (Erk1/2), p38,
and c-jun N-terminal kinase (JNK) pathways] in controlling embryogenesis, cell differentiation, cell
proliferation, and cell death [15], we wondered whether the MAPK signaling pathway and
replicative senescence were involved in the potential mechanisms underlying seeding densitybased cell expansion. In this study, we hypothesized that low seeding density expansion could
retain hSDSC “stemness”, defined as higher proliferation and multi-differentiation capacity;
retention of stemness likely occurs through the MAPK signaling pathway.
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MATERIALS AND METHODS
Expansion of hSDSCs at low and high density
Adult human synovium fibroblasts, referred to as hSDSCs [16], were pooled from two donors
(one Hispanic female, 43 years old; one Caucasian male, 60 years old; both had no known joint
disease). These cells were obtained at passage 1 from Asterand (North America Laboratories,
Detroit, MI, USA). Passage 2 hSDSCs were expanded for two consecutive passages at either low
2

2

density (30 cells/cm ) or high density (3,000 cells/cm ) in conventional plastic flasks in complete
medium [α-minimum essential medium (Invitrogen, Carlsbad, CA, USA) containing 10 % fetal
bovine serum (FBS, Atlanta Biologicals, Lawrenceville, GA, USA), 100 U/mL penicillin, 100 "g/mL
streptomycin, and 0.25 "g/mL Fungizone (Invitrogen)] at 37 °C in a humidified 5 % CO2 and 21 %
O2 incubator. Culture medium was changed every 3 days. Cell number was counted using a
hemocytometer and cell morphology was photographed by phase contrast microscope.
Cell surface area measurement
At day 4 during cell expansion, images were taken from 10 fields in culture flasks from both lowand high-density groups. Cell surface areas were measured quantitatively using Image J software
(NIH Image, National Institutes of Health, Bethesda, MD, USA). Fifty cells were randomly
selected from either low- or high-density groups. Values were presented as vertical scatter plot.
Cell proliferation and apoptosis assay
Cell number fold change was calculated by expanded cell number {cell number per flask [total cell
number/ number of flasks (n)] in high-density group (n=6) and low-density group (n=26)} divided
by seeded cell number (seeding density × surface area). Human SDSCs were pre-labeled with
CellVue

®

Claret (Sigma, St. Louis, MO, USA) at 2×10

-6

M for 5 min according to the

manufacturer’s protocol. After a 9-day expansion, cells from both low- and high-density groups
were collected and analyzed using BD dual laser FACS Calibur (BD Biosciences, San Jose, CA,
USA). For each sample, 20,000 events were collected using CellQuest Pro software (BD
Biosciences) and cell proliferation index was analyzed by ModFit LT™version 3.1 (Verity
Software House, Topsham, ME, USA).
After cell expansion, Annexin V-FITC Apoptosis Detection Kit (Biovision, Mountain View, CA,
5

USA) was used to detect apoptosis. Briefly, 2 × 10 cells from both low- and high-density groups
(n=3 each) were labeled with FITC annexin V and propidium iodide for 15 min at room
temperature. For each sample, 10,000 events were collected; samples were analyzed using
FACS Calibur (BD Biosciences). FCS Express 3 software package (De Novo Software, Los
Angeles, CA, USA) was used to generate histograms.
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Surface marker analysis using flow cytometry
5

After cell expansion, 2 × 10 hSDSCs from each group were incubated on ice for 30 min in PBS
containing 0.1 % ChromPure Human Immunoglobulin (IgG) whole molecule (Jackson Immuno
Research, West Grove, PA, USA) and 1 % NaN3 (Sigma), and then incubated on ice for 30 min
with mouse anti-human monoclonal FITC-conjugated antibodies to the stage-specific embryonic
antigen-4 (SSEA-4) (Biolegend, San Diego, CA, USA) and isotype-matched IgG3 (Beckman
Coulter, Fullerton, CA, USA). After washing with cold PBS, hSDSCs were fixed in 300 μL of 0.4
% paraformaldehyde. Cells were analyzed on a BD dual laser FACS Calibur (BD Biosciences)
using the FCS Express 3 software package (De Novo Software).
Chondrogenic induction of expanded hSDSCs
5

After cell expansion, 3 × 10 of passage 4 hSDSCs from each group were centrifuged at 500×g
for 5 min in a 15- mL polypropylene tube to form a pellet. After overnight incubation, the pellets
were transferred to a serum-free chondrogenic medium consisting of high-glucose Dulbecco’s
-7

Modified Eagle’s Medium, 40 μg/mL proline, 10 M dexamethasone, 100 U/mL penicillin, 100 μ
g/mL streptomycin, 0.1 mM ascorbic acid-2-phosphate, and 1× ITS™ Premix (6.25 μg/mL insulin,
6.25 μg/mL transferrin, 6.25 μg/mL selenous acid, 5.35 μg/mL linoleic acid, and 1.25 μg/mL
bovine serum albumin, from BD Biosciences) with the supplementation of 10 ng/mL transforming
growth factor-beta3 (TGF-β3; PeproTech Inc., Rocky Hill, NJ, USA) in a 37°C, 5% O2 incubator
for up to 27 days. At days 0, 9, and 27, pellets from each group were collected for evaluation of
chondrogenic differentiation using histochemistry, immunohistochemistry, biochemistry, and
quantitative real-time polymerase chain reaction (PCR).
Histochemistry and immunohistochemistry
The pellets (n=2) were fixed in 4 % paraformaldehyde at 4 °C overnight, followed by dehydrating
in a gradient ethanol series, clearing with xylene, and embedding in paraffin blocks. Fivemicrometer sections were histochemically stained with Alcian blue (Sigma, counterstained with
fast

red)

and

Safranin

O

(Sigma,

counterstained

with

hematoxylin)

for

sulfated

glycosaminoglycans (GAG). For immunostaining, the sections were immunolabeled with primary
antibodies against collagen I (Abcam, Cambridge, MA, USA), collagen II (II-II6B3; Developmental
Studies Hybridoma Bank, Iowa City, IA, USA), and collagen X (Sigma), followed by the secondary
antibody of biotinylated horse anti-mouse IgG (Vector, Burlingame, CA, USA) or IgM (Vector).
Immunoactivity was detected using Vectastain ABC reagent (Vector) with 3,3’-diaminobenzidine
as a substrate.
Biochemical analysis for DNA and GAG content
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The pellets (n04) were digested at 60 °C for 6 h with 125 μg/mL papain in PBE buffer (100 mM
phosphate, 10 mM EDTA, pH 6.5) containing 10 mM cysteine. To quantify cell density, the
®

amount of DNA in the papain digestion was measured using the QuantiT™ PicoGreen dsDNA
®

Assay kit (Invitrogen) with a CytoFluor Series 4000 (Applied Biosystems, Foster City, CA, USA).
GAG was measured using dimethylmethylene blue dye and a Spectronic™ BioMate™ 3
Spectrophotometer (Thermo Scientific, Milford, MA, USA) with bovine chondroitin sulfate (Sigma)
as a standard.
TaqMan quantitative PCR
Total RNA was extracted from the pellets (n=4) using an RNase-free pestle in TRIzol

®

(Invitrogen). Two micrograms of mRNA was used for reverse transcriptase with High- Capacity
cDNA Archive Kit (Applied Biosystems) at 37 °C for 120 min. Chondrogenic marker genes
[collagen I (assay ID Hs00164004_m1), collagen II (assay ID Hs00156568_m1), collagen X
(assay ID Hs00166657_m1), aggrecan (assay ID AIQJAP5), and SRY (sex determining region
Y)-box 9 (Sox9) (assay ID Hs00165814_m1)] were customized by Applied Biosystems as part of
®

the Custom TaqMan Gene Expression Assays. Eukaryotic 18S rRNA (assay ID HS99999901-s1
ABI) was carried out as the endogenous control gene. Real-time PCR was performed with iCycler
iQ™Multi-Color Real-Time PCR Detection System and the data were calculated by computer
software (Perkin-Elmer, Wellesley, MA, USA). Relative transcript levels were calculated as χ=2
Δ Ct

-Δ

, in which ΔΔCt=ΔE-ΔC, ΔE=Ctexp-Ct18s, and ΔC=Ctct1-Ct18s.

Adipogeneic induction and analysis of expanded hSDSCs
2

Expanded hSDSCs (n = 3) were replated at 10,000 cells/ cm . Once cells reached confluence,
the culture medium was switched to adipogenic induction medium consisting of complete medium
supplemented with 1 μ M dexamethasone, 0.5 mM isobutyl-1-methyxanthine, 200 μ M
indomethacin, 10 μg/mL insulin, and 1 nM 3,3’5’-triiodo-L-thyronine (T3) for an additional 21
days. Oil Red O (ORO) staining and quantitative assay were conducted as described in our
previous study [17]. Briefly, cells were fixed in 4 % paraformaldehyde for 60 min and stained with
0.3 % ORO solution (Sigma) for 30 min. After rinsing in distilled water, cells were photographed
using AMSCOPE MP1900 digital camera (Amscope, iScope Corporation, USA). ORO was
extracted from cells using 100 % isopropanol and the absorbance at 510 nm was determined. For
a blank control, we used 100 % isopropanol. ORO optical density (OD) value was normalized by
total DNA content.
Osteogenic induction of expanded hSDSCs
2

Expanded hSDSCs were replated at 8,000 cells/cm . Once cells reached 90 % confluence, the
culture medium was switched to osteogenic induction medium consisting of complete medium
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supplemented with 0.01 μM dexamethasone, 10 mM β-glycerolphosphate, 50 μM ascorbate-2phosphate, and 0.01 μ M 1,25-dihydroxyvitamin D3 for an additional 21 days. Osteogenic
differentiation was assessed using alkaline phosphatase (ALP) and Alizarin Red S (ARS) staining
as described before [17]. ALP activity and accumulated calcium quantitative assay were
conducted using a spectrophotometric method.
ALP staining and activity assay
After a 21-day incubation in osteogenic medium, hSDSCs were stained using the Leukocyte
Alkaline Phosphatase Kit (Sigma). Expanded hSDSCs (n=3) were also collected for ALP activity
assay by measuring the formation of p-nitrophenol (p-NP) from p-nitrophenyl phosphate. Briefly,
cell cultures were lysed in a buffer containing 1.5 M Tris–HCl, 1 mM ZnCl2, and 1 mM MgCl2, pH
9.0, containing 2 % Triton X-100, and reacted with phosphatase substrate reagent (2 mg/mL) in a
microplate. p-NP was quantified based on the spectrophotometric absorbance at 405 nm and
enzymatic activity was expressed as millimoles of p-NP per microgram of protein.
ARS staining and extracellular calcium quantitative assay
Expanded hSDSCs (n=3) cultured for 21 days in osteogenic medium were fixed with 70 % icecold ethanol for 1 h, and then incubated in 40 mM ARS at pH 4.2 for 20 min at room temperature
with agitation on an orbital shaker (60 rpm). After two rinses with deionized water, matrix mineralbound staining was photographed under a Nikon TE300 phase-contrast microscope (Nikon,
Japan). Accumulated calcium was extracted using 0.5 mL of 0.5 N HCl and quantified according
to the manufacturer’s instructions in Quanti-Chrom Calcium Assay Kit (BioAssay Systems,
Hayward, CA, USA). Total calcium was calculated from standard solutions prepared in parallel
and normalized to the total protein content. The values of blank controls were subtracted from the
corresponding samples.
Western blot
To investigate whether the MAPK signaling pathway was involved in seeding density-based cell
expansion, the expanded cells from each group were homogenized and dissolved in the lysis
buffer (Cell Signaling, Danvers, MA, USA) with protease inhibitors. Total proteins were quantified
using BCA™ Protein Assay Kit (Thermo Fisher Scientific, Rockford, IL, USA). Thirty micrograms
®

®

of protein from each sample was denatured and separated using NuPAGE Novex Bis–Tris Mini
Gels (Invitrogen) in the XCell Sure-Lock™ Mini-Cell (Invitrogen) at 120 V at 4 °C for 3 h. Bands
were transferred onto a nitrocellulose membrane (Invitrogen) using an XCell II™ Blot module
(Invitrogen) at 15 V at 4 °C overnight. The membrane was incubated with primary mono-clonal
antibodies in 5 % bovine serum albumin (BSA) in TBST buffer (10 mM Tris–HCl, pH 7.5, 150 mM
NaCl, and 0.05 % Tween-20) at room temperature for 1 h (β-actin served as an internal control),
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followed by the secondary antibody of horseradish peroxidase-conjugated goat anti-mouse
(Thermo Fisher Scientific) at room temperature for 1 h. SuperSignal West Femto Maximum
Sensitivity Substrate (Thermo Fisher Scientific) and CL-XPosure Film (Thermo Fisher Scientific)
were used for exposure. The primary antibodies used in immunoblotting included MAPK family
antibody sampler kit [p44/42 MAPK (Erk1/2), MAPK/JNK, and p38 MAPK] and phosphor-MAPK
family antibody sampler kit, p21, and caveolin-1; all were from Cell Signaling.
Statistical methods
Numerical data are presented as the mean and the standard error of the mean. Mann–Whitney U
test was used for pair-wise comparison in biochemistry, ALP activity, calcium assay, ORO assay,
and real-time PCR data analysis. All statistical analyses were performed with SPSS 13.0
statistical software (SPSS Inc., Chicago, IL, USA). P values less than 0.05 were considered
statistically significant.
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RESULTS

	
  
Low-density expansion enhanced hSDSC proliferation capacity
Expanded hSDSCs at low and high density exhibited differences in cell morphology, cell number,
and cell size. Compared to cells grown at high density, low-density expanded cells remained
spindle shaped and smaller in size, and formed colony-forming units (Fig. 2.1a). When cells
plated at high density became confluent, cell number change was compared between the high2

2

density group from six 175-cm flasks and the low-density group from twenty-six 175 cm flasks.
We found that 9-day expansion of passage 2 hSDSCs yielded a 5.1-fold increase in cell number
2

(15,200 cells/cm ) when seeded at high density compared to an 84.4-fold increase (2,533
2

cells/cm ) when plated at low density. Passage 3 hSDSCs continued to expand at the same
density for another passage. Compared to the previous passage (passage 2), 9-day expansion at
2

high density yielded a lower cell number increase (11,429 cells/cm , 3.8-fold) while low-density
2

expansion yielded a higher cell number increase (2,725 cells/cm , 90.8-fold) (Fig. 2.1b). Cell
seeding density-based changes were also reflected in cell size. Low-density expansion cell size
(3,065.2 ± 2,540.1 pixels) was significantly smaller (p = 0.0000) than those grown at high density
(8,407.9 ± 4,240.6 pixels) (Fig. 2.1c).
Our flow cytometry data showed that cell changes were also reflected in the stem-cell-related
marker, proliferation index, and apoptosis in expanded cells at low and high density (Fig. 2.2). We
found that low-density expansion yielded cells with higher levels of SSEA-4 expression not only in
percentage (51.9 % vs. 47.5 %) but also in median fluorescence intensity (58.8 vs. 50.0)
compared to those seeded at high density. SSEA-4 data also corroborated proliferation index
data showing that low-density expansion yielded cells with a higher proliferation index (89.6 vs.
5.7) compared to those grown at high density. Intriguingly, there was a similar apoptotic cell rate
(4.1 % vs. 3.0 %) in the cells expanded at low and high density.
Low-density expansion enhanced hSDSC multi-differentiation potentials
To determine whether seeding density affected cell multi-differentiation potential, expanded cells
at either low or high density were evaluated for their chondrogenic, adipogenic, and osteogenic
differentiation capacity.
After a 27-day incubation in chondrogenic induction medium, low-density expanded cells yielded
pellets with intensified staining of sulfated GAG and collagens I, II, and X compared to those
expanded at high density (Fig. 2.3a). The pellet size from cells expanded at high density was
slightly larger than those from low-density expanded cells (Fig. 2.3a), which might be explained
by the higher cell viability in day 27 pellets from cells expanded at high density (Fig. 2.3b). Our
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biochemical analysis data showed that, compared to the cells plated at high density, low-density
expanded cells yielded pellets with a significantly higher ratio of GAG to DNA (chondrogenic
index) (Fig. 2.3b). Consistent with the above data, our real-time PCR data also showed that lowdensity expansion yielded day 27 pellets with higher mRNA levels of Sox9 (p=0.0000), aggrecan
(p=0.0002), collagen I (p=0.0015), collagen II (p=0.0002), and collagen X (p=0.0007) than those
from high-density groups (Fig. 2.4).
After a 21-day incubation in osteogenic induction medium, low-density expanded cells exhibited
intensified staining of ALP while high-density expanded cells had much weaker ALP staining; this
finding is corroborated by quantitative data that ALP activity was higher (p=0.0030) in cells
expanded at low density than those grown at high density (Fig. 2.5a). Surprisingly, both groups
showed weak staining for calcium deposition using alizarin red S staining without a significant
difference (p=0.6492) between the groups (Fig. 2.5b). Similar to osteogenic potential, after a 21day incubation in adipogenic induction medium, low-density expanded cells exhibited intensified
staining of lipid droplets detected using Oil Red O staining compared to those from high-density
expanded cells; this finding was supported by quantitative data (p=0.0002) (Fig. 2.5c).
Potential mechanisms underlying low seeding density-mediated cell rejuvenation
To further determine potential mechanisms underlying low seeding density-mediated cell
rejuvenation, western blot was used to investigate the expression of the MAPK signaling pathway
(Erk1/2, p38, and JNK) and senescence-associated markers (p21 and caveolin-1) in hSDSCs
after expansion at low and high density. Image J analysis showed that Erk1/2 expression was
about one fifth the level in the cells expanded at low density than at high density; JNK expression
followed that same trend. In contrast, p38 MAPK had a 2.3-fold increase in the cells expanded at
low density than at high density (Fig. 2.6a). As expected, senescence-associated markers, p21
and caveolin-1, decreased to some extent in the cells expanded at low density compared to high
density (Fig. 2.6b).
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DISCUSSION
Stem cell ex vivo expansion is an approach to overcome the shortage in cell number in cartilage
engineering and regeneration. However, replicative senescence is a concomitant consequence
during monolayer expansion; expanded cells lose their proliferation and multi-differentiation
capacity [18]. Though challenging, strategies to expand stem cells in vitro with intact self-renewal
and differentiation potentials have focused on identifying molecules and signaling pathways
involved. A variety of methods have been investigated to fulfill this need especially in long-term ex
vivo culture [19, 20]. Optimization of cell seeding density is a promising solution to protect stem
cells from undergoing replicative senescence. Our study, for the first time, demonstrated that low
seeding density not only benefited hSDSC proliferation but also enhanced expanded cell multidifferentiation capacity. We also found that the MAPK signaling pathway was involved in seeding
density-based cell expansion and low seeding density tended to retard hSDSC replicative
senescence.
Generally, low seeding density expansion results in dense colony formation while high seeding
density expanded cells are more evenly distributed across the culture plate. Relatively sparse
distribution of high seeding density expanded cells does not benefit colony formation [21] and
may not provide the necessary stimuli for growth due to loss of cell-cell contact [7]. Single-cellderived colonies in low seeding density were directly related to expanded cell adipogenic
potential [21], which may explain why the cells expanded at low density had higher adipogenic
capacity in our study. Cell morphology changes, such as cell shape in the low- seeding-density
group, have been reported to favor DNA synthesis [22], which might be responsible for higher cell
proliferation potential. Cell shape has also been reported to regulate the switch in lineage
commitment by modulating endogenous RhoA activity [23]. Rho kinases (ROCKs), the major
downstream effector of RhoA GTPase, regulate renewal and neuronal differentiation of
embryonic stem cells in a cell-seeding-density-dependent manner [24]. RhoA was also reported
to regulate BMSCs undergoing adipogenic and osteogenic differentiation through ROCKs [23].
Smaller size hSDSCs from low-density expansion benefited generation of single-cell-derived
colonies and therefore apparently retained their multi-potentiality for differentiation, which was
consistent with previous reports from other groups [4, 6, 21].
Consistent with other reports [5, 21], we found that low seeding density promoted hSDSC
proliferation and produced a higher percentage of smaller sized cells; in expanded hSDSCs, low
seeding density enhanced proliferation index and SSEA-4 expression but not apoptosis,
indicating that low- seeding-density expansion can retain hSDSC “stemness”. The retention of
“stemness”

was

also

demonstrated

by
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low-seeding-density-expanded

hSDSCs’

multi-

differentiation capacity, despite low osteogenic differentiation in the cells expanded at both low
and high density. This effect is probably because hSDSCs are a tissue-specific stem cell for
chondrogenesis [8, 11]. In contrast, expansion at high seeding density resulted in decreased cell
proliferation, increased cell senescence, and loss of multi-differentiation capacity, which is
consistent with a previous report [25].
Three MAPK conduits, Erk1/2, p38, and JNK, rank among the most extensively examined signal
transduction networks, and their contribution in MSC chondrogenesis has been thoroughly
reviewed recently [26]. For the first time, our study found that low seeding density expansion
yielded hSDSCs with down-regulation of the Erk1/2 and JNK levels and up-regulation of the p38
level, which might be responsible for enhancing expanded cell “stemness” in terms of proliferation
and multi-differentiation capacity. Consistent with our findings, other investigators found that
Erk1/2 was remarkably up-regulated in senescent cells [27] and Erk1/2 and p38 exerted an
opposite role in the regulation of chondrogenesis of mesenchymes [28]. The progression of
spontaneous chondrogenesis in micromass cultures of embryonic chick limb bud MSCs is
accompanied by a gradual increase in endogenous p38 phosphorylation [28]. Treatments with
p38 inhibitors have been shown to decrease cartilage matrix formation in embryonic chick or
mouse limb MSCs [28, 29] and to inhibit chondrogenic marker genes (Sox9, Col2a1, and
aggrecan) as well [30]. The transfection of prechondrogenic limb mesenchymes with
constitutively active MKK6, which activates p38, was shown to significantly increase Sox9
expression [29]. To sum up, the p38 signaling pathway is a positive regulator of the differentiation
of prechondrogenic limb mesenchyme cells into hyaline chondrocytes. The loss of Erk1/2 and
JNK expression in the low seeding density group could possibly be related to increased
adipogenic differentiation [31–33].
Expression of caveolin-1 and p21 is down-regulated in the cells expanded at low density.
Caveolins are major structural components of caveolae, the lipid rafts on cell membranes.
Caveolin functions as a scaffolding protein that interacts with signaling molecules and growth
factor receptors. Caveolin-1 expression is up-regulated in senescent human diploid fibroblasts
and MSCs [34, 35]. Decreased expression of caveolin-1 in hSDSCs expanded at low seeding
density might also be responsible for the enhanced adipogenic differentiation potential [34].
Caveolin-1 is reported to be able to induce expression of p21 and further cellular senescence
[36]. Expression of p21, the inhibitor of cyclin-dependent kinase, was found to be increased in
late-passage MSCs. Knockdown of p21 promoted proliferation and enhanced osteogenic
potentials of human MSCs, possibly through increasing telomere length and telomerase activity
without chromosomal abnormalities [37, 38]. Despite no difference in calcium deposition between
low- and high-density groups, our data suggested that the slight down-regulation of p21 was
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possibly responsible for the increase of ALP level in the cells expanded at low density after
osteogenic induction.
In summary, our study demonstrates that low seeding density can protect expanded cells from
replicative senescence and enhance hSDSC proliferation and multi-differentiation capacity,
especially for expanded cell chondrogenic potential. Similar to our previous study in expanding
SDSCs using basic fibroblast growth factor (FGF-2) [39], chondrogenically differentiated SDSCs
exhibited an increased amount of collagen I and collagen X compared with the high-density
group, indicating that low seeding density may favor multi- differentiation capacity instead of a
specific tissue lineage, such as chondrogenesis. This study was done using pooled cells from two
donors. One donor was male and one was female; one was middle-aged and one was elderly.
Even with this range of donors, donor-to-donor variability cannot be determined, which is a
limitation of the study. Our finding also suggests that the MAPK signaling pathway is involved in
cell-seeding-density-based cell expansion. Despite the fact that the underlying mechanism is still
under investigation, low seeding density provides a feasible and promising approach to yield a
sufficient number of cells for hSDSC-based cartilage engineering and regeneration.
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FIGURE LEGENDS
Figure 2.1 Cell seeding density affected expanded cell morphology, cell number, and cell size. a
Human SDSCs were expanded at high and low density on conventional plastic flasks for 9 days.
Scale bar is 200 µm. b Cell number was presented as a fold increase by initially seeded cell
amount during two consecutive passages. c Cell size was measured in pixels using Image J
software from 50 cells chosen randomly in 10 fields.
Figure 2.2 Cell seeding density affected expanded cell stem cell marker expression, proliferation
index, and apoptosis. a Flow cytometry was used to evaluate SSEA-4 expression in the cells
expanded at either high or low density. b Passage 3 expanded cells were measured for
proliferation index using CellVue® Claret flow cytometry kit. c Flow cytometry was used to
evaluate apoptosis in the cells expanded at either high or low density.
Figure 2.3 Cell seeding density affected expanded cell chondrogenic potential at the protein
level. a After a 27-day incubation in chondrogenic induction medium, representative pellets were
photographed for the final size. Safranin O (SO) and Alcian blue (AB) were used to stain sulfated
GAG. Immunostaining was used to detect collagens I, II, and X. b Biochemical analysis was used
to measure DNA and GAG amounts. DNA ratio, DNA amount adjusted by that at day 0, indicates
cell viability in a serum-free pellet culture system; ratio of GAG to DNA indicates chondrogenic
index. Significant differences were indicated as follows: **p<0.01 and ***p<0.001. Data were
shown as average±SD for n=4.
Figure 2.4 Cell seeding density affects expanded cell chondrogenic potential at the mRNA level.
Chondrogenic markers Sox9, aggrecan (AG), collagen I (Col I), collagen II (Col II), and collagen X
(Col X) were measured at the mRNA level in pellets from the cells expanded at either high or low
density. Significant differences were indicated as follows: **p <0.01 and ***p<0.001. Data were
shown as average±SD for n=4.
Figure 2.5 Cell seeding density affects expanded cell osteogenic and adipogenic potential. After
a 21-day incubation in osteogenic medium, osteogenesis was evaluated using alkaline
phosphatase (ALP) staining and quantitative activity assay (a) and Alizarin Red S (ARS) staining
and quantitative extracellular calcium assay (b). After a 21-day incubation in adipogenic medium,
adipogenesis was evaluated using Oil Red O (ORO) staining and quantitative lipid assay (c).
Significant differences were indicated as follows: **p<0.01 and ***p<0.001. Data were shown as
average±SD for n=4.
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Figure 2.6 Western blot was used to measure the expression of Erk1/2, JNK, and p38 in the
MAPK signaling pathway (a) and the expression of p21 and caveolin-1 (senescence-associated
markers) (b) in the cells expanded at either high or low density. A band (with an asterisk) between
Jnk bands (46 and 54 kDa) was a contamination from a previous binding with another antibody
but could not be stripped from 1.2 the membrane. Image J software was used to measure
immunoblotting bands. The activation of Erk1/2, JNK, or p38 was represented by phosphorylated
protein adjusted by total protein; the activation of p21 or caveolin-1 was represented by
expressed protein adjusted by β-actin. The value of interest was set up as 1 in the high-density
group.
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ABSTRACT

	
  
Adult stem cells gradually lose their stemness when plated in monolayer culture after isolation
from their in vivo niche. In this study, we hypothesized that the in vitro microenvironment can be
optimized by modulating oxygen tension andmitotic signal in a tissue-specific extracellularmatrix
(ECM) deposited by synovium-derived stem cells (SDSCs) to rejuvenate expanded SDSC
proliferation and chondrogenic potential. Passage 3 SDSCs were plated on either SDSC-derived
ECM or plastic flask and incubated in either hypoxia (5% O2) or normoxia (21% O2) with or
without the supplementation of 10 ng/mL of basic fibroblast growth factor-2 (FGF-2) for 7 days,
followed by pellet culture in a serum-free chondrogenic medium for 14 days. Our data showed
that, compared with the mitotic effect of FGF-2 on SDSCs, ECM expansion greatly enhanced
SDSC proliferation while retaining SDSC stem cell characteristics. More importantly, ECM
pretreatment yielded SDSC pellets with a comparable chondrogenic index to FGF-2 pretreatment,
both of which were much higher than SDSC expansion on plastic flask alone. FGF-2 pretreatment
led to the highest glycosaminoglycans and DNA content; intriguingly, it also contributed to the
highest expression level of hypertrophic marker genes. Surprisingly, the hypertrophic marker
genes could be downregulated if the pretreatment was combined with hypoxia or ECM. The
combination of hypoxia, FGF-2, and SDSC-derived ECM contributed to the highest cell number in
SDSC expansion. Our study indicates that the three-dimensional microenvironment for ex vivo
expansion can be optimized to provide high-quality stem cells for stem cell-based cartilage defect
repair.
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INTRODUCTION
Damage to the articular cartilage caused by osteoarthritis is becoming a significant clinical
problem due to the limited ability of cartilage to regenerate and the increase in the elderly
population. Autologous cartilage transplantation is a solution but is limited by donor-site
availability.

1

Recently, significant advances and tremendous progress have been made in

exploring the potential of adult stem cells in cartilage repair. Adult stem cells have proliferation
and multi-lineage differentiation capacity; however, once isolated from the body and expanded in
monolayer, they lose their proliferation and multi-lineage differentiation ability (stemness) during
passaging. Reconstructing a three-dimensional (3D) microenvironment by imitating an in vivo
stem cell niche for ex vivo expansion becomes an important priority for stem cell-based therapy of
cartilage defects.
Recent studies suggest that growth factors can enhance proliferation and differentiation potential
of adult stem cells. Of them, basic fibroblast growth factor-2 (FGF-2) is unique because
mesenchymal stem cells (MSCs) expanded in FGF- supplemented medium were smaller and
grew more rapidly than those in non-FGF-supplemented medium. Eighty percent of differentially
expressed extracellular matrix (ECM)-related genes were downregulated; moreover,MSC
2

expansion in the presence of FGF-2 enhanced their chondrogenic potential. Another important
parameter, low oxygen, also contributes to the establishment of an undifferentiated niche
microenvironment. Early embryonic development takes place in a hypoxic microenvironment and
hypoxia seems to prevent cellular differentiation and to maintain pluripotency of stem/ progenitor
3

cells. When exposed to hypoxia, MSCs increased expression of a subset of genes normally
found in embryonic cells, such as OCT-4 and Rex-1,

4,5

as well as SSEA-4.

4

Hypoxia-

preconditioned MSCs acquired higher colony forming units and increased differentiation
potential.

5–7

It is well established that stem cells reside, proliferate, and differentiate inside the body within a
complex 3D microenvironment, indicating that a tissue-specific stem cell canbeusedto prepare its
own in vitro microenvironment for stem cell proliferation while maintaining and enhancing its
lineage-specific stemness. As a new member in MSC families, synovium-derived stem cells
(SDSCs) are reported as a tissue-specific stem cell for chondrogenesis.

8–11

Our previous studies

suggested that SDSCs could be negatively isolated from the synovial membrane
cartilage tissue engineering

13

and in vivo cartilage regeneration.

14

12

for in vitro

Our most recent study

indicated that SDSC-derived extracellular matrix (S-ECM) can serve as an in vitro 3D
microenvironment, greatly enhancing SDSC propagation and allowing restoration of stem cell
stemness toward chondrogenesis.

15

Considering that articular chondrocytes reside in a hypoxic
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condition

16

2

and mitogens such as FGF- 2 are involved in MSC chondrogenesis, three important

microenvironmental factors—oxygen tension and mitogens as well as 3D ECM—are assumed to
contribute to the regulation of the seeded SDSCs for chondrogenesis. In this study, we
hypothesized that the in vitro microenvironment can be optimized by modulating oxygen tension
and mitotic signal in ECM deposited by SDSCs to rejuvenate expanded SDSCs’ proliferation and
chondrogenic differentiation capacity. The ability to reconstitute an in vitro 3D microenvironment
will greatly benefit SDSC-based therapy for cartilage defects.
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MATERIALS AND METHODS
Isolation and culture of SDSCs
Two 3-month-old pigs were collected from a local slaughterhouse and synovial tissue was
harvested from both knees. After finely mincing, synovial tissue was digested in 0.1% trypsin
(Roche, Indianapolis, IN) at 37°C for 30 min and then in 0.1% collagenase P (Roche) for 2 h. The
released synovial cells were collected from the filtrate and plated in a complete medium (aminimum essential medium containing 10% fetal bovine serum, 100U/mL penicillin, 100 mg/mL
streptomycin, and 0.25 mg/mL fungizone [Invitrogen, Carlsbad, CA]). Nonadherent cells were
removed during the medium change every 2 days. For negative isolation of synovial fibroblasts
7

7

from primary cultures, the synovial cell suspension (10 cells/mL) was incubated with 5✕10 /mL
®

Dynabeads M-450 CD14 containing a monoclonal antibody specific for macrophages (Dynal
Biotech, Oslo, Norway) at 4°C for 1 h. The conjugatedcells andthe unboundDynabeads were
collected using the Dynal Magnetic Particle Concentrator

®

(Dynal Biotech), and the depleted
12

supernatant with synovial fibroblasts (characterized as SDSCs in our previous study ) was saved
for further passaging.
Preparation of SDSC-derived ECM
The preparation method of SDSC-derived ECM was described in our previous study.15 Briefly,
plastic flasks (P-Flask) were precoated with 0.2% gelatin (Sigma, St. Louis, MO) at 37°C for 1h
and seeded with passage 3 SDSCs. After cells reached 90% confluence, 50mM L-ascorbic acid
phosphate (Wako Chemicals USA Inc., Richmond, VA) was added for 8 days. The deposited
ECM was incubated with 0.5% Triton X-100 containing 20mM ammonium hydroxide at 37°C for
5min and stored at 4°C in phosphate-buffered saline containing 100U/mL penicillin, 100mg/mL
streptomycin, and 0.25 mg/mL fungizone.
SDSC expansion under different microenvironmental conditions
Passage 3 SDSCs were plated at 3,000 cells/cm2 in P-Flask (‘‘P’’) or ECM-coated flasks (SECM, ‘‘E’’) and incubated in hypoxia (5% O2, ‘‘5’’) or normoxia (21% O2, ‘‘21’’) in the complete
medium with or without treatment of 10ng/mL FGF-2 (‘‘F’’) for one passage. There were eight
pretreatments in SDSC expansion: ‘‘P-Flask+21% O2’’ (P21), ‘‘P-Flask+5% O2’’ (P5), ‘‘PFlask+FGF-2+21% O2’’ (PF21), ‘‘P-Flask+FGF-2+5% O2’’ (PF5), ‘‘S-ECM+21% O2’’ (E21), ‘‘SECM 5% O2’’ (E5), ‘‘S-ECM+FGF-2+21% O2’’ (EF21), and ‘‘SECM+FGF-2+5% O2’’ (EF5). During
SDSC expansion, cell number was counted and morphology was photographed.
Chondrogenic differentiation of SDSCs
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6

After in vitro expansion, 0.3X10 of SDSCs from each pretreatment were centrifuged at 500g for
5min in a 15-mL polypropylene tube to form a pellet. After overnight incubation, the pellets were
cultured in a serum-free chondrogenic medium consisting of high-glucose Dulbecco’s modified
Eagle’s medium, 40 mg/mL proline, 100nM dexamethasone, 100U/mL penicillin, 100mg/mL
streptomycin, 0.1mM ascorbic acid-2-phosphate, and 1XITS™ Premix (6.25 mg/mL insulin, 6.25
mg/mL transferrin, 6.25 mg/mL selenous acid, 5.35 mg/mL linoleic acid, and 1.25 mg/mL bovine
serum albumin, from BD Biosciences, Bedford, MA) with the supplementation of 10ng/mL
transforming growth factor beta 3 (PeproTech Inc., Rocky Hill, NJ) for 14 days. At days 0, 7, and
14, the pellets were collected for chondrogenic evaluation.
Histochemistry and immunohistochemistry
The pellets (n = 2) were fixed in 4% paraformaldehyde at 4°C overnight, followed by dehydrating
in a gradient ethanol series, clearing with xylene, and embedding in paraffin blocks. About 5-mm
sections were histochemically stained with Alcian blue (Sigma; counterstained with fast red) and
Safranin O (Sigma; counterstained with hematoxylin) for sulfated glycosaminoglycans (GAG). For
immunohistochemical analysis, the sections were immunolabeled with primary antibodies against
collagen II (II-II6B3; DSHB, Iowa City, IA), collagen I (Abcam, Cambridge, MA), and collagen X
(Sigma), followed by the secondary antibody of biotinylated horse anti-mouse IgG (Vector,
Burlingame, CA). Immunoactivity was detected using Vectastain ABC reagent (Vector) with 3,30diaminobenzidine (DAB) as a substrate.
Biochemical analysis for DNA and GAG content
The pellets (n=4) were digested for 4h at 608C with 125 mg/mL papain in PBE buffer (100mM
phosphate and 10mM EDTA, pH 6.5) containing 10mM cysteine, by using 200 mL enzyme per
sample. To quantify cell density, the amount of DNA in the papain digestion was measured using
the QuantiT™ PicoGreen® dsDNA assay kit (Invitrogen) with a CytoFluor® Series 4000 (Applied
Biosystems, Foster City, CA). GAG was measured using dimethylmethylene blue dye and a
Spectronic™ BioMate™ 3 Spectrophotometer (Thermo Scientific, Milford, MA) with bovine
chondroitin sulfate (Sigma) as a standard.
Real-time polymerase chain reaction
Total RNA was extracted from samples (n=4) using an RNase-free pestle in TRIzol®
(Invitrogen). About 1mgof mRNA was used for reverse transcriptase with High-Capacity cDNA
Archive Kit (Applied Biosystems) at 37°C for 120 min. Chondrogenic marker genes [collagen II,
aggrecan, and SRY (sex determining region Y)-box 9 (Sox9)] and hypertrophic marker genes
(collagen X, alkaline phosphatase [ALP], and matrix metalloproteinase 13 [MMP13]) were
customized by Applied Biosystems as part of the Custom TaqMan® Gene Expression Assays
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(Table 3.1). Eukaryotic 18S rRNA (Assay ID HS99999901_s1 ABI) was carried out as the
endogenous control gene. Real-time polymerase chain reaction (PCR) was performed with the
iCycler iQ™ Multi Color reverse transcriptase-PCR Detection and calculated by computer
software (Perkin-Elmer, Wellesley, MA). Relative transcript levels were calculated as χ=2

-ΔΔCt

, in

which ΔΔCt = ΔE - ΔC, ΔE = Ctexp - Ct18s, and ΔC=Ctct1-Ct18s.
Statistics
The Mann–Whitney U-test was used for pairwise comparison in biochemistry analysis and realtime PCR data. All statistical analyses were performed with SPSS 13.0 statistical software (SPSS
Inc., Chicago, IL). ρ-Values <0.05 were considered statistically significant.
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RESULTS
In vitro microenvironment to rejuvenate SDSC proliferation
After SDSCs reached confluence, ascorbic acid supplementation stimulated SDSCs to produce
ECM in a 3D format. Three key components (S-ECM, hypoxia, and FGF-2) of the stem cell niche
were evaluated for their roles in enhancing stem cell proliferation and maintaining stem cell
unique morphology. Compared with flattened and irregular shapes (characteristic of aged cells) in
the ‘‘P21’’ and ‘‘P5’’ groups, the expanded SDSCs had shorter and glistening shapes in the
‘‘PF21’’ and ‘‘PF5’’ groups, and longer and glistening fibroblast-like shapes in all ECM groups
(‘‘E21,’’ ‘‘EF21,’’ ‘‘E5,’’ and ‘‘EF5’’). Compared with the random arrangement of cells plated on PFlask, S-ECM-expanded cells were aligned with matrix fibers (Fig. 3.1).
To assess proliferation efficiency in various microenvironments, after a 6-day expansion, the cell
number increased 2.39-fold in the ‘‘P5’’ group, 2.61-fold in the ‘‘P21’’ group, 6.90- fold in the
‘‘PF21’’ group, 12.50-fold in the ‘‘PF5’’ group, 34.52- fold in the ‘‘E21’’ group, 54.52-fold in the
‘‘EF21’’ group, 77.38-fold in the ‘‘E5’’ group, and 93.45-fold in the ‘‘EF5’’ group (Fig. 3.2A).
Compared with SDSC expansion on P-Flask in normoxia, a hypoxic culture did not improve
SDSC proliferation until combined with FGF-2 and/or S-ECM. In contrast, FGF-2 improved SDSC
proliferation not only when combined with hypoxia and/or S-ECM but alsowhen applied alone in
P-Flask culture. SDSC expansion on S-ECM acquired a higher cell number than the
pretreatments with hypoxia and/or FGF-2. Intriguingly, the highest cell number was in the
pretreated groups with S-ECM, hypoxia, and FGF-2. Despite the fact that the same cell number
6

(0.3×10 ) was used to form a pellet followed by incubation in a serum-free chondrogenic medium,
SDSC pellets from S-ECM pretreatments were initially smaller in size (not shown here) but
became much bigger after a 14-day incubation compared with those from hypoxia or normoxia in
P-Flask culture (Fig. 3.2B).
In vitro microenvironment to rejuvenate SDSCs for chondrogenic differentiation
To characterize the effects of various pretreatments on SDSC chondrogenesis, pellets from P4
SDSCs expanded on P-Flask or S-ECM under normxia or hypoxia with or without FGF-2 were
induced in a serum-free chondrogenic medium for 14 days. Our histology data (Fig. 3.3) showed
that P-Flask expansion yielded SDSC pellets with comparable sulfated GAGs, collagen I, and
collagen II staining under normoxia (P21) and hypoxia (P5), mainly located in the peripheral
regions of pellets. In contrast, other pretreatments with FGF-2 and/or S-ECM dramatically
increased pellet size, sulfated GAGs, and collagen II intensity with homogenous distribution
throughout the pellets under either normoxia (PF21) or hypoxia (PF5); on the contrary, collagen I
was only detected at the edge of the pellets. Our data suggested that pretreatments with FGF-2
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and S-ECM were key components in the in vitro microenvironment for SDSC chondrogenic
potential. Our data also suggested that pretreatment with low oxygen alone in P-Flask culture did
not make a significant difference in SDSC chondrogenic potential.
Compared with a decrease in cell number (about 60%) in the groups pretreated with P-Flask (P21
and P5), our DNA data (Fig. 3.4) showed that pretreatment with ECMs (E21, E5, EF21, and EF5)
yielded SDSC pellets with a cell number around 86% at day 14, which was comparable to those
pretreated with FGF-2 under hypoxic condition (PF5), despite the fact that FGF-2 pretreatment
(PF21) yielded pellets with increased cell number up to 124% after 14-day incubation with
chondrogenic medium.
For the pretreated effect of oxygen tension on SDSC chondrogenic potential, our biochemical
data (Fig. 3.4) showed that when SDSCs were plated on ECM, pretreatment with hypoxia (E5)
yielded SDSC pellets with a higher chondrogenic index (GAG/DNA) than those from pretreatment
with normoxia (E21). However, there was no significant difference in chondrogenic index from
either pretreatment with hypoxia (P5) and normoxia (P21) when SDSCs were plated on P-Flask,
or pretreatment with and without FGF-2 presence, regardless of culture on ECM (EF21 vs. EF5)
or P-Flask (P21 vs. P5).
For the pretreated effect of FGF-2 on SDSC chondrogenic potential, our biochemical data (Fig.
3.4) showed that when SDSCs were plated on P-Flask, pretreatment with FGF-2 yielded SDSC
pellets with a higher chondrogenic index than those cultured in basal medium alone, at either
normoxic (PF21 vs. P21, p<0.001) or hypoxic conditions (PF5 vs. P5, p<0.001). When SDSCs
were seeded on ECM, however, supplementation with FGF-2 yielded SDSC pellets with no
significant difference in chondrogenic index from those cultured in the basal medium alone,
regardless of normoxia (EF21 vs. E21) or hypoxia (EF5 vs. E5).
For the pretreated effect of ECM on SDSC chondrogenic potential, our biochemical data (Fig. 3.4)
showed that ECM-treated SDSCs yielded pellets with much higher chondrogenic index than
those from P-Flask-expanded SDSCs (p<0.001) no matter if they were incubated in a normoxic or
hypoxic incubator. Intriguingly, with supplementation of FGF-2, the chondrogenic index in ECMtreated SDSCs was not statistically different from that of P-Flask-expanded SDSCs, in either the
normoxic (EF21 vs. PF21) or hypoxic condition (EF5 vs. PF5).
Our real-time PCR data (Fig. 3.5) were consistent with our biochemical data. There was no
significant difference in chondrogenic marker gene levels (collagen II, aggrecan, and Sox9)
between hypoxia and normoxia when the SDSCs were pretreated on either P-Flask (P5 vs. P21)
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or ECM (E5 vs. E21 or EF5 vs. EF21). With the supplementation of FGF-2 in P-Flasks, however,
hypoxic pretreatment (PF5) yielded SDSC pellets with comparable aggrecan and Sox9 marker
genes to all ECM groups. In contrast, normoxic pretreatment (PF21) yielded SDSC pellets with
the highest aggrecan and Sox9 marker genes than the other groups as well as comparable
collagen II marker level to the hypoxic group (PF5).
To identify if a higher chondrogenic index was associated with chondrocyte hypertrophy, real-time
PCR (Fig. 3.6) was used to evaluate three hypertrophic marker genes (collagen X, ALP, and
MMP13). Our finding was that pretreatment with ECM and FGF-2 yielded pellets with higher
expression of collagen X at day 0; these results were much closer after a 14- day incubation in a
serum-free chondrogenic medium despite the highest expression level in FGF-2-expanded
SDSCs. Pretreatment with FGF-2 yielded pellets with the highest ALP and MMP13 mRNA levels
than the other pretreated groups, indicating that the supplementation of FGF-2 was associated
with chondrogenic hypertrophy of expanded cells. Surprisingly, hypoxic pretreatment could
decrease the hypertrophic marker gene level of FGF-2-expanded SDSCs (PF5 vs. PF21).
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DISCUSSION
The goal for stem cell research is to eventually provide differentiated products for regenerative
medicine; thus, the promotion of stem cell self-renewal at the expense of differentiation is not an
option. Considering the signals that govern the transition between self-renewal and differentiation
programs being of utmost importance when designing defined stem cell culture and derivation
formats, our study, for the first time, investigated three key components for the in vitro 3D
microenvironment reconstruction: ECM (supporting 3D structure), hypoxia (environmental factor),
and FGF-2 (growth modulating factor). We demonstrated that the in vitro microenvironment can
be optimized by modulating oxygen tension and mitotic signal in a 3D ECM deposited by SDSCs
to rejuvenate SDSC expansion and chondrogenic differentiation capacity. Our data indicated that,
compared with the mitotic effect of FGF-2 on SDSCs, ECM expansion greatly enhanced SDSC
proliferation while retaining SDSC stem cell morphology. More importantly, ECM pretreatment
yielded SDSC pellets with a comparable chondrogenic index to FGF-2 pretreatment, both of
which were closer to that from cartilage pellets (50.43±1.22, data not shown) and much higher
than that in SDSCs expanded on P-Flask alone. FGF-2 pretreatment led to the highest GAG and
DNA content; intriguingly, it also contributed to the highest expression level of hypertrophic
marker genes. Surprisingly, the hypertrophic marker genes could be down-regulated if
pretreatment was combined with hypoxia or ECM. The combination of hypoxia, FGF-2, and SECM contributed to the highest cell number in SDSC expansion.
Strategies for influencing MSC proliferation and differentiation are not yet well defined.

17,18

Microenvironmental factors, such as FGF-2, ECM, and oxygen tension, largely contribute to the
regulation of these MSCs. FGF-2 could maintain MSCs in an immature state during in vitro
expansion and enhance MSC proliferation and differentiation potential

2,19–22

through the

regulation of mitogen-activated protein kinase (MAPK) and the canonical Wingless-type MMTV
2

integration site family (Wnt) signaling. There is an increasing body of evidence demonstrating a
role for the MAPK signaling cascade in the regulation of chondrogenic differentiation that requires
exquisite temporal regulation of P38 and extracellular signal-regulated kinases (ERK1/2)
phosphorylation.

23–25

Wnts are a family of secreted proteins that play important roles in

development, including chondrogenesis. Wnt pathways have been linked to the MAPK pathway in
the regulation of chondrogenesis.

26,27

Recently, Solchaga et al. found that eighty percent of the

differentially expressed ECM-related genes were downregulated on MSCs expanded in the
presence of FGF-2, suggesting the maintenance of the undifferentiated status of the cells by
FGF-2 through the downregulation of genes that encode the specialized ECM components of
2

differentiated tissues. Similarly, Ito et al. found that the overall insulin-like growth factor I and
transforming growth factor beta (differentiationrelated) signaling pathways were inactivated by
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FGF-2, suggesting that FGF-2 suppresses MSC senescence.
MSC chondrogenic potential.

29

28

FGF-2 was also found to promote

However, the enhanced chondrogenic differentiation was

accompanied by increased expression of hypertrophic marker genes, indicating that MSCs
expanded in the presence of FGF-2 also acquired osteogenic differentiation capacity.

29

Our

findings corroborated the above studies. Although FGF-2 pretreatment greatly enhanced SDSC
chondrogenic differentiation potential, the expanded SDSCs also exhibited the highest level of
hypertrophic marker genes when incubated in a serum-free chondrogenic medium.
As an in vitro 3D structure, ECM was deposited by SDSCs, which appears to approximate native
tissue more closely and presents a unique opportunity for in vitro studies of cell behavior under in
vivo-like conditions.

30,31

In 3D cultures, the steady-state level of ERK1/2 activity was enhanced

when compared with that by 2D signaling.30 This steady-state level may be responsible for ECMexpanded SDSCs acquiring a higher proliferation capacity with comparable chondrogenic
potential because in the same way signaling through ERK1/2 pathway is required to shift
embryonic stem cells from a program of self-renewal to one allowing for differentiation and
lineage commitment.

32

Our study also suggested that SDSC expansion in the presence of ECM

combined with FGF-2 yielded more stem cells without compromised chondrogenic potential. This
increase in cell proliferation may reflect the reciprocal interaction of ECM and FGF-2 in the body.
In vivo, numerous growth factors and morphogens are immobilized by binding to the ECM
through specific heparin-binding domains or by direct binding to ECM molecules such as
collagen, or direct anchoring to cell membranes.

33

Immobilization of growth factors in this manner

can serve to increase local concentration of the protein by hindering diffusion and receptormediated endocytosis. Heparin sulfate-proteoglycans are required for functional FGF-FGF
receptor binding and also act as reservoirs for local ligand availability, regulating diffusion,
gradient formation, and degradation of FGFs as well as other morphogenetic proteins that have
important roles to play in the development of musculoskeletal tissues.

34–36

Surprisingly, the

combined application of ECM decreased osteogenic potential of FGF-2-pretreated SDSCs though
the underlying mechanism remains to be elucidated.
Hypoxia alters fundamental and physiologically important intracellular pathways and has long
been recognized as a critical stimulus for chondrocyte development.

37

Because MSCs are

adapted to low oxygen in vivo, standard in vitro culture may be inherently stressful to these MSCs
and appears to induce an oxidative stress response in these cells. However, MSCs expanded in
low oxygen appeared to be adapted to the physiological environment, in which low oxygen
5

selected a population of cells with faster proliferation potentials. Moreover, gene analysis
revealed that a low oxygen condition affects specific regulatory pathways in MSCs, leading to the
activation of several molecular and cellular events that favor the production of chondrogenic-

63

specific ECM components.

38

Induction of collagen II in hypoxia-expanded cells is attributed to

enhanced chondrogenic ability.

39

These data suggest that low oxygen tension is a key regulatory

factor of proliferation, differentiation, and activity of chondrogenic cells. In our study, pretreatment
with low oxygen alone did not show a role in SDSC expansion and subsequent chondrogenic
differentiation; however, hypoxia pretreatment increased SDSC proliferation when combined with
ECM and acquired the highest cell number when combined with ECM and FGF-2. More
importantly, hypoxia decreased osteogenic potential of FGF-2-preteated SDSCs without
40–42

compromising chondrogenic capacity, which is consistent with previous investigations.

It was

reported that expanded MSCs under low oxygen showed attenuated osteogenic responsiveness
in vitro.

40

Similarly, hypoxia has also recently been suggested to inhibit expression of type X

collagen, which is the major marker of chondrocyte hypertrophy, during the chondrogenesis of
epiphyseal chondrocytes

41

and of adipose-derived MSCs,

42

thereby preventing the potential

calcification of engineered cartilage. This result strongly suggested that hypoxia is a useful tool
for cartilage tissue engineering.
The stress of in vitro culture could induce cell senescence.

43

The causative role of oxidative

stress in cell senescence has been confirmed by studies in which cells cultured under hyperoxia
displayed accelerated onset of telomere-driven replicative senescence,

44

whereas these treated

with oxidants senesced prematurely in a telomere-independent manner.

45

In contrast to

fibroblasts and other somatic cells, the role of reactive oxygen species (ROS) in MSC growth and
senescence remains elusive. Some indirect evidence showing the involvement of ROS in MSC
proliferation is derived from studies on bone marrow and adipose tissue-derived cells, whose
growth

rate

antioxidants.

and

46,47

replicative

lifespan

were

markedly

improved

upon

treatment

with

Other studies have shown that significant MSC growth prolongation may also be

achieved in cells cultured under reduced oxygen pressure,
expression of genes favoring MSC proliferation.

49

48

which may be attributed to over-

Recently, MSCs cultured on this ECM showed

remarkable promotion of proliferation and retention of stem cell population with a lower level of
ROS and higher level of telomerase activity when compared with those cultured on uncoated PFlask.

50

However, a high level of ROS was reported to be associated with a loss of stem cell

characteristics and increased differentiation and apoptosis.

51

Therefore, the ability of hypoxia and

ECM to suppress ROS may contribute to the retention of stem cell characteristics.
Taken together, FGF-2, low oxygen, and ECM may play a key role in reconstituting an in vitro
tissue-specific microenvironment. To provide large-scale and high-quality stemcells for cartilage
tissue

engineering

microenvironment

and
for

regeneration,

expansion

and

the

potential

reprogramming

mechanisms
of

SDSCs

underlying
toward

the

3D

chondrogenic

differentiation need to be elucidated. The functionality of tissue constructs engineered using
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microenvironment-expanded stem cells needs to be further evaluated for mechanical properties.
Inaddition, bonemarrowstromal cells also deserve to be compared with SDSCs for the difference
in tissue-specific induction after expansion in such a 3D microenvironment.
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FIGURE LEGENDS
Figure 3.1 SDSC morphology in preparation of ECM (before and after the supplementation of
ascorbic acid [AA]) and after plating on S-ECM (‘‘E’’) or plastic flasks (P-Flask, ‘‘P’’) and
incubated in hypoxia (5% O2, ‘‘5’’) or normoxia (21% O2, ‘‘21’’) with or without 10ng/mL of
fibroblast growth factor-2 for 5 days. SDSC, synovium-derived stem cell; S-ECM, SDSC-derived
extracellular matrix.
6

2

Figure 3.2 After 6-day plating with initial cell number as 0.53 × 10 in one 175cm flask, the
expanded SDSCs under different pretreatments were counted for cell number (A) followed by a
14-day incubation of SDSC pellets in a serum-free chondrogenic medium (B).
Figure 3.3 Histology and immunohistochemistry of SDSC pellets after 7-day and 14-day
chondrogenic induction in a serum-free chondrogenic mediu. Safranin-O (SO) and Alcian blue
(AB) were used to detect collagen I (Col I) and collagen II (Col II). The scale bar is 800 µm. GAG,
glycosaminoglycans.
Figure 3.4 Biochemical analysis for DNA and GAG contents in SDSC pellets after 14-day
chondrogenic induction in a serum-free chondrogenic medium. Cell proliferation was shown as
DNA content adjusted by that at day 0. The ratio of GAG to DNA was used to represent
chondrogenic index. Data are shown as average ± SD for n=4. SD, standard deviation.
Figure 3.5 TaqMan real-time polymerase chain reaction for evaluation of chondrogenic marker
genes (Col II, aggrecan, and Sox9) in SDSC pellets after 14-day chondrogenic induction. 18S
RNA was used as an internal control. The mRNA level in SDSC pellets at day 0 from P21 was set
as 1. Data are shown as average±SD for n=4.
Figure 3.6 TaqMan real-time polymerase chain reaction for evaluation of hypertrophic marker
genes (Col X, ALP, and MMP-13) in SDSC pellets after 14-day chondrogenic induction. 18S RNA
was used as an internal control. The mRNA level in SDSC pellets at day 0 from P21 was set as 1.
Data are shown as average±SD for n=4. ALP, alkaline phosphatase; MMP, matrix
metalloproteinase.
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Table 3.1 TaqMan-customized porcine marker gene primers and probes
Name

Primer/probe

Sequence (5’-3’)

Gene ID

Forward

TCCTGGCCTCGTGGGT

397323

Reverse

GGGATCCGGGAGAGCCA

Probe

CTCCCCTGGGAAACC

Forward

GCCACTGTTACCGCCACTT

Reverse

CACTGGCTCTCTGCATCCA

Probe

CTGACCGGGCGACCTG

Forward

TGGCAAGGCTGACCTGAAG

Reverse

GCTCAGCTCGCCGATGT

Probe

CCCCATCGACTTCCGC

Forward

GGCCCGGCAGGTCATC

Reverse

TGGGATGCCTTTTGGTCCTT

Probe

TCAGACCTGGTTCCCC

Forward

CCCTTCACTGCCATCCTGTAC

Reverse

CCATGGAGACGTTCTCTCTCTCA

Probe

ACGGCCCTGGCTACAA

Forward

AGTTTGGCCATTCCTTAGGTCTTG

Reverse

GGCTTTTGCCAGTGTAGGTATAGAT

Probe

ACCACTCCAAGGACCC

Chondrogenic markers
Collagen II α1

Aggrecan

Sox9

397255

396840

Hypertrophic markers
Collagen X α1

ALP

MMP13
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448809

100170147

397346

Figure 3.1
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Figure 3.2
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Figure 3.3
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Figure 3.4
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Figure 3.5
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Figure 3.6
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ABSTRACT

	
  
Application of cell-based therapy in cartilage defect repair remains challenging due to the
shortage of autologous chondrocytes and limited regenerative capacity of cartilage. Alternative
cell source such as synovium-derived stem cell (SDSC) has been characterized as tissue-specific
stem cell for chondrogenesis. Decellularized extracellular matrix (DECM) deposited by SDSCs
served as ex vivo expansion system for maintaining stemness and enhancing chondrogenic
potential. However, whether other potential and more accessible cell deposited DECMs could
also provide an ex vivo microenvironment as human SDSC-derived DECM (SE) is not known. In
this study, we found that human adipose-, urine-derived stem cell and dermal fibroblast deposited
DECMs (AE, UE and DE) could also serve as ex vivo expansion system for promoting SDSC
proliferation and chondrogenic potential. Compared to the plastic flask (PL) expansion, all DECMexpanded SDSCs yield higher cell number and proliferation index. The highest cell number and
proliferation index were obtained in UE, followed by AE, DE, SE and PL. The expansion on AE,
UE, and DE resulted the SDSCs with an elongated and less spread cell shape than SDSCs on
SE and PL analyzed by scanning electron microscopy. The significantly lower elasticity was
observed in SDSC expanded on DECMs than SDSCs on PL accordingly, which is consistent with
the elasticity measurement of DECMs (DE>SE>AE>UE). Despite a robust and enhanced
chondrogenesis was also observed in DECM-expanded SDSCs pellets compared to PL
expanded cells, AE, DE and UE pretreated SDSCs yielded pellets exhibited the larger size,
higher DNA content and chondrogenic index (GAG/DNA), and higher level of chondrogenic
marker genes expression than SE-expanded pellets. Histological staining and immunostaining for
sulfated GAGs, collagens I and II were consistent with the biochemistry and real-time PCR data.
However, the higher hypertrophic marker gene expression is also observed in DE-expanded
SDSC pellets, which could be explained by the higher stiffness of DE. There was no concomitant
enhancement of osteogenic and adipogenic potential of DECM-pretreated SDSCs. In conclusion,
the DECM deposited by the adipose, skin and urine-derived cells can serve as ex vivo expansion
substrates, enhancing the maintenance of the embedded SDSCs and rejuvenate them with
higher chondrogenic potential. Although the mechanisms underlying the greatest chondrogenic
potential in SDSCs expanded on AE, DE and UE are under further investigated, the potential
application of these easily accessible sources would provide great opportunity for repairing
cartilage defects in patients with autologous cells.

	
  

81

INTRODUCTION
Adult articular cartilage exhibits little capacity for intrinsic repair. Injury and joint degeneration
resulted minor lesions may lead to progressive damage, causing significant pain and disability.
The successful repair of articular cartilage defects is a major clinical challenge. There have been
numerous attempts to develop tissue-engineered grafts or patches to repair focal chondral and
osteochondral defects. Cell-based therapy remains the most promising for articular cartilage
repair. However, with the practical clinical limitations (donor morbidity, shortage of healthy
donors) surrounding the use of autologous chondrocytes, the cartilage engineering filed rapidly
move towards other progenitor cell sources.
Mesenchymal stem cells (MSCs) were firstly isolated from bone marrow by Johnstone and
Pittenger

1;2

and widely applied in tissue engineering since then. Other than bone marrow, MSCs
3

4

5

has also been identified in adipose, skeletal muscle and other tissues. In determining the
optimal source of cells for cartilage repair, the two primary criteria that are generally considered
are the performance of the cells and their ease of access. MSCs from different sources
suggested their tissue-specificity. Synovium-derived stem cells (SDSCs) has been suggested as
6

a tissue-specific stem cell for chondrogenesis. Low yield and high donor morbidity makes bone
marrow-derived stem cells (BMSCs) less abundant and accessible than adipose-derived stem
cells (ASCs). Recently, urine-derived stem cells (USCs) have been demonstrated to express
7

MSC surface markers and possess multi-lineage differentiation potentials. Dermal fibroblasts
8

(DFs) from skin was also reported to acquire multi-lineage differentiation potentials. Thus, the
skin, adipose, urine derived MSCs constitutes promising cell source in clinical applications.
Dedifferentiation of chondrocytes due to traditional two-dimensional cell culture and cell
senescence due to repeated passaging and elderly donor bring challenge for large-scale ex vivo
expansion.

9;10

Potential genetic modification, biomaterial scaffolds and growth factors have been

investigated to improve the efficiency.

11

Our previous studies indicated that decellularized

extracellular matrix (DECM) deposited by SDSCs can serve as an in vitro three-dimensional
expansion system, greatly enhancing SDSC propagation and facilitating restoration of stem cell
stemness toward chondrogenesis.

12;13

However, whether MSCs derived from easily accessible

sources such as skin, adipose or urine can be used to deposit DECMs and served as
microenvironment for maintaining or promoting SDSC stemness is not known.
In this study, we intended to investigate whether DECMs from the more accessible human cell
sources, including ASCs, USCs and DFs, can serve as in vitro microenvironment for stem cell
expansion while promoting chondrogenic potential.
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MATERIALS AND METHODS
Preparation of DECMs
Adult human synovium-derived stem cells (SDSCs), adipose-derived stem cells (ASCs) and
dermal fibroblasts (DFs) purchased from ZenBio Inc., Research Triangle Park, NC and human
urine-derived stem cells (USCs), a generous gift from Dr. Yuanyuan Zhang, Wake Forest Institute
for Regenerative Medicine, were used to prepare DECMs. Methods for preparing these DECMs
were described in our previous study.

10

Briefly, plastic flasks were pre-coated with 0.2% gelatin

(Sigma, St. Louis, MO) at 37°C for 1 h and seeded with passage 4 SDSCs, ASCs, DFs and USCs
2

at 6,000 cells per cm . After cells reached 90% confluence, 250 µM L-ascorbic acid phosphate
(Wako Chemicals USA Inc., Richmond, VA) was added for another 10 days. The deposited ECM
flasks were incubated with 0.5% Triton X-100 containing 20 mM ammonium hydroxide at 37°C for
5 min to remove the cells and stored at 4°C in PBS containing 100 U/mL penicillin, 100 µg/mL
streptomycin and 0.25 µg/mL fungizone until use.
SDSCs expansion on plastic flasks or different DECMs
2

Passage 3 SDSCs (3,000 cells per cm ) were plated on either DECM-coated flasks (SE, AE, DE,
UE) or conventional uncoated plastic flasks (PL) for one passage. The growth medium was
changed every three days. Cell number was counted by hemacytometer (Hausser Scientific,
Horsham, PA) and morphology was photographed by phase contrast microscopy during cell
expansion.
Proliferation index assay
Before passage 3 SDSCs were seeded on plastic flasks or DECMs, cells from each group were
-6

labeled with CellVue® Claret (Sigma) at 2 × 10 M for 5 minutes according to the manufacture
protocol. After 6-day expansion, cells were collected and measured by a BD dual laser FACS
Calibur (BD Biosciences). 20,000 events of each sample were collected using CellQuest Pro
software (BD Biosciences) and cell proliferation index was analyzed by ModFit LTTM version 3.1
(Verity Software House).
Fluorescence-activated cell sorting analysis
The following primary antibodies were used to detect expanded SDSC surface immunophenotype
profiles: CD29 (Abcam, Cambridge, MA), CD90 (BD Pharmingen, San Jose, CA), CD105
(BioLegend, San Diego, CA), stage-specific embryonic antigen 4 (SSEA4) (BioLegend) and
isotype- matched IgGs (Beckman Coulter, Fullerton, CA). The secondary antibody was goat antimouse IgG (H + L) R-phycoerythrin conjugated (Life Technologies). Samples (n = 3) of each 2 ×
5

10 expanded cells were incubated on ice in cold PBS containing 0.1% Chrom-Pure Human IgG

1

whole molecule (Jackson ImmunoR- esearch Laboratories, West Grove, PA) and 1% NaN3
(Sigma) for 30 min. The cells were then sequentially incubated in the dark in the primary and
secondary antibodies for 30 min. Fluorescence was analyzed by a FACS Calibur (BD
Biosciences) using FCS Express software package (De Novo Software, Los Angeles, CA).
Chondrogenic differentiation of SDSCs
6

Expanded SDSCs (0.3 × 10 ) from each pretreatment group were centrifuged at 500 × g for 5 min
in a 15-mL polypropylene tube to form a pellet. After overnight incubation, the pellets were
cultured in a serum-free chondrogenic medium consisting of high-glucose DMEM, 40 µg/mL
proline, 100 nM dexamethasone, 100 U/mL penicillin, 100 µg/mL streptomycin, 0.1 mM ascorbic
acid-2-phosphate, and 1 × ITS™ Premix (6.25 µg/mL insulin, 6.25 µg/mL transferrin, 6.25 µg/mL
selenous acid, 5.35 µg/mL linoleic acid and 1.25 µg/mL bovine serum albumin, from BD
Biosciences, Bedford, MA) with the supplementation of 10 ng/mL transforming growth factor
beta3 (TGF-β3, PeproTech Inc., Rocky Hill, NJ) in 5% O2 incubator as long as 35 days. At days
0, 14, and 35, pellets from each group were collected for evaluation of chondrogenesis.
Immunofluorescent staining of DECMs
Decellularized ECMs were fixed with 4% paraformaldehyde for 30 min. After blocking in 10%
normal goat serum for 1 h, ECMs were incubated with monoclonal antibody for type I collagen
(Sigma), fibronectin (Santa Cruz Biotechnology, Dallas, TX), or laminin (Santa Cruz
Biotechnology) overnight followed by Alexa Fluor 488 goat anti-mouse IgG (Life Technologies) for
30 min. DECMs were visualized with a Zeiss LSM 510 confocal on an AxioImager Z1 microscope
using a 63 × objective lens (Carl Zeiss, Jena, Germany).
Adipogeneic differentiation and detection of SDSCs
Expanded cells were cultured for 21 days in adipogenic medium (growth medium supplemented
with 1 mM dexamethasone, 0.5 mM isobutyl-1-methyxanthine, 200 mM indomethacin, and 10 mM
insulin). The cultures (n = 3) were fixed in 4% paraformaldehyde and stained with a 0.6% (w/v)
Oil Red O (ORO) solution (60% isopropanol, 40% water) for 15 min. Intracellular lipid-filled
droplet-bound staining was photographed under a Nikon TE300 phase-contrast microscope
(Nikon, Tokyo, Japan).
Osteogenic differentiation and detection of SDSCs
Expanded cells (n = 3) cultured for 21 days in osteogenic medium (growth medium supplemented
with 0.1 mM dexamethasone, 10 mM β-glycerol phosphate, 50 mM ascorbate-2-phosphate, and
0.01 mM 1,25-dihydroxyvitamin D3) were collected for alkaline phosphatase (ALP) activity assay
with a reagent kit (Sigma) by measuring the formation of p-nitrophenol (p-NP) from p-nitro-phenyl

2

phosphate following the manufacturer’s instructions. p-NP was quantified based on the
spectrophotometric absorbance at 405 nm, and enzymatic activity was expressed as millimoles of
p-NP/min/mg DNA. For evaluation of calcium deposition, induced cells (n = 3) were fixed with
70% ice-cold ethanol for 1 h, and then incubated in 40 mM Alizarin Red S (ARS) at pH 4.2 for 20
min with agitation. After rinsing, matrix mineral-bound staining was photographed. Quantification
of staining was performed by incubating cells with a solution of 10% acetic acid and 20%
methanol for 15 min to extract the calcium-chelated ARS stain. Samples were analyzed for
absorption at 450 nm, which was normalized to total DNA amount for standardization.
Histochemistry and immunostaining
Representitive pellets (n=2) were fixed in 4% paraformaldehyde at 4°C overnight, followed by
dehydrating in a gradient ethanol series, clearing with xylene, and embedding in paraffin blocks.
5-µm sections were histochemically stained with Alcian blue (Sigma, counterstained with fast red)
and Safranin O (Sigma, counterstained with hematoxylin) for sulfated glycosaminoglycans (GAG).
For immunostaining, the sections were immunolabeled with primary antibodies against collagen II
(II-II6B3, DSHB, Iowa City, IA), collagen I (Abcam, Cambridge, MA., USA), and collagen X
(Sigma), followed by the secondary antibody of biotinylated horse anti-mouse IgG or IgM (Vector,
Burlingame, CA., USA). Immunoactivity was detected using Vectastain ABC reagent (Vector) with
3, 3’-diaminobenzidine as a substrate.
Biochemical analysis for DNA and GAG content
The pellets (n=4) were digested for 4 h at 60°C with 125 µg/mL papain in PBE buffer (100 mM
phosphate, 10 mM EDTA, pH 6.5) containing 10 mM cysteine. To quantify cell density, the
amount of DNA in the papain digestion was measured using the QuantiT™ PicoGreen® dsDNA
assay kit (Invitrogen) with a CytoFluor® Series 4000 (Applied Biosystems, Foster City, CA). GAG
was measured using dimethylmethylene blue dye and a Spectronic™ BioMate™ 3
Spectrophotometer (Thermo Scientific, Milford, MA) with bovine chondroitin sulfate (Sigma) as a
standard.
Real-time polymerase chain reaction (PCR)
Total RNA was extracted from samples (n=4) using an RNase-free pestle in TRIzol® (Invitrogen).
2 µg of mRNA was used for reverse transcriptase (RT) with High-Capacity cDNA Archive Kit
(Applied Biosystems) at 37ºC for 120 min. Chondrogenic marker genes [collagens II (Assay ID
Hs00156568_m1), SRY (sex determining region Y)-box 9 (SOX9)	
   (Assay ID Hs00165814_m1),
and aggrecan(ACAN)	
   (Assay ID AIQJAP5) and hypertrophic marker genes (collagen X) (Assay
ID Hs00166657_m1)] were customized by Applied Biosystems as part of the Custom Taqman®
Gene Expression Assays. Eukaryotic 18S rRNA (Assay ID HS99999901_s1 ABI) was carried out

3

as the endogenous control gene. Real-time PCR was performed with the iCycler iQ™ Multi Color
RT-PCR Detection and calculated by computer software (Perkin-Elmer, Wellesley, MA). Relative
transcript levels were calculated as χ=2

-∆∆Ct

, in which ∆∆Ct=∆E-∆C, ∆E=Ctexp-Ct18s, and ∆C=Ctct1-

Ct18s.
Atomic force microscopy (AFM)
Elasticity of decellularized ECMs and expanded cells was investigated using an MFP-3D-BIO
AFM (Asylum Research, TE2000- U, Santa Barbara, CA) integrated with an inverted fluorescence
microscope (Nikon Eclipse, TieU, Nikon Instruments Inc., Melville, NY) and Olympus TR400-PB
cantilevers with spring constant of 0.09 N/m. The samples were imaged in Petri dishes filled with
aMEM containing 10% FBS. The location of the cantilever on the sample was confirmed using a
10 microscopy objective; each sample was mapped in five randomly selected 50 mm by 50 mm
areas for a total of 2000 data points/sample. For the quantitative nanomechanical analysis, a
Sneddon’s modification of the Hertz model developed for a four-sided pyramid was employed.
The ECM and cell elasticity (Young’s modulus, E) were corrected with the indentation of the tip, d,
2

2

through the following equation: E = π/2 ! (1 - ν F)/tanαδ , where E is the Elastic modulus, ν is
Poisson’s ratio with a value of 0.5 for ECM and cells, F is the force given by the cantilever
deflection multiplied with the cantilever spring constant (0.09 N/m), a is the open angle used in
this study which had a value of 36 º, and lastly δ is the indentation depth.
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Scanning electron microscope (SEM)
Representative samples (n = 2) were primarily fixed in 2.5% glutaraldehyde (Sigma) for 2 h,
followed by secondary fixation in 2% osmium tetroxide (Sigma) for another 2 h. The samples
were then dehydrated in a gradient ethanol series, in hexamethyldisila- zane (HMDS, Sigma) at a
ratio of 1:1 with ethanol twice for 1 h each time, in HMDS at a ratio of 1:2 with ethanol overnight,
and in HMDS three times for 4 h each time. The samples were air-dried for 24 h and gold sputter
was added. The images were recorded by an SEM (Hitachi, Model S 2400).
Statistics
Kruskal-Wallis test was used to determine significant differences among all groups and the MannWhitney U test was used to determine differences when there were only two groups in
biochemistry analysis and real-time PCR data. All statistical analyses were performed with SPSS
13.0 statistical software (SPSS Inc., Chicago, IL). P values less than 0.05 were considered
statistically significant.
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RESULTS
Evaluation of proliferative capacity and MSC surface marker expression on DECMs expanded
SDSCs
To evaluate the proliferative effect exerted by DECMs, human SDSCs were seeded on five
different substrates. After one passage expansion on plastic flasks or DECMs, the embedded
cells exhibited a flattened and irregular shape with enlarged size (characteristic of aged cells) in
Plastic groups (PL) and a glistening spindle shape in all DECM groups (SE, AE, DE and UE).
Compared to the random distribution of cells plated on Plastic, DECM-expanded cells were more
organized (Figure 4.1A). Compared to that in the PL group, after 8-day-expansion cell number
increased 1.08-fold in the SE group, 5-fold in the DE, 6-fold in the AE and 11-fold in the UE group
(Figure 4.1a). Proliferation index results also suggested the same trend (Figure 4.1B and 4.1b).
Median fluorescence intensity (MFI) of MSCs surface marker including CD29, CD90 and CD105
were significantly decreased especially in DE, UE and AE, despite the percentages of positive
staining was the same. SSEA-4 expression was also higher in all four DECMs expanded SDSC
groups than SDSC from PL group (Figure 4.1C and 4.1c).
Evaluation of DECMs and expanded SDSC ultra-morphology, elasticity and composition on
different culture substrates
Scanning electron microscopy was employed to observe the fine cell and matrix morphology
during expansion on different substrates. SDSC expanded on PL exhibited enlarged, well spread
and flatten shape; in contrast, SDSCs expanded on DECMs groups (especially DE, UE and AE)
were less spread and embedded in the matrix, with an elongated and spindle fibroblast like shape
(Figure 4.2A). Compared to a fiber-like surface appearance in DE, AE and SE, UE exhibited a
smoother appearance, indicative of fine matrix fibers.
To characterize DECMs physically, we analyzed the elasticity properties of DECMs alone and
elasticity of SDSCs expanded on these DECMs. The elasticity of plastic flasks is considered
infinite. Compared to SE, AE [25.65 ± 9.38 versus 61.82 ± 35.86 (kPa)] and UE [21.41 ± 11.3
versus 61.82 ± 35.86 (kPa)] have lower elasticity; accordingly SDSCs seeded on these DECMs
also have lower elasticity than SDSCs on SE [3.29 ± 1.42 versus 3.58 ± 1.94] [1.9 ± 1.15 versus
3.58 ± 1.94]. However, DE has highest elasticity among all DECMs (88.29 ± 49.9 kPa) and
SDSCs expanded on DE also have higher elasticity than SDSCs on SE [4.87 ± 2.16 versus 3.58
± 1.94] though lower than PL [4.87 ± 2.16 versus 9.07 ± 4.56] (Figure 4.2B).
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Three main common components of ECM were immunostained to probe the composition of
DECM-derived from different cell sources (Figure 4.2C). Both fibronectin and collagen I but not
laminin were detected (data not shown).
Evaluation of DECM-mediated SDSC chondrogenic capacity
To determine the rejuvenating effects of DECMs on SDSC chondrogenic potential, expanded
SDSC were chondrogenically induced for up to 35 days. The evaluation of chondrogenesis
consisted of biochemical, histological and real-time PCR for chondrogenic markers.
As shown in Figure 4.3A, chondrogenic index (ratio of GAG to DNA) of PL expanded pellet is the
highest among all groups. After 14-day differentiation, all four DECM-treated SDSCs yielded
pellets with higher GAG content than PL expanded SDSCs; however, only pellets from the DE
had the highest chondrogenic index among all groups (Figure 4.3B). At day 35, all pellets from
DECM groups had a higher DNA content suggesting higher cell viability, and higher chondrogenic
index than pellets in the PL group, especially for pellets from the UE and AE groups, which had
the highest chondrogenic index, followed by DE and SE (Figure 4.3C). Consistent with
biochemistry data, day 35 pellets from all DECM groups had bigger size compared to the PL
group, especially pellets from the AE, DE and UE groups were larger than the SE group. Among
the four DECM groups, pellets from the UE group had the biggest size. Sulfated GAGs stained by
alcian blue and safarnin O and immunostaining for collagens II also suggested the strongest
staining in pellets from SDSCs expanded in the UE groups, followed by DE, AE and SE (Figure
4.4). Chondrogenic marker genes (SOX9, ACAN, COL2A1) expression was highest in UE at day
14 and highest in DE, followed by AE, UE and SE at day 35 (Figure 4.5A). Interestingly, the
hypertrophic marker COL1A1 and COL10A1 were also highly expressed in DE (Figure 4.5B).
Evaluation of DECM-expanded SDSC adipogenic and osteogenic potentials
To determine the rejuvenation effect of DECM expansion on SDSC, expanded SDSC were
induced in adipogenic or osteogenic medium for 21 days. Our adipogenic induction data showed
that all DECM expanded SDSC exhibited comparable level of positive staining for ORO. The AE
expanded SDSC showed the highest adipogenesis among all groups though no significant
difference was observed (Figure 4.6A). Osteogenic induction data showed that expanded SDSC
from all substrates stained positive and comparable level for ALP except UE groups being the
highest. However, the ARS staining for calcium deposition as later stage osteogenic marker and
quantitative assessment showed low level of positive staining and calcium but not significant in
DE and AE expanded SDSCs (Figure 4.6B).
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DISCUSSION
Large quantity and high quality of cells is urgently needed for successful cartilage regeneration.
Our previous studies have indicated that decellularized extracellular matrix (DECM) deposited by
stem cells especially the tissue-specific synovium-derived stem cells (SDSCs) for chondrogenesis
could serve as expansion substrates for promoting proliferative and chondrogenic potentials.
Recently, adipose, urine-derived mesenchymal stem cells (MSCs) and dermal fibroblasts and
their deposited matrixes have been intensively studied in regenerative medicine due to their
availability. However, whether these more accessible autologous stem cells deposited matrix
could exhibit same or even better effect than SDSC-derived DECM in terms of enhancing SDSC
stemness is not known. In this study, we successfully deposited DECMs using MSCs from
synovium, adipose and urine and dermal fibroblasts. We demonstrated that DECMs derived from
these sources could significantly enhance not only proliferative but also chondrogenic potentials
without concomitant adipogenic and osteogenic potentials of the recellularized SDSCs. The
evaluation of microstructure and elasticity of the DECMs and cells suggested that the optimized
DECMs could maintain stem cell function and rejuvenate the SDSC stemness.
Currently, the decellularization of tissue or organ has been widely shown to be an attractive
scaffold for tissue engineering. However, the potential risks of pathogen transmission and the
provocation of undesirable inflammatory and immunological reactions could rise during the
application of xenogenic or allogenic decellularized matrix and lead to negative outcomes for the
regenerated tissues and organs. Autologous subcutaneous adipose tissue depots a potential
source of adult or somatic stem cells. Within the increase incidence of obesity in the United
States and abroad, subcutaneous adipose tissue is abundant and readily accessible.

15

Approximately 400,000 liposuction surgeries are performed in the United States each year.

16

These procedures yield anywhere from 100 mL to >3 L of lipoaspirate tissue, which is routinely
discarded.

16

Within these tissue, up to 300-fold more stem cells can be obtained from 100 g of

adipose tissue compared to 100 mL of bone marrow aspirate.

17;18

Application of human adipose-

derived stem cells (ASCs) and decellularized adipose tissue have been intensively investigated in
recent years. The mutlipotent ASCs were investigated for their potentials to become adipocyte,
cardiomyocyte, chondrocyte, endothelial cell, myocyte, neuronal-like cell, osteoblasts etc. as
recently reviewed.

19;20

Flynn et al. showed that decellularized adipose tissue can enhance

adipogenesis in human ASCs.

21

However, the enormous potential of ASC-deposited DECM is not

fully uncovered yet. Cerqueira et al. suggested that human ASC-derived cell sheet-based
constructs could potentially treat full-thickness excisional skin wounds.

22

Infrapatellar fat pad

tissue derived ASC-deposited matrix expansion could also enhance chondrogenic potential in
porcine ASCs.

23
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Similarly, human voided urine and urine obtained from the upper urinary tract could be used to
isolate and expand stem/progenitor cells.

24;25

The urine-derived stem cells (USCs) isolated from

one single urine specimen can generate up to 100 million cells at early passage. Our recent work
showed that these nonchondrogenic USCs deposited DECM can strengthen the chondrogenic
capacity of repeated passaged bone marrow-derived stem cells.

26

Dermal fibroblasts (DFs) can

be extracted from biopsies. It is useful for obtaining cells from smaller specimens. It can
synthesize and deposit ECM components and has been widely applied in tissue engineering,
such as tendon/ligament.

27

All the above evidences suggest that sufficient numbers of these

autologous cells could be obtained from simple procedure and few specimens and used for cellbased therapy. In this study, ASC, USC and DF-deposited DECMs exhibited proliferative and
chondrogenic potential enhancing effect on the tissue-specific SDSC. This provides great
opportunity for repairing cartilage defect with patient’s own stem cells. These easily accessible
cells deposited DECM expansion system could serve as expansion system for providing enough
tissue specific cells for cell based transplantation or therapy.
The exploration of DECMs deposited by different cells is from the concept of mimicking the “stem
cell niche” in vivo. Stem cells reside within instructive and tissue-specific niches in the body,
which is a complex and controlled biochemical mixtures of soluble and insoluble factors.

28;29

It is

widely accepted that stem cells display high sensitivity to the ECM composed of complex and
well-defined nanostructures of protein fibers such as fibrillar collagens and elastins with feature
sizes (diameter and spacing). Only if we find the best microenvironment, we can bring out the
best potentials of the stem cells. It is well known that physical properties of the substrates can
influence the MSC spreading and differentiation potentials. When cultured on stiff substrate, MSC
are well spread, with high cytoskeletal tension, and express high levels of bone cell markers.

30

In

contrast, cells on soft substrate are less spread, have low cytoskeletal tension, and become
quiescent.

31

Our study also showed similar finding. The expansion of SDSCs on the lower elastic

DECMs exhibiting a less spread morphology compared to the well spread shape SDSCs on
plastic flasks. The maintained or enhanced stemness were demonstrated by higher proliferation
and chondrogenesis after induction for 35 days in SDSCs expansion on DECM groups. The
higher expression of COL10A1 as a hypertrophic marker in DE also corroborated the higher
elasticity of DE.
Other than substrate elasticity, cell shape has also been known to regulate human MSCs lineage
commitment.

32

Kim et al. fabricated the nanogrooves with different widths and spacing to study

the adhesion, migration and differentiation response of human MSCs. Interestingly, the
proliferation is not influenced but the osteogenic and neurogenic potentials were enhanced at the
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1:3 spacing ratio rather than 1:1 or 1:5 spacing ratio, suggesting an existence of potentially
optimized nanotographical density for stem cell function.

33

The interplay between matrix elasticity

and cell shape has been revealed by a recent study. It indicated that cells cultured on 1000 µm

2

circles, squares, and rectangles tend to commit to primarily adipogenic and osteogenic lineage
2

regardless of matrix elasticity, while cell cultured on 2500 and 5000 µm shapes more heavily
depend on shape and elasticity for lineage specification.

34

Similarly, we also observed that SDSC

expanded on DE, AE and UE exhibiting a more spindle and enlongated shape compared to
enlarged shape of SDSC expanded on SE and PL. Correspondently, we also observed higher
proliferative and chondrogenic potentials in the DE, AE and UE expanded SDSCs than SE and
PL groups. Since there has been no studies correlated the specific cell shape, matrix elasticity
with chondrogenic potential, the further investigation is on the way.
The future direction of this study is that the fully characterization of DECMs with biochemical
methods. Although our immunofluorescence data suggested that all these DECMs contained
collagen I and fibronectin (two of the most common components in the ECMs), we cannot
exclude that differences among these DECMs existed since they are deposited by different cells.
Consistently, Lu et al. investigated the ECM scaffolds prepared by autologous chondrocytes,
MSC and dermal fibroblasts also showed differences among them.

35

However, not only the

composition but also the quantification of these components within the ECMs matters since a
subtle difference might provide important cues for proliferation and differentiation of cells in vivo
and in vitro.
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FIGURE LEGENDS
Figure 4.1 DECMs expansion enhanced SDSC proliferation. SDSCs were expanded on five
different substrates, including plastic flasks (PL), SECM (SE), AECM (AE), DECM (DE) and
UECM (UE) for one passage (A). Cell number was counted (a). Proliferation index in expanded
SDSCs was analyzed by flow cytometry (B and b). Histogram (C) and the quantification of
percentage and median fluorescence intensity of positive MSC surface markers including CD90,
CD29, CD105 and SSEA-4 were analyze by flow cytometry (c).
Figure 4.2 Cell and DECMs morphology was observed by scanning electron microscopy (A).
Elasticity of SDSCs during expansion and matrix alone was analyzed by atomic force microscopy
(B). Immunofluorescent staining of collagen I and fibronectin was used to characterize the
components of DECMs (C).
Figure 4.3 Biochemical analysis of sulfated GAG and DNA content in expanded SDSC after
chondrogenic differentiation for up to 35 days. (A) Chondrogenic index in day 0 pellets. (B and C)
DNA and GAG content was analyzed in day 14 and day 35 pellets from expanded SDSCs.
Chondrogenic index was calculated as ratio of GAG to DNA.
Figure 4.4 Histological staining and immunostaining for chondrogenic differentiation markers in
day 35 pellets of SDSC after expansion. Alcian blue (AB) and Safranin O (SO) were used to stain
sulfated GAGs and immunohistochemistry staining (IHC) was used to stain collagen II, I and X.
Figure 4.5 Real-time PCR was employed to detect the chondrogenic and hypertrophic marker
gene expression. Chondrogenic marker genes (SOX9, ACAN, COL II) (A) and hypertrophic
marker gene (COL I and X) (B) was detected in both day 14 and 35 pellets.
Figure 4.6 Adipogenic and osteogenic potential was analyzed in expanded SDSCs after
induction for 21 days. Oil Red O staining (ORO) was used to evaluate the adipogenesis. Alkaine
phosphatase (ALP) staining as well as Alizarin Red staining (ARS) was applied to evaluate the
osteogenesis (A). Quantification of ORO, ALP activity and extracellular calcium assay was also
evaluated.
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ABSTRACT
Our aim was to assess the feasibility of the sequential application of extracellular matrix (ECM)
and low oxygen to enhance chondrogenesis in human fetal synovium-derived stem cells
(hfSDSCs). Human fetal synovial fibroblasts (hfSFs) were characterized and found to include
hfSDSCs, as evidenced by their multi-differentiation capacity and the surface phenotype markers
typical of mesenchymal stem cells. Passage-7 hfSFs were plated on either conventional plastic
flasks (P) or ECM deposited by hfSFs (E) for one passage. Passage-8 hfSFs were then reseeded
for an additional passage on either P or E. The pellets from expanded hfSFs were incubated in a
serum-free chondrogenic medium supplemented with 10 ng/ml transforming growth factor-β3
under either normoxia (21% O2; 21) or hypoxia (5% O2; 5) for 14 days. Pellets were collected for
evaluation of the treatments (EE21, EE5, EP21, EP5, PE21, PE5, PP21, and PP5) on expanded
hfSF chondrogenesis by using histology, immunostaining, biochemistry, and real-time
polymerase chain reaction. Our data suggest that, compared with seeding on conventional plastic
flasks, hfSFs expanded on ECM exhibit a lower expression of senescence-associated βgalactosidase and an enhanced level of stage-specific embryonic antigen-4. ECM-expanded
hfSFs also show increased cell numbers and an enhanced chondrogenic potential. Low oxygen
(5% O2) during pellet culture enhances hfSF chondrogenesis. Thus, we demonstrate, for the first
time, the presence of stem cells in hfSFs, and that modulation of the in vitro microenvironment
can enhance hfSDSC chondrogenesis. hfSDSCs might represent a promising cell source for
cartilage tissue engineering and regeneration.
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INTRODUCTION
Cartilage defects are a common feature of joint diseases. Despite progress in orthopaedic
1

surgery, the avascular nature of cartilage renders cartilage defect repair challenging . The
application of mesenchymal stem cell (MSC)-based tissue engineering has provided a new and
exciting opportunity for cartilage repair and regeneration. As a tissue-specific MSC for
2-5

chondrogenesis ,

synovium-derived

stem

cells

(SDSCs),

contained

amongst

synovial

fibroblasts, are a promising source of stem cells for cartilage tissue engineering and
6-9

regeneration . However, adult MSCs have less plasticity and limited proliferation capacity. Adult
MSCs cultured in vitro lack telomerase activity

10-11

, resulting in telomere shortening with serial

12

passaging . In contrast, fetal MSCs have longer telomeres and higher telomerase activity than
13

adult MSCs , indicating that this stem cell source is preferable for tissue engineering and
regeneration. Fetal MSCs not only grow more rapidly with more population doublings

14-15

, but also

express pluripotency markers, such as Oct-4, Nanog, and stage-specific embryonic antigen-4
(SSEA-4)

13,16

. Fetal MSCs from umbilical cord blood have demonstrated multilineage potential,

including chondrogenic differentiation

16-21

. Therefore, the application of fetal MSCs might meet

the tremendous demand of patients suffering from cartilage defects.
Like other MSCs, SDSCs tend to become senescent during ex vivo monolayer expansion. Our
recent studies have suggested that extracellular matrix (ECM) deposited by porcine adult SDSCs
(paSDSCs) can serve as an in vitro three-dimensional microenvironment, facilitating paSDSC
22

propagation and allowing the restoration of cell-stemness toward chondrogenesis . However, no
studies have investigated whether human fetal synovial fibroblasts (hfSFs) contain human fetal
SDSCs (hfSDSCs). Whether ECM deposited by hfSFs can enhance hfSF chondrogenic potential
23

remains to be determined. As articular chondrocytes reside in a hypoxic environment , low
oxygen tension has been assumed to benefit expanded hfSF chondrogenic differentiation in a
pellet culture system. In this study, we have hypothesized that hfSFs include hfSDSCs, and that
the sequential application of ECM for cell expansion and low oxygen for expanded cell
differentiation can enhance hfSDSC chondrogenesis. Our long-term goal is to promote hfSDSCbased cartilage tissue engineering and regeneration.

22

MATERIALS AND METHODS
Characterization of hfSF multilineage differentiation capacity
hfSFs were obtained from ScienCell Research Laboratories (catalog number: 4700; Carlsbad,
Calif., USA) and characterized for multilineage differentiation capacity. Briefly, hfSFs were plated
in growth medium [αMEM containing 10% fetal bovine serum (FBS), 100 U/ml penicillin, 100
µg/ml streptomycin, and 0.25 µg/ml fungizone] until 90% confluence. For adipogenesis, the
medium was switched to adipogenic medium consisting of growth medium supplemented with 1
µM dexamethasone, 0.5 mM isobutyl-1-methyxanthine (IBMX), 200 µM indomethacin, and 10 µM
insulin for an additional 14 days. Adipogenic differentiation was assessed by using Oil Red O
22

staining for adipocytes . For osteogenesis, the medium was switched to osteogenic medium
consisting of growth medium supplemented with 0.1 µM dexamethasone, 10 mM β-glycerol
phosphate, 50 µM L-ascorbic acid phosphate, and 0.01 µM 1,25-dihydroxyvitamin D3 for an
additional 14 days. Osteogenic differentiation was assessed by using alkaline phosphatase
staining for bioactivity 24 (Kroeze et al. 2011). Cells incubated in growth medium served as a
control. For chondrogenesis, hfSFs were incubated in a pellet culture system supplemented with
a serum-free chondrogenic medium for 14 days. Chondrogenic differentiation was assessed by
using immunostaining for collagen II and Alcian blue staining for sulfated glycosaminoglycans
(GAGs); the detailed protocol is described below.
Preparation of hfSF-derived ECM
25

hfSFs were used to prepare ECM according to our published method . Briefly, conventional
plastic flasks were precoated with 0.2% gelatin (Sigma, St. Louis, Mo., USA) at 37°C for 1 h and
seeded with hfSFs. After cells reached 90% confluence, 50 µM L-ascorbic acid phosphate was
added for 8 days. The deposited ECM was incubated with 0.5% Triton X-100 containing 20 mM
ammonium hydroxide at 37°C for 5 min to remove the cells and then stored until use at 4°C in
phosphate-buffered saline (PBS) containing 100 U/ml penicillin, 100 µg/ml streptomycin, and 0.25
µg/ml fungizone.
ECM-mediated hfSF expansion
2

Passage 7 hfSFs (3000 cells per cm ) were plated in growth medium in either ECM-coated flasks
(ECM; E) or conventional plastic flasks (plastic; P) for one passage. Passage 8 hfSFs were then
reseeded for an additional passage in either E or P. This gave four pretreatment groups in total :
EE, EP, PE, and PP. The medium was replaced every 3 days.
Flow cytometry assay
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6

Triple individual samples of 0.3×10 cells each were incubated on ice in PBS containing 0.1%
ChromPure Human IgG (Jackson Immuno Research, West Grove, Pa., USA) and 1% NaN3 for
30 min. Primary monoclonal antibodies (fluorescein-isothiocyanate-conjugated) were applied for
30 min, including CD29 (catalog number: ab21845; Abcam, Cambridge, Mass., USA), CD90
(catalog number: 555595; BD Pharmingen, San Jose, Calif., USA), CD105 (catalog number:
312403; Biolegend, San Diego, Calif., USA), the SSEA-4 (catalog number: 330409; Biolegend),
and isotype-matched IgGs (Beckman Coulter, Fullerton, Calif., USA). After being washed with
cold PBS, hfSFs were fixed in 300 µl 0.4% paraformaldehyde. Cells were analyzed on a BD dual
laser FACSCalibur (BD Biosciences, San Jose, Calif., USA) by using FCS Express Version 3 (De
Novo Software, Los Angeles, Calif., USA) software package.
Senescence β-galactosidase staining
The Senescence β-galactosidase Staining Kit (Cell Signaling Technology, Mississauga, ON,
Canada; catalog number: 9860) was used to detect senescence-associated β-galactosidase
activity in expanded hfSFs according to the manufacturer’s protocol. Briefly, hfSFs expanded on
either ECM or plastic were fixed in 2% formaldehyde/0.2% glutaraldehyde. After being rinsed,
they were incubated in the staining solution [5 mM potassium ferrocyanide, 5 mM potassium
ferricyanide, 1 mg X-gal in N-N- dimethylformamide, 40 mM citric acid/sodium phosphate (pH 6),
0.15 M NaCl, and 2 mM MgCl2] at 37°C for 48 h. Development of a cytoplasmic blue color was
visualized under a phase-contrast microscope.
Chondrogenic differentiation of expanded hfSFs
6

Expanded hfSFs (0.3×10 ) from each pretreatment group were centrifuged at 500g for 5 min in a
15-ml polypropylene tube to form a pellet. After overnight incubation (day 0), the pellets were
cultured in a serum-free chondrogenic medium consisting of high-glucose DMEM, 40 µg/ml
proline, 100 nM dexamethasone, 100 U/ml penicillin, 100 µg/ml streptomycin, 0.1 mM L-ascorbic
acid phosphate, and 1× ITS Premix (6.25 µg/ml insulin, 6.25 µg/ml transferrin, 6.25 µg/ml
selenous acid, 5.35 µg/ml linoleic acid, and 1.25 µg/ml bovine serum albumin; BD Biosciences,
Bedford, Mass., USA) with supplementation of 10 ng/ml transforming growth factor beta3 (TGFβ3; PeproTech, Rocky Hill, N.J., USA) for 14 days. The pellets were incubated under either
normoxic (21% O2; 21) or hypoxic (5% O2; 5) conditions for 14 days. This gave a total of eight
treatment groups: EE21, EE5, EP21, EP5, PE21, PE5, PP21, and PP5. The pellets were
collected for evaluation of the effect of ECM and/or hypoxia on expanded hfSF chondrogenesis.
Histochemistry and immunohistochemistry
7-9

The protocols for histochemistry and immunochemistry were as given in Pei et al. . Pellets (n=2)
were fixed in 4% paraformaldehyde at 4°C overnight, followed by dehydrating in a gradient
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ethanol series, clearing with xylene, and embedding in paraffin blocks. Sections (5 µm thick) were
histochemically stained with Alcian blue for sulfated GAGs. For immunohistochemical analysis,
the sections were immunolabeled with primary antibodies against collagen I (Abcam) and
collagen II (II-II6B3; DSHB, Iowa City, Iowa, USA), followed by the secondary antibody
(biotinylated horse anti-mouse IgG; Vector, Burlingame, Calif., USA). Immunoactivity was
detected by using Vectastain ABC reagent (Vector) with 3,3’-diaminobenzidine as a substrate.
Biochemical analysis for DNA and GAG content
Pellets (n=6) were digested for 4 h at 60°C with 125 µg/ml papain in PBE buffer (100 mM
phosphate, 10 mM EDTA, pH 6.5) containing 10 mM cysteine, by using 200 µl enzyme per
sample. The amount of DNA per pellet was measured by using the QuantiT PicoGreen dsDNA
assay kit (Invitrogen, Carlsbad, Calif., USA) with a CytoFluor Series 4000 (Applied Biosystems,
Foster City, Calif., USA). The amount of GAG per pellet was measured by using
dimethylmethylene blue dye and a Spectronic BioMate 3 Spectrophotometer (Thermo Scientific,
Milford, Mass., USA) with bovine chondroitin sulfate as a standard.
Real-time polymerase chain reaction
Total RNA was extracted from pellets (n=4) by using RNase-free pestles in TRIzol (Invitrogen).
Samples of 1 µg mRNA were used for reverse transcriptase (RT) with the High-Capacity cDNA
Archive Kit (Applied Biosystems) at 37°C for 120 min. Chondrogenic marker genes [collagen II
(Assay ID Hs00156568_m1), aggrecan (Assay ID AIQJAP5), and SRY (sex determining region
Y)-box 9 (Sox9; Assay ID Hs00165814_m1)] and a hypertrophic marker gene [collagen X (Assay
ID Hs00166657_m1)] were customized by Applied Biosystems as part of their Custom TaqMan
Gene Expression Assays. Eukaryotic 18S RNA (Assay ID HS99999901_s1 ABI) was employed
as the endogenous control gene. Real-time polymerase chain reaction (PCR) was performed with
the iCycler iQ™ Multi Color RT-PCR Detection System and calculated by computer software
(Perkin-Elmer, Wellesley, Mass., USA). Relative transcript levels were calculated as χ=2

-ΔΔCt

, in

which ΔΔCt=ΔE-ΔC, ΔE=Ctexp-Ct18s, and ΔC=Ctct1-Ct18s.
Statistics
The Mann-Whitney U test was used to determine differences when there were only two groups
for comparison in the biochemistry analysis and real-time PCR data. All statistical analyses were
performed with SPSS 13.0 statistical software (SPSS, Chicago, Ill., USA). P values less than 0.05
were considered to indicate statistical significance.
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RESULTS AND DISCUSSION
hfSFs exhibited mesenchymal stem cell properties
To determine whether hfSFs included hSDSCs, hfSFs were characterized for their multilineage
differentiation capacity (Fig. 5.1a-f). After incubation in an adipogenic medium, hfSFs were
intensively stained with Oil Red O suggesting their adipogenic differentiation. Following
incubation in an osteogenic medium, hfSFs were positively stained with alkaline phosphatase
indicating their osteogenic potential. After incubation in a serum-free chondrogenic medium, hfSF
pellets were intensively stained with sulfated GAGs and collagen II indicative of their
chondrogenic differentiation. hfSFs were also characterized for MSC surface phenotype markers
by using flow cytometry (Fig. 5.1g-i). A high percentage of expression of CD29 (99.4%), CD90
(99.6%), and CD105 (96.5%) was recorded in hfSFs. For the first time, our data provide evidence
supporting the idea that hfSFs include stem cells (referred to as hfSDSCs); we have previously
8

found stem cells in adult synovial fibroblasts .
ECM-expanded hfSFs exhibited “anti-senescence” and enhanced “stemness”
To identify whether ECM could prevent senescence in expanded hfSFs and enhance their
chondrogenic potential, hfSFs were expanded for two passages on PP, PE, EP, or EE.
Compared with expansion on P during the last passage (PP and EP), hfSFs incubated on ECM
during the last passage (PE and EE) produced longer, more fibroblast-like cells (Fig. 5.2a-d).
After incubation in a serum-free chondrogenic medium for 14 days, intriguingly, the hfSF-pellet
sizes in the ECM groups (PE21, PE5, EE21, EE5) were generally larger than those in the P
groups (PP21, PP5, EP21, EP5; Fig. 5.2a-d). Our β-galactosidase data suggested that ECM
could effectively decrease expansion-associated senescence compared with that on conventional
plastic flasks (11.70±1.51% versus 37.21±0.75%, P=0.0000; Fig. 5.2e-g). In contrast, our flow
cytometry data showed that ECM could increase expanded hfSF “stemness” by up-regulation of
SSEA-4 expression (percentage: 76.2% versus 46.1%; mean fluorescence intensity: 31.9 versus
24.1, compared with conventional plastic flasks; Fig. 5.2h, i).
ECM-expanded hfSFs exhibited enhanced chodrogenic potential
In vitro expansion of fetal synovial fibroblasts was different from that of their adult counterpart.
When expanded on conventional plastic flasks, adult synovial fibroblasts easily became
senescent, as evidenced by their decreased proliferation rate and differentiation potential and
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their increased size . In contrast, hfSFs retained their fibroblast shape and smaller size for many
passages (at least nine passages in this study). We collected hfSFs from passages 2, 7, and 9
and then incubated hfSFs in a pellet culture system supplemented with a serum-free
chondrogenic medium for 14 days. We found that the chondrogenic index (GAG/DNA) was
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2.48±0.24 in pellets from passage-2 cells, 3.61±0.29 in pellets from passage-7 cells, and
12.26±0.45 for pellets from passage-9 cells (data not shown), suggesting that hfSFs maintained
excellent differentiation capabilities until at least passage 7. Therefore, hfSFs at passage 7 were
chosen for expansion and comparison after a two-passage incubation on ECM and/or plastic. Our
biochemical analysis showed that, compared with those from PP21, hfSFs from EE21
(131.82±3.43%

versus

115.98±8.12%,

P=0.0171)

and

PE21

(170.31±17.37%

versus

115.98±8.12%, P=0.0021) yielded pellets with a higher DNA ratio, and compared with those from
PP5, hfSFs from PE5 (190.20±2.05% versus 167.73±10.55%, P=0.0102) yielded pellets with a
higher DNA ratio (Fig. 5.3a). Our chondrogenic index data showed a similar trend. Compared with
those from PP21, hfSFs from EE21 (16.47±0.70 versus 12.26±0.45, P=0.0001) and PE21
(15.07±0.69 versus 12.26±0.45, P=0.0012) yielded pellets with a higher chondrogenic index, and
compared with those from PP5, hfSFs from PE5 (22.92±1.09 versus 15.82±1.12, P=0.0004)
yielded pellets with a higher chondrogenic index; the difference was not statistically significant
(16.49±0.78 versus 15.82±1.12, P=0.4232) in pellets from EE5 and PP5 (Fig. 5.3b). Taken
together, the pellets from the ECM groups exhibited a higher cell number and greater matrix
deposition contributing to their larger size.
Our histology data showed that pellets from cells with a plastic pretreatment and grown under
normoxic conditions (PP21) displayed less intensity for sulfated GAGs and collagen II staining,
even than those with pretreatment of ECM followed by plastic (EP21). The pellets from the ECM
groups (PE21, PE5, EE21, EE5) exhibited an intense distribution of sulfated GAGs (Fig. 5.3c-j)
and collagen II (Fig. 5.3c2-j2) throughout the pellets. Real-time PCR data showed that pellets
from cells with a plastic pretreatment and grown under normoxic conditions (PP21 and EP21) had
lower mRNA levels of aggrecan (Fig. 5.4a), collagen II (Fig. 5.4b), and Sox9 (Fig. 5.4c), whereas
pellets from cells with ECM pretreatment and grown under hypoxic conditions (PE5) yielded the
highest mRNA levels of aggrecan (Fig. 5.4a) and collagen II (Fig. 5.4b). The pellets from the ECM
groups had relatively comparable collagen X mRNA (Fig. 5.4d) expression compared with those
from the plastic group. Intriguingly, despite the significant difference between EE21 and EE5 with
regard to mRNA levels of aggrecan, collagen II, and Sox9, no significant difference was noted in
the chondrogenic index or for the histological staining.
Low oxygen enhanced hfSF chondrogenesis in a pellet culture system
To identify whether hypoxia enhanced expanded hfSF chondrogenesis, hfSF pellets were
incubated in a serum- free chondrogenic medium in a 5% or 21% O2 incubator for 14 days. The
pellets cultured under low oxygen were larger in size than the corresponding pellets under normal
oxygen incubation (Fig. 5.2a-d). Expanded hfSFs on plastic yielded pellets with a higher DNA
ratio when incubated under low oxygen compared with normal oxygen (PP5 versus PP21,
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P=0.0002; EP5 versus EP21, P=0.0001). Intriguingly, 5% O2 incubation failed to result in a DNA
difference in the pellets from hfSFs expanded on ECM (Fig. 5.3a). In addition, expanded hfSFs
yielded pellets with a higher chondrogenic index when incubated under low oxygen compared
with normal oxygen (PP5 versus PP21, P=0.0010; EP5 versus EP21, P=0.0000; PE5 versus
PE21, P=0.0005), except for the EE group (EE5 versus EE21, P=0.9778; Fig. 5.3b). Our
histology data showed that hfSF-pellets incubated in 5% O2 yielded intense staining of sulfated
GAGs (Fig. 5.3c-j) and collagen II (Fig. 5.3c2-j2) compared with those under normoxic conditions,
despite similar staining between EE21 and EE5; these results are in accord with our biochemistry
data and real-time PCR data, indicating that 5% O2 incubation enhances hfSF-pellet
chondrogenesis. Our real- time PCR data also suggested that plastic-expanded hfSFs yielded
pellets with a higher mRNA level of collagen X when incubated under 5% O2 instead of 21% O2.
However, this phenomenon did not apply to hfSFs expanded on ECM (Fig. 5.4d).
Our study demonstrated that low oxygen (5% O2) played a key role in hfSF chondrogenesis.
Upregulation of Sox9 mRNA (a chondrogenic transcriptional factor) in hfSF pellets treated with
low oxygen might be responsible for the enhanced mRNAs of chondrogenic marker genes, such
23

as aggrecan and collagen II. Hypoxia is a critical factor in cartilage development . Hypoxia
inducible factors (HIF) 1α and 2α are induced when cells surviving hypoxia exposure are involved
in inducing genes related to cell proliferation, apoptosis, and resistance to oxidative stress. Our
data might be explained on the basis that hypoxia and HIF-1α upregulate Sox9 expression
and subsequent chondrogenic matrix formation
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in mesenchymal cells.

Concluding remarks
To the best of our knowledge, we have demonstrated, for the first time, that (1) hfSFs include
hfSDSCs; (2) ECM deposited by hfSFs enhances hfSDSC “anti-senescence” and “stemness” and
chondrogenic potential; (3) low oxygen improves hfSDSC chondrogenesis in a pellet culture
system. The mechanism underlying the enhancement of the chondrogenic potential of the
expanded hfSDSCs by the ECM microenvironment needs to be further investigated. hfSDSCs
might provide a robust cell source for cartilage tissue engineering and regeneration.
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FIGURE LEGENDS
Figure 5.1 Characterization of multilineage differentiation capacity (a–f) and mesenchymal stem
cell properties (g–i) of human fetal synovial fibroblasts (hfSF). Adipogenic differentiation was
assessed by using Oil Red O staining for lipid droplets (a) with cells incubated in growth medium
serving as a control (b); osteogenic differentiation was assessed by using alkaline phosphatase
(ALP) staining for ALP activity (c) with cells incubated in growth medium serving as a control (d);
chondrogenic differentiation was assessed by using Alcian blue staining for sulfated
glycosaminoglycans (GAGs; e) and immunostaining for collagen II (f). Bar 800 µm. Flow
cytometry was used to characterize MSC surface phenotype markers, namely, CD29 (g), CD90
(h), and CD105 (i), in hfSFs
Figure 5.2 Effect of extracellular matrix (ECM) on hfSF expansion and anti-senescence.
Following substrate pre-treatment, hfSFs were expanded on either plastic (P) or ECM (E) for two
passages with either the same substrate (PP, a; EE, b) or a different substrate (PE, c; EP d). Cell
morphology was studied 6 days post-expansion by phase-contrast microscopy; expanded cells
were centrifuged to form pellets and cultured in a serum-free chondrogenic medium for 14 days
under either normoxia (21% O2, 21) or hypoxia (5% O2, 5). Cell senescence was evaluated by
using β-galactosidase (Beta-gal) staining (g) after expansion for 48 h on either plasitc (e) or ECM
(f). Data are shown as average ± SD for n=4; ***P<0.001 indicates a statistically significant
difference. Flow cytometry was used to determine the stage-specific embryonic antigen-4 level in
hfSFs after expansion on either ECM (h) or plastic (i)
Figure 5.3 Assessment of expanded hfSF chondrogenic differentiation at the protein level.
Biochemistry analyses were used to measure DNA and GAG contents per pellet. The DNA ratio
was used to represent cell proliferation (a) and was calculated from the DNA content at day 14
adjusted by that at day 0 to minimize the initial difference in cell amounts in pellet preparation.
The ratio of GAG to DNA at day 14 was used to represent the chondrogenic index in pellets (b).
Data are shown as average ± SD for n=6; *P<0.05, **P<0.01, ***P<0.001 indicate a statistically
significant difference. Alcian blue staining was conducted for sulfated GAGs (c-j) and
immunohistochemical staining was carried out for collagen I (c 1 -j 1 ) and collagen II (c 2 -j 2 ).
Treatments as explained in Fig. 2. Bar 800 µm
Figure 5.4 Assessment of expanded hfSF chondrogenic differentiation at the molecular level.
TaqMan real-time polymerase chain reaction was used to assess quantitatively the mRNA levels
of aggrecan (AG, a), collagen II (Col II, b), Sox9 (c), and collagen X (Col X, d) in the pellets from
expanded hfSFs at day 14. Treatments as explained in Fig. 2. Data are shown as average ± SD
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for n=4; *P<0.05, **P<0.01, ***P<0.001 indicate a statistically significant difference
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Figure 5.1
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Figure 5.2
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Figure 5.3
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Figure 5.4
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ABSTRACT
Autologous cells suffer from limited cell number and senescence during ex vivo expansion for
cartilage repair. Here we found that expansion on extracellular matrix (ECM) deposited by fetal
synovium-derived stem cells (SDSCs) (FE) was superior to ECM deposited by adult SDSCs (AE)
in promoting cell proliferation and chondrogenic potential. Unique proteins in FE might be
responsible for the rejuvenation effect of FE while advantageous proteins in AE might contribute
to differentiation more than to proliferation. Compared to AE, the lower elasticity of FE yielded
expanded adult SDSCs with lower elasticity which could be responsible for the enhancement of
chondrogenic and adipogenic differentiation. MAPK and noncanonical Wnt signals were actively
involved in ECM-mediated adult SDSC rejuvenation.
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INTRODUCTION
	
  
Cartilage regeneration is a primary focus in the tissue engineering field due to the limited
regenerative abilities of cartilage. Presently, the most effective treatment for repairing cartilage
defects is autologous chondrocyte implantation (ACI). Though this technique has developed
through generations and achieved short-term success, it is still mostly restricted by availability of
a large quantity of high quality autologous chondrocytes. Despite the fact that bone marrowderived stem cells (BMSCs) and adipose-derived stem cells (ASCs) have been investigated,
there are increasing concerns of donor site morbidity due to harvesting, chondrogenic
hypertrophy, and unstable chondrogenic phenotype [1,2]. Fortunately, mesenchymal stem cells
(MSCs) derived from synovial tissue (SDSC) are currently attractive solutions due to their
characteristic as a tissue- specific stem cell for chondrogenesis as well as the ease of harvesting
through a small punch biopsy during arthroscopic surgery [3]. However, challenges remain in
lengthened culturing time for preparing a sufficient number of such autologous cells, especially
when elderly patients are considered [4].
To optimize the application of adult stem cells, an efficient expansion system that can rejuvenate
or at least maintain the self- renewal and differentiation potentials of adult SDSCs (ASDSCs) is
urgently needed. Recent work from our laboratory suggested that decellularized extracellular
matrix (ECM) derived from 3-month- old porcine SDSCs enhanced proliferation and subsequent
chondrogenic differentiation of both stem cells [5-11] not only in vitro [12] but also in vivo [13].
Different from the above reports using young porcine cells, in clinics, patients with cartilage
defects are usually middle-aged. Adult MSCs lack telomerase activity resulting in telomere
shortening after serial passaging in vitro [14]. Studies have shown that decellularized ECM from
human adult stem cells, such as SDSCs [15] or BMSCs [16], exhibited a limited capacity to
rejuvenate expanded stem cells’ chondrogenic potential. Compared to adult MSCs, fetal MSCs
maintained longer telomeres and higher telomerase activity [17]. Further, our recent studies
demonstrated that human fetal SDSCs (FSDSCs) possessed multi-differentiation capacities,
including chondrogenesis, osteogenesis, and adipogenesis [18], suggesting SDSCs from a fetal
source could be a cell source for deposition of a decellularized ECM, which provides a young and
healthy microenvironment for ASDSC rejuvenation.
In this study, we hypothesized that ECM deposited by FSDSCs provided a better in vitro
microenvironment for ASDSC expansion and retention of chondrogenic potential. We explored
potential

mechanisms

underlying

ASDSC

rejuvenation

by

using

proteomics

and

immunofluorescent staining for chemical composition of ECM, atomic force microscopy (AFM) for
elastic modulus of both ECM and expanded ASDSCs, and Western blot for potential involvement
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of the mitogen-activated protein kinase (MAPK) and Wnt signaling pathways. We also evaluated
ECM expanded cells in adipogenic and osteogenic potentials to determine whether this
rejuvenation only favored a tissue-specific lineage.
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MATERIALS AND METHODS
DSCM preparation
Human fetal source SDSCs (FSDSCs) were obtained from Scien-Cell™, Research Laboratories
(Carlsbad, CA) and adult source SDSCs (ASDSCs) were obtained from Asterand (North America
Laboratories, Detroit, MI). Both cell types were used to prepare decellularized ECM, termed FE
and AE, respectively, as described previously [15,18]. Briefly, plastic flasks (PL) were precoated
with 0.2% gelatin (Sigma, St. Louis, MO) at 37 °C for 1 h and seeded with passage 3 SDSCs at
6000 cells per cm2. After cells reached 90% confluence, 250 mM of L-ascorbic acid phosphate
(Wako Chemicals USA Inc., Richmond, VA) was added for 10 days. The deposited ECMs were
incubated with 0.5% Triton X-100 containing 20 mM ammonium hydroxide at 37 °C for 5 min to
remove the cells; they were stored at 4 °C in phosphate-buffered saline (PBS) containing 100
U/mL penicillin, 100 mg/mL streptomycin, and 0.25 mg/mL fungizone until use.
Evaluation of cell proliferation and apoptosis
Cell counting and morphology
PL expanded passage 3 ASDSCs (PL3) were plated at 3000 cells per cm2 on FE, AE, or PL for
one passage with growth medium containing alpha-minimum essential medium (αMEM), 10%
fetal bovine serum (FBS), 100 U/mL penicillin, 100 mg/mL streptomycin, and 0.25 mg/mL
fungizone. Expanded ASDSCs were termed FE4, AE4, and PL4. Cell number was counted in 175
cm2 flasks (n = 6) using a hemocytometer. To observe cell morphology, FE4, AE4, and PL4 were
fixed in 4% paraformaldehyde; the cell membrane was labeled with Vybrant® Dil Cell-labeling
solution (Life Technologies, Grand Island, NY) and mounted with Prolong® Gold antifade reagent
with 4’,6-diamidino-2-phenylindole (DAPI) (Life Technologies). Both FE and AE were
immunostained using monoclonal antibody for type I collagen (Sigma) conjugated with fluorescein
isothiocyanate (FITC) and visualized with a Nikon TE2000-S Eclipse inverted microscope
(Melville, NY).
Proliferation index
Before cell expansion, passage 3 ASDSCs were labeled with CellVue® Claret (Sigma) at 2 × 106 M for 5 min according to the manufacturer’s protocol. After eight days, expanded cells were
collected and measured using a BD FACS Calibur™ flow cytometer (dual laser) (BD Biosciences,
San Jose, CA). Twenty thousand events of each sample were collected using CellQuest Pro
software (BD Biosciences) and cell proliferation index was analyzed by ModFit LT™ version 3.1
(Verity Software House, Topsham, ME).
Flow cytometry analysis
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The following primary antibodies were used to detect expanded SDSC surface immunophenotype
profiles: CD29 (Abcam, Cambridge, MA), CD90 (BD Pharmingen, San Jose, CA), CD105 (BioLegend, San Diego, CA), stage-specific embryonic antigen 4 (SSEA4) (BioLegend), integrin b5
(Cell Signaling, Danvers, MA), and isotype-matched IgGs (Beckman Coulter, Fullerton, CA). The
secondary antibody was goat anti-mouse IgG (H + L) R-phycoerythrin conjugated (Life
Technologies). Samples (n = 3) of each 2 × 105 expanded cells were incubated on ice in cold
PBS containing 0.1% Chrom-Pure Human IgG whole molecule (Jackson ImmunoResearch
Laboratories, West Grove, PA) and 1% NaN3 (Sigma) for 30 min. The cells were then
sequentially incubated in the dark in the primary and secondary antibodies for 30 min.
Fluorescence was analyzed by a FACS Calibur (BD Biosciences) using FCS Express software
package (De Novo Software, Los Angeles, CA).
Apoptosis assay
Apoptosis of expanded cells was detected using the Annexin V-FITC Apoptosis Detection Kit
(BioVision Inc., Milpitas, CA). Briefly, 2 × 105 detached cells from each group (n = 3) were
labeled with FITC conjugated annexin V and propidium iodide for 15 min. Samples were
measured using FACS Calibur (BD Biosciences) and analyzed using the FCS Express software
package (De Novo Software).
Resistance to oxidative stress
Expanded cells were incubated with 1 mM hydrogen peroxide (H2O2) at 37 °C for 1 h. To
measure intracellular reactive oxygen species (ROS), cells were incubated with 1 µM 2’,7’dichlorodihydrofluorescein diacetate (H2DCFDA) (Life Technologies) for 15 min. The plates were
read on a FlUOstar OPTIMA (BMG Labtech Inc., Cary, NC) with an excitation wavelength of 485
nm and emission of 530 nm. Samples were assayed in triplicate.
Cell and ECM interaction: evidence in morphology, chemistry, and elasticity
Scanning electron microscope (SEM)
Representative samples (n = 2) were primarily fixed in 2.5% glutaraldehyde (Sigma) for 2 h,
followed by secondary fixation in 2% osmium tetroxide (Sigma) for another 2 h. The samples
were then dehydrated in a gradient ethanol series, in hexamethyldisilazane (HMDS, Sigma) at a
ratio of 1:1 with ethanol twice for 1 h each time, in HMDS at a ratio of 1:2 with ethanol overnight,
and in HMDS three times for 4 h each time. The samples were air-dried for 24 h and gold sputter
was added. The images were recorded by an SEM (Hitachi, Model S 2400).
Proteomics analysis of AE and FE
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Decellularized ECMs were collected in 25 mM Tris-HCl (pH 7.6)/ 150 mM NaCl/0.5% SDS buffer
solution containing protease inhibitors. Samples were precipitated with cold acetone and the
pellet was solubilized with ProteaseMax (Promega, Madison, WI) detergent prepared in 50 mM
NH4HCO3 buffer (pH 7.9). Protein samples were reduced with dithiothreitol (DTT) at 56 °C for 45
min and alkylated with 20 mM iodoacetamide in the dark at room temperature for 0.5 h. Trypsin
digestion was performed at 37 °C overnight. Digested peptide mixtures were each separated by
high pH reversed phase chromatography on a C18 column and 40 fractions (600 mL each) were
collected and pooled into eight larger fractions due to the preliminary nature of the experiment.
Samples were concentrated under vacuum to approximately 50 mL, and 8 mL of sample was
analyzed on an LTQ-FT Ultra hybrid mass spectrometer (Thermo Fisher Scientific, San Jose,
CA). In addition, we performed chemical digestion on the remaining pellets using CNBr for 24 h.
The digests were neutralized and peptides were separated by 1D SDS-PAGE; the entire lanes
were cut and the bands subjected to trypsin digestion and tandem mass spectrometry analysis as
described

above.

Data

analysis

was

performed

as

previously

reported

(reference:

http://www.ncbi.nlm.nih.gov/pubmed/ 22897585) with the following exceptions: Spectra were
searched against human entries in the Swissprot sequence database (release 04/18/2012;
20,324 sequences), and identifications required a minimum protein confidence of >99%, two or
more unique peptides, and peptide confidence of >95%.
Immunofluorescent staining of AE and FE
Decellularized ECMs were fixed with 4% paraformaldehyde for 30 min. After blocking in 10%
normal goat serum for 1 h, ECMs were incubated with monoclonal antibody for type I collagen
(Sigma), fibronectin (Santa Cruz Biotechnology, Dallas, TX), or laminin (Santa Cruz
Biotechnology) overnight followed by Alexa Fluor 488 goat anti-mouse IgG (Life Technologies) for
30 min. ECMs were visualized with a Zeiss LSM 510 confocal on an AxioImager Z1 microscope
using a 63 objective lens (Carl Zeiss, Jena, Germany).
Atomic force microscopy (AFM)
Elasticity of decellularized ECMs and expanded cells was investigated using an MFP-3D-BIO
AFM (Asylum Research, TE2000U, Santa Barbara, CA) integrated with an inverted fluorescence
microscope (Nikon Eclipse, TieU, Nikon Instruments Inc., Melville, NY) and Olympus TR400-PB
cantilevers with spring constant of 0.09 N/m. The samples were imaged in Petri dishes filled with
αMEM containing 10% FBS. The location of the cantilever on the sample was confirmed using a
10 × microscopy objective; each sample was mapped in five randomly selected 50 µm by 50 µm
areas for a total of 2000 data points/sample. For the quantitative nanomechanical analysis, a
Sneddon’s modification of the Hertz model developed for a four-sided pyramid was employed.
The ECM and cell elasticity (Young’s modulus, E) were corrected with the indentation of the tip, δ,
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through the following equation: E = π/2 ! (1 - ν F)/tanαδ , where E is the Elastic modulus, ν is
Poisson’s ratio with a value of 0.5 for ECM and cells, F is the force given by the cantilever
deflection multiplied with the cantilever spring constant (0.09 N/m), α is the open angle used in
this study which had a value of 36°, and lastly δ is the indentation depth [19].
Chondrogenic induction and evaluation
Chondrogenic induction
5

Expanded cells (3 × 10 ) were centrifuged at 500g in a 15-mL polypropylene tube to form a pellet.
After overnight incubation (day 0), the pellets were cultured in a serum-free chondrogenic
medium consisting of high-glucose Dulbecco’s modified Eagle’s medium (DMEM), 40 mg/mL
proline, 100 nM dexamethasone, 100 U/mL penicillin, 100 mg/mL streptomycin, 0.1 mM ascorbic
acid-2-phosphate, and 1 ✕ ITS™ Premix (BD Biosciences) with the supplementation of 10 ng/mL
transforming growth factor beta3 (TGF-β3, PeproTech Inc., Rocky Hill, NJ) in a 5% O2 incubator
as long as 21 days.
Histology and immunostaining
Representative pellets (n = 2) were fixed in 4% para-formaldehyde at 4 °C overnight, followed by
dehydrating in a gradient ethanol series, clearing with xylene, and embedding in paraffin blocks.
Five-µm sections were stained with Alcian blue (counterstained with fast red) and Safranin O
(counterstained

with

hematoxylin)

for

sulfated

glycosaminoglycans

(GAGs).

For

immunohistochemistry, the sections were immunolabeled with primary antibody against type II
collagen [II-II6B3, Developmental Studies Hybridoma Bank (DSHB), Iowa City, IA], followed by
the secondary antibody of biotinylated horse anti-mouse IgG or IgM (Vector, Burlingame, CA).
Immunoactivity was detected using Vectastain ABC reagent (Vector) with 3,3’-diaminobenzidine
as a substrate.
Biochemical analysis for DNA and GAG content
Representative pellets (n = 4) were digested at 60 °C for 4 h with 125 mg/mL papain in PBE
buffer (100 mM phosphate, 10 mM ethyl-enediaminetetraacetic acid, pH 6.5) containing 10 mM
cysteine. To quantify cell density, the amount of DNA in the papain digestion was measured using
the QuantiT™ PicoGreen® dsDNA assay kit (Life Technologies) with a CytoFluor® Series 4000
(Applied Bio-systems, Foster City, CA). GAG was measured using dimethyl-methylene blue dye
and a Spectronic™ BioMate™ 3 Spectrophotometer (Thermo Fisher Scientific) with bovine
chondroitin sulfate (Sigma) as a standard.
TaqMan® real-time polymerase chain reaction (PCR)
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Total RNA was extracted from pellets (n 1⁄4 4) using an RNase-free pestle in TRIzol® (Life
Technologies). Two mg of mRNA was used for reverse transcriptase with the High-Capacity
cDNA Archive Kit (Applied Biosystems) at 37 °C for 120 min. Chondrogenic marker genes [SRY
(sex determining region Y)-box 9 (SOX9) (Assay ID Hs00165814_m1), aggrecan (ACAN) (Assay
ID AIQJAP5), and type II collagen (COL2A1) (Assay ID Hs00156568_m1)] were customized by
Applied Biosystems as part of their Custom TaqMan® Gene Expression Assays. Eukaryotic 18S
rRNA (Assay ID HS99999901_s1 ABI) was carried out as the endogenous control gene. Realtime PCR was performed with the iCycler iQ™ Multi Color RT-PCR Detection and calculated by
computer software (PerkineElmer, Wellesley, MA). Relative transcript levels were calculated as χ
=2

-ΔΔCt

, in which ΔΔCt = ΔE – ΔC, ΔE = Ctexp – Ct18s, and ΔC = CtCt1 – Ct18s.

Biomechanical testing
Representative pellets (n = 6) were placed into a reservoir filled with PBS and loaded onto the
custom miniature stepper motor driven compression device. This device used a 10 g load cell and
a miniature differential variable reluctance transducer (DVRT) for displacement readout. A small
preload of 0.0001 N was applied followed by a 10% strain at 1s duration. From the linear portion
of the load displacement curve, the Stiffness and Young’s modulus (YMOD) were calculated for
the spherical shaped pellet according to Rodriguez et al. [20].
Potential mechanisms underlying ECM-based cell expansion and subsequent chondrogenic
differentiation
Western blot
Adult SDSCs from cell expansion and pellets before (day 0) and after (day 10) chondrogenic
induction were dissolved in the lysis buffer (Cell Signaling) with protease inhibitors. Total proteins
were quantified using BCA™ Protein Assay Kit (Thermo Fisher Scientific). Thirty micrograms of
protein from each sample were denatured and separated using NuPAGE® Novex® Bis-Tris Mini
Gels in the XCell SureLock™ Mini-Cell (Life Technologies) at 120 V at 4°C for 3 h. Bands were
transferred onto a nitrocellulose membrane using an XCell II™ Blot module (Life Technologies) at
15 V at 4°C overnight. The membrane was incubated with primary monoclonal antibodies in 5%
bovine serum albumin (BSA) in TBST buffer (10 mM Tris-HCl, pH 7.5, 150 mM NaCl, 0.05%
Tween-20) for 1 h (β-actin served as an internal control), followed by the secondary antibody of
horseradish peroxidase-conjugated goat anti-mouse (Thermo Fisher Scientific) for 1 h.
SuperSignal West Femto Maximum Sensitivity Substrate and CL-XPosure Film (Thermo Fisher
Scientific) were used for exposure. The primary antibodies used in immunoblotting included the
MAPK family antibody sampler kit [extracellular signal-regulated protein kinases 1 and 2 (Erk1/2),
Jun N-terminal kinase (Jnk), and p38], phosphorylated (p-) MAPK family antibody sampler kit,
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and Wnt signaling antibody sampler kit (Cell Signaling). Wnt11 polyclonal antibody was obtained
from Thermo Fisher Scientific.
Adipogenic and osteogenic induction and evaluation
Adipogenic differentiation
Expanded cells were cultured for 21 days in adipogenic medium (growth medium supplemented
with 1 mM dexamethasone, 0.5 mM isobutyl-1-methyxanthine, 200 mM indomethacin, and 10 mM
insulin). The cultures (n = 3) were fixed in 4% paraformaldehyde and stained with a 0.6% (w/v)
Oil Red O (ORO) solution (60% iso-propanol, 40% water) for 15 min. Intracellular lipid-filled
droplet-bound staining was photographed under a Nikon TE300 phase-contrast microscope
(Nikon, Tokyo, Japan). Adipogenic marker genes [lipoprotein lipase (LPL, Assay ID
Hs00173425_m1) and peroxisome proliferator-activated receptor gamma (PPARG, Assay ID
Hs01115513_m1)] were quantified using TaqMan® real-time PCR.
Osteogenic differentiation
Expanded cells (n = 3) cultured for 21 days in osteogenic medium (growth medium supplemented
with 0.1 mM dexamethasone, 10 mM β-glycerol phosphate, 50 mM ascorbate-2-phosphate, and
0.01 mM 1,25-dihydroxyvitamin D3) were collected for alkaline phosphatase (ALP) activity assay
with a reagent kit (Sigma) by measuring the formation of p-nitrophenol (p-NP) from p-nitrophenyl
phosphate following the manufacturer’s instructions. p-NP was quantified based on the
spectrophotometric absorbance at 405 nm, and enzymatic activity was expressed as millimoles of
p-NP/min/mg DNA. For evaluation of calcium deposition, induced cells (n = 3) were fixed with
70% ice-cold ethanol for 1 h, and then incubated in 40 mM Alizarin Red S (ARS) at pH 4.2 for 20
min with agitation. After rinsing, matrix mineral-bound staining was photographed. Quantification
of staining was performed by incubating cells with a solution of 10% acetic acid and 20%
methanol for 15 min to extract the calcium-chelated ARS stain. Samples were analyzed for
absorption at 450 nm, which was normalized to total DNA amount for standardization.
Statistical analysis
ManneWhitney U test was used for pairwise comparison. All statistical analyses were performed
with SPSS 13.0 statistical software (SPSS Inc., Chicago, IL). p values less than 0.05 were
considered statistically significant.
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RESULTS
Evaluation of ECM-expanded ASDSC proliferation and viability
To evaluate the proliferative effect exerted by FE and AE, human ASDSCs were seeded on three
substrates: PL, AE, or FE. Cell morphology showed that PL4 exhibited flattened and enlarged
morphology (red color); in contrast, ASDSCs grown on ECMs, especially FE4, exhibited a
spindle-like shape overlapped with matrix fibers immunostained with type I collagen (initial color
was green and merged color was yellow); cell expansion on FE yielded the highest cell number
followed by AE with PL having the lowest cell number (Fig. 6.1A). Consistent with the cell
counting, AE expansion yielded a 2.1-fold increase and FE expansion yielded a 2.6-fold increase
in proliferation index compared with PL expansion (Fig. 6.1B). Our flow cytometry data showed
that MSC surface markers, CD29, CD90, and CD105, were down-regulated slightly in percentage
but heavily at the median; SSEA4 was up-regulated both in percentage and at the median despite
an up-regulation only in percentage for integrin β5 (Fig. 6.1C). To evaluate cell viability after
expansion on these substrates, flow cytometry was used to measure the percentage of apoptotic
cells as well as expanded cells’ resistance to apoptotic stimuli; the data showed that FE4
exhibited the fewest apoptotic cells (Fig. 6.1D) and both FE4 and AE4 produced about half the
ROS compared with PL4 upon treatment with H2O2 (Fig. 6.1E).
Evaluation of ECM microstructure, composition, and elasticity
SEM was used to evaluate cell and matrix morphology and help characterize the expansion of
ASDSCs on their culture substrates. In accord with cell morphology under confocal microscopy
(Fig. 6.1A), SEM data showed that PL4 exhibited an enlarged and flattened cell shape (Fig.
6.2A); in contrast, both AE4 and FE4, with a fibroblast-like shape, were embedded in the
corresponding matrix (Fig. 6.2B and C, respectively). Compared to a rough surface in AE (Fig.
6.2B), FE exhibited a smoother appearance (Fig. 6.2C), indicative of fine matrix fibers.
From proteomics analyses, we identified peptides that were mapped to approximately 260
proteins or protein families; the most prominent proteins were from the ECM. Collagens were the
most abundant as reflected by number of peptides identified, sequence coverage, and ion
envelope areas (Fig. 6.2D,E). As shown in Table 6.1, several proteins of interest were identified
and the number of spectra assigned to a given protein for both ECMs was listed. Intriguingly, we
found that fibrillar collagens shifted into the “insoluble” fraction for AE but not in FE; in contrast,
FE contained a fair amount of clusterin but none was detected in AE. Furthermore, we found that
some unique matrix proteins existed in FE, such as fibrillin-2, tenascin, and versican core protein,
while AE had advantageous matrix proteins, such as elastin, fibulin-6, periostin, thrombospondin1, and TGFB1. Intriguingly, no laminin was measured in either ECM despite plenty of fibronectin
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and type I collagen, which was confirmed by our immunostaining data in both AE (Fig. 6.2F) and
FE (Fig. 6.2G).
To determine the effect of mechanical properties of culture substrates on grown cells, AFM was
used to measure the elasticity of both substrates and expanded cells. The elasticity of PL could
be considered as infinite [21]; AE exhibited a higher elasticity than FE [61.82 ± 35.86 versus
58.26 ± 13.37 (kPa) (p = 0.000)] (Fig. 6.2H). Interestingly, the elasticity of expanded ASDSCs
was parallel to their substrate; the comparison between PL4 and AE4 was 9.07 ± 4.56 versus
3.60 ± 1.79 (kPa) (p = 0.000) while the comparison between AE4 and FE4 was 3.60 ± 1.79
versus 3.45 ± 2.29 (kPa) (p = 0.024) (Fig. 6.2I).
ECM-mediated ASDSC chondrogenic capacity and potential mechanisms
To determine the rejuvenation effects of ECM expansion on ASDSC chondrogenic potential,
expanded ASDSCs were chondrogenically induced for 21 days. The evaluation consisted of
chondrogenic mechanism analysis at the early stage and chondrogenic functionality assessment
at the later stage. At the early stage, 10-day pellets were evaluated for chondrogenic
differentiation using histology, immunostaining, and real-time PCR. The pellets from PL4 were the
smallest in size while those from FE4 were the largest; the pellets from FE4 were also intensely
stained with both Alcian blue and Safranin O for sulfated GAGs and immunostained for type II
collagen (Fig. 6.3A). All chondrogenic marker genes (SOX9, ACAN, and COL2A1) showed a
similar trend, which was that plastic expansion down-regulated while ECM expansion upregulated chondrogenic genes with FE4 being the highest (Fig. 6.3B). To determine potential
mechanisms underlying ECM expansion and subsequent chondrogenic differentiation, the MAPK
and Wnt signaling pathways were evaluated using Western blot. Our data showed that, compared
to up-regulation of p-p38 and p-Jnk, ECM expansion dramatically down-regulated p-Erk; despite
the fact that p-Erk bounced back in the cell condensation phase, the lowest level was seen in FE4
pellets; different from the change of p- Erk, ECM expansion yielded ASDSC pellets with a
relatively lower level of p-Jnk in the cell condensation phase though no significant difference was
found among groups after 10-day chondrogenic induction (Fig. 6.4A). Our data also showed that
ECM pretreatment down-regulated Wnt3a but up-regulated Wnt5a and Wnt11 in expanded
SDSCs; these effects were relayed through cell condensation and chondrogenic differentiation,
especially for the Wnt11-mediated non-canonical pathway (Fig. 6.4B).
At the later stage, 21-day pellets were evaluated for chondrogenic differentiation using histology,
immunostaining, real-time PCR, biochemistry, and mechanical properties. Similar to the data at
day 10, the pellets from PL4 were the smallest in size while those from FE4 were the largest; the
pellets from ECM expansion, particularly from FE4, were intensely stained for sulfated GAGs and
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immunostained for type II collagen (Fig. 6.5A). The pellets from FE4 exhibited the highest level of
chondrogenic marker genes (SOX9, ACAN, and COL2A1) followed by those from AE4 (ACAN
and COL2A1); pellets from the plastic expansion group had the lowest level (Fig. 6.5B). Our
biochemistry data showed that AE expansion yielded higher cell viability (DNA% by day 0) during
chondrogenic induction; FE expansion yielded the highest GAG amount per pellet and ratio of
GAG to DNA (chondrogenic index) followed by those from AE expansion with PL expansion
having the least (Fig. 6.5C). Our functionality data showed that ECM expansion yielded ASDSC
pellets with significantly enhanced size and comparable Stiffness and Young’s modulus (Fig.
6.5D).
Evaluation of ECM-expanded ASDSC adipogenic and osteogenic potentials
To determine the rejuvenation effect of ECM expansion on ASDSC adipogenic and osteogenic
potentials, expanded ASDSCs were incubated in corresponding lineage induction medium for 21
days. Our adipogenic induction data showed that expanded ASDSCs from varied substrates all
stained positive for ORO (Fig. 6.6A); FE4 exhibited the highest levels of LPL and PPARG mRNAs
followed by AE4 (LPL); PL expansion had the lowest levels (Fig. 6.6B). Our osteogenic induction
data showed that expanded SDSCs from varied substrates all stained positive for ARS (Fig.
6.6C) and ALP (Fig. 6.6E); the quantitative assessment for relative ARS density (Fig. 6.6D) and
ALP activity (Fig. 6.6F) did not show a significant difference among groups.
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DISCUSSION
Aging is characterized by reduced tissue and organ functions and regenerative capacities,
accompanied by decreases in tissue resident stem cell numbers and loss of potency. Ever since
Conboy et al.’s study [22], researchers focused their interest on the influence of ECM on stem cell
rejuvenation; however, none have investigated the effect of young ECM on old tissue-specific
stem cells’ chondrogenic potential. In this study, we found that decellularized ECM, especially
from young donors, rejuvenated ASDSCs in expansion, as evidenced by increased cell
proliferation and resistance to apoptosis. Chondrogenic differentiation also improved, as
evidenced by enhanced pellet size, pellet composition (aggrecan and type II collagen at both
mRNA and protein levels), and pellet functionality (Stiffness and Young’s Modulus). We found
that the MAPK and Wnt signaling pathways were also actively involved in ECM-mediated ASDSC
expansion and chondrogenic potential. In the characterization of cell and matrix interaction, we
found that unique proteins in FE favored ASDSC rejuvenation; the low elasticity of FE decreased
expanded ASDSC elasticity, which might benefit cell chondrogenic and adipogenic potentials.
In previous reports, we discussed the rejuvenation effect and underlying potential mechanisms of
decellularized ECM on expanded ASDSCs compared with plastic expansion [5,12]. In this study,
we were interested in the comparison between FE and AE in composition and their influence on
rejuvenation. We found that FE was better than AE in promoting cell proliferation and preventing
apoptosis, which might be explained by the discrepancy in chemical composition of these two
matrices. Our proteomics data showed that FE had more fibrillin-2 (76:2), tenascin C (259:120),
and clusterin (5:0) than AE. Fibrillins are produced by fibroblasts physiologically in developing or
regenerating tissues; fibrillin-2 binds to other ECM proteins, forming microfibrils, and is mostly
expressed during embryogenesis [23]. Tenascin C is a hexameric ECM glycoprotein, which is
responsible for various dynamic cellular activities, including adhesion [24], tissue remodeling [25],
migration [25], proliferation [26], and growth [24]. Absence of tenascin C alters neural stem cell
number and function in the subventricular zone [27]; tenascin C deletion has also been shown to
affect primitive cell populations in the hematopoietic system, raising the possibility that it
participates in several stem cell niches as a modulator of growth factor signaling [28]. Despite the
fact that both are largely restricted to developing fetal tissues [29], enhanced expression of
fibrillin-2 and tenascin C has been observed in adults with fibroproliferative conditions, such as
wound healing and sclerosis [23,25,30]. Moreover, a fair amount of clusterin was found in FE
while none was detected in AE, which might be responsible for less apoptosis observed in FE
expanded ASDSCs since clusterin could inhibit apoptosis by interacting with activated Bax [31].
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In contrast, AE had more biglycan (95:37), decorin (95:40), dermatopontin (35:16), elastin (18:2),
periostin (400:125), thrombospondin-1 (79:6), and TGFβ1 (258:164) than FE. Small leucin-rich
proteoglycans (SLRPs) decorin and biglycan were reported to reduce proliferation of preadipocytes, partly by induction of apoptosis [32]. Dermatopontin has been implicated in
chondrogenic differentiation [33,34]. Periostin was first identified in osteoblast-like cells [35] and it
is thought to play an important role in bone formation and development of periodontal ligaments
[36,37]. Notably, periostin and TGFβ are all involved in osteo-chondrogenesis [38].
Thrombospondin-1 signaling through CD47 inhibits self-renewal by regulating c-Myc and other
stem cell transcription factors [39]. Elastin, a structural component of ECM that confers elasticity
to tissues, has been used to make biopolymers for MSC differentiation [40]. The low level of
elastin measured in FE is because donor cells were contributed by a 6-month-old fetus and
elastin expression occurs from midgestation [41]. The above data showed that, compared with
the role of FE during cell expansion, AE has more matrix components favoring cell differentiation
and apoptosis rather than cell proliferation, which is consistent with the observed differences in
elasticity and ECM/collagen architecture, i.e. fibrillar collagens were shifted into the “insoluble”
fraction in AE but not in FE.
Our previous study using flow cytometry in human BMSCs showed that ECM expansion
dramatically increased the level of integrin β5 but decreased integrin β1 (also termed CD29) at
median rather than in percentage [16] and is further confirmed by this report. We also found that
FE expansion yielded human ASDSCs with even higher integrin β5 but lower integrin β1
expression than AE, which might be associated with ECM elasticity. Matrix elasticity could have
an effect on lineage differentiation potential according to a recent report that ECM elasticity
affects integrin activity and trafficking to modulate integrin bone morphogenetic protein (BMP)
receptor internalization, thus contributing to stem cell lineage specification [42]. The lower level of
elastin in FE may be responsible for lower matrix elasticity compared with AE, which is confirmed
by the AFM data; lower elasticity in FE might be associated with enhancement of ASDSC
chondrogenic and adipogenic potentials, suggesting that matrix elasticity might contribute to
lineage-specific differentiation. In contrast to previous reports in which direct differentiation effects
assessed matrix elasticity [43,44], in this study, matrix elasticity was investigated for its influence
on cell proliferation and differentiation potential.
There have been few studies investigating potential mechanisms underlying the rejuvenating
effect of ECM on stem cells. Heterochronic parabiosis by exposure of satellite cells from old mice
to young serum restored the activation of Notch signaling as well as the proliferation and
regenerative capacity of aged satellite cells [22]. Young matrix derived from human diploid
fibroblasts restored senescent fibroblasts evidenced by resumption of proliferative potential,
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growth factor responsiveness, reduction of intracellular ROS levels, recovery of mitochondrial
membrane potential, and increased telomere length [45]. Besides the mechanisms mentioned
above, in this study, we investigated ECM expansion related changes of the MAPK and Wnt
signals, two key pathways involved in cell proliferation and chondrogenic differentiation. ECM
pretreatment down-regulated p-Erk level in expanded ASDSCs, indicative of a decline in cell
senescence [46]; p- Erk was then up-regulated during cell condensation and down- regulated
after 10-day chondrogenic induction, in particular for those expanded on FE, in accord with
previous reports that p-Erk signals could promote stem cell chondrogenesis in the early stage but
inhibit chondrogenic differentiation in the later stage [47]. The functional switch of p-Erk during
chondrogenesis supported the claim that expansion on ECM, especially from a young donor,
favored ASDSC proliferation and chondrogenic potential.
Our data also showed that Wnt3a, a typical canonical signal, was down-regulated in ECM
expanded ASDSCs and then maintained a comparable level with plastic expanded cells during
chondrogenic differentiation; in contrast, Wnt5a and Wnt11, two typical noncanonical signals,
were dramatically up-regulated in ECM expanded cells, especially those cells grown on FE, and
subsequent chondrogenic differentiation. This finding is surprising because Wnt3a was previously
considered a stimulator of MSC proliferation [48] while Wnt5a and Wnt11 function by inhibiting βcatenin signaling and favoring cell migration and differentiation [49,50], despite the fact that both
Wnt5a and Wnt11 were also involved in cell proliferation. Wnt5a controlled the proliferation of
undifferentiated limb mesenchymal cells in vivo [51] and Wnt11 regulated transcriptional factors
octamer-binding transcription factor 4 (OCT4) and NANOG associated with the pluripotent state
and affected lineage specification genes toward mesodermal development [52]. Our
immunoblotting data showed that Wnt5a and p38 shared a similar trend in cell expansion and
condensation, which is in agreement with a previous report that the stimulatory roles of Wnt5a on
chondrogenesis in micromass cultures are dependent on the activation of both p38 and protein
kinase C (PKC) signaling [53]; PKC is required for MSC chondrogenesis [54]. After a 10-day
chondrogenic induction, FE expanded ASDSCs exhibited a down- regulation of p-p38 but an upregulation of Wnt5a which corresponds to the highest chondrogenic differentiation because the
inhibition of p38 can cause early stage hypertrophic chondrocytes to revert back to a
prehypertrophic phenotype [55] while Wnt5a conversely blocks chondrocyte hypertrophy [56].
The up-regulation of p-Jnk in ASDSCs after expansion on ECM might contribute to an increase of
Wnt11. Wnt11 was found to have expression sites restricted within the prehypertrophic
chondrocytes of the cartilage elements; it enhanced chondrogenesis without promoting terminal
differentiation [57]. Despite the fact that Wnt3a might be transiently up-regulated in the early
stage of ECM expansion, our data indicated that noncanonical Wnt signals dominated ECM
expanded ASDSCs and subsequent chondrogenic differentiation.
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Our study demonstrated that decellularized ECM deposited by fetal SDSCs can provide a
rejuvenating effect and a tissue-specific stem cell microenvironment to enhance adult SDSC
expansion and chondrogenic potential, possibly through the MAPK and Wnt signaling pathways.
The detailed mechanisms underlying ECM enhanced cell proliferation and chondrogenic potential
need further investigation. Decellularized ECM from fetal SDSCs, which demonstrates a
“Fountain of Youth” effect for adult SDSC rejuvenation, provides hope for solving the challenge of
cell senescence in cartilage engineering and regeneration.
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FIGURE LEGENDS
Figure 6.1 ECM expanded ASDSCs exhibited an enhanced proliferative and anti-apoptotic
capacity, especially for cell expansion on FE. (A) ASDSCs were expanded on three substrates
(PL, AE, and FE) for one passage; the cell membrane was labeled with Vybrant Dil Cell labeling
solution (red) and the nuclei were stained using DAPI (blue), the ECM fibers were immunostained
with type I collagen (green); cell number was counted in 175 cm

2

flasks (n = 6) using a

hemocytometer. (B) Flow cytometry was used to measure the proliferation index of expanded
ASDSCs. (C) Flow cytometry was used to measure both percentage and median of MSC surface
markers (CD29, CD90, and CD105), SSEA4, and integrin β5 of expanded ASDSCs. (D) Flow
cytometry was used to measure percentage of apoptotic cells after expansion on the three
substrates. (E) Generation of ROS followed by hydrogen peroxide incubation was evaluated.
Relative fluorescence emitted by fluorescent dye 2′7′-dichlorofluorescein diacetate was measured
and presented as means ± standard deviation (SD) of the mean for n = 3. *p < 0.05 indicated a
statistically significant difference.
Figure 6.2 Contribution of ECM structure and composition to ASDSC rejuvenation. SEM was
used to observe ASDSC morphology during expansion on PL (A), AE (B), or FE (C). Scale bar:
50 µm. Surface topography and morphology of AE (B) and FE (C) were also observed. Scale bar:
5 µm. Proteomics was used to measure chemical composition of AE (D) and FE (E). Image
figures of both AE and FE showed phase-contrast microscope (PCM) for cell morphology and
structure before making ECM and immunostaining for type I collagen, fibronectin, and laminin.
AFM was used to measure elasticity of both expanded substrates (H) and expanded ASDSCs (I).
Figure 6.3 FE promoted expanded ASDSCs' early chondrogenic differentiation. PL expanded
passage 3 ASDSCs (PL3) were grown on either PL, AE, or FE for one passage; the expanded
cells were PL4, AE4, and FE4. The above four cells were chondrogenically induced in a pellet
culture system for 10 days. (A) Before histological staining, pellet size was measured with a scale
bar as mm; Alcian blue (AB) and Safranin O (SO) were used to stain sulfated GAGs and
immunohistochemistry staining (IHC) was used to detect type II collagen (Col II). (B) Real-time
polymerase chain reaction (PCR) was used to evaluate chondrogenic marker gene expression
(SOX9, ACAN, and COL2A1) in day-10 pellets. Data are shown as average ± standard deviation
(SD) for n = 4. *p < 0.05 indicated a statistically significant difference.
Figure

6.4 Potential mechanisms underlying ECM-mediated ASDSC proliferation and

chondrogenic potential. Western blot was used to detect the MAPK signals (Erk, p38, and Jnk) at
both phosphorylation and total protein levels and Wnt signals (Wnt3a, Wnt5a, and Wnt11). β-
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actin was also measured as an internal control. ImageJ software was used to quantify
immunoblotting bands.
Figure 6.5 FE promoted expanded ASDSCs' later chondrogenic differentiation. PL expanded
passage 3 ASDSCs (PL3) were expanded on either PL, AE, or FE for one passage; the
expanded cells were PL4, AE4, and FE4. The above four cells were chondrogenically induced in
a pellet culture system for 21 days. (A) Before histological staining, pellet size was measured with
a scale bar as mm; Alcian blue (AB) and Safranin O (SO) were used to stain sulfated GAGs and
immunohistochemistry staining (IHC) was used to detect type II collagen (Col II). (B) Real-time
polymerase chain reaction (PCR) was used to evaluate chondrogenic marker gene expression
(SOX9, ACAN, and COL2A1). (C) Biochemical analysis was used for DNA and GAG contents of
pellets; cell viability in chondrogenic medium was evaluated using DNA ratio (DNA content at day
21 adjusted by that at day 0); a ratio of GAG to DNA indicated chondrogenic index. (D)
Functionality of chondrogenically differentiated pellets was evaluated using pellet size, Stiffness,
and Young's modulus. Data are shown as average ± standard deviation (SD) for n = 4. *p < 0.05
indicated a statistically significant difference.
Figure

6.6 ECM pretreatment promoted expanded ASDSC adipogenesis rather than

osteogenesis. After expansion on PL, AE, or FE, ASDSCs were replated in either adipogenic or
osteogenic induction medium. After a 21-day incubation in adipogenic medium, adipogenesis was
evaluated using Oil Red O (ORO) staining (A) and quantitative adipogenic marker genes (LPL
and PPARG). After a 21-day incubation in osteogenic medium, osteogenesis was evaluated
using Alizarin Red S (ARS) staining and quantitative extracellular calcium assay as well as
alkaline phosphatase (ALP) staining and quantitative activity assay. Data were shown as
average ± SD for n = 4. *p < 0.05 indicated a statistically significant difference.
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Table 6.1 Select ECM and ECM interacting proteins identified in fetal and adult ECMs
Swiss-Port accession

Assigned spectra

% of protein in the
insoluble pellet

FE

AE

FE

AE

Selected ECM proteins
P98160

Perlecan

91

95

22%

51%

P21810

Biglycan

37

95

14%

53%

P07585

Decorin

40

95

65%

54%

Q07507

Dermatopontin

16

35

100%

66%

P15502

Elastin

2

18

100%

89%

Q9Y6C2

EMILIN-1

131

113

1%

25%

Q9BXX0

EMILIN-2

35

46

46%

43%

P35555

Fibrillin-1

394

529

39%

53%

P35556

Fibrillin-2

76

2

0%

0%

P02751

Fibronectin

767

873

29%

43%

P23142

Fibulin-1

5

4

0%

50%

P98095

Fibulin-2

149

150

68%

63%

Q96RW7

Fibulin-6 (hemicentin-1)

1

12

0%

0%

P09382

Galectin-1

22

12

0%

0%

P55001

Microfibrillar-assoc. prot. 2

39

47

85%

81%

Q13361

Microfibrillar-assoc. prot. 5

28

37

86%

68%

P20774

Mimecan

16

6

0%

17%

Q14112

Nidogen-2

7

6

0%

0%

Q15063

Periostin

125

400

15%

57%

P24821

Tenascin

259

120

3%

36%

P22105

Tenascin-X

59

49

10%

0%

P07996

Thrombospondin-1

6

79

33%

68%

Q15582

TGFBI

164

258

45%

44%

P13611

Versican core protein

58

22

74%

50%

P02452

Collagen alpha-1(I) chain

250

494

11%

86%

P08123

Collagen alpha-2(I) chain

206

339

6%

59%

P02461

Collagen alpha-1(III) chain

41

31

0%

81%
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P20908

Collagen alpha-1(V) chain

18

36

28%

47%

P05997

Collagen alpha-2(V) chain

7

12

0%

75%

P12109

Collagen alpha-1(VI) chain

602

799

79%

68%

P12110

Collagen alpha-3(VI) chain

3019

3542

67%

56%

Q99715

Collagen alpha-1(XII) chain

798

1563

30%

64%

Q05707

Collagen alpha-1(XIV) chain

163

47

17%

34%

0%

Additional proteins
Q6UY14

ADAMTS-like protein 4

8

18

0%

P10909

Clusterin

5

0

0%

Q08397

Lysyl oxidase homolog 1

22

23

36%

35%

P21980

Transglutaminase 2

18

44

28%

30%
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ABSTRACT
Low back pain is often related to intervertebral disc (IVD) degeneration and herniation that results
from a progressive loss of proteoglycans and water content in the nucleus pulposus. Autologous
disc cell-based therapy is a promising approach for IVD regeneration. Unfortunately, the quantity
and quality of the autologous herniated nucleus pulposus cells (NPCs) is limited and
compromised. The current in vitro expansion of NPCs in monolayer results in dedifferentiation of
these cells. Our previous studies indicated that decellularized extracellular matrix (DECM)
deposited by stem cell could serve as an in vitro expansion system for enhancing proliferative
and chondrogenic differentiation potential in the recellularized cells. Moreover, such an in vitro
three-dimensional microenvironment benefits porcine NPCs by allowing them to expand more
efficiently while maintaining their differentiation phenotypes. Our most recent study also
suggested the young DECM was superior to old DECM in rejuvenating cells with higher
proliferation and chondrogenic capacities. However, there has been no study investigated if the
DECM deposited by human NPCs (NECM) has the same or better effect than DECM deposited
by human SDSCs (SECM) and whether cells derived from fetal donors can serve as a better
tissue-specific high-quality microenvironment than adult donors for ex vivo expansion of human
NPCs from middle-aged patients while promoting re-differentiation potential. In this study, for the
first time, we evaluated the rejuvenating effect of DECMs deposited by human NPCs and SDSCs
and compared the effect of fetal and adult donors’ NPCs and SDSCs deposited DECMs. First,
both fetal and adult SDSC and NPCs were used to prepare young and old SECMs and NECMs.
Cell proliferation after expansion evaluated by cell number and proliferation index showed
significantly enhanced proliferation in both SECMs and NECMs compared to plastic flasks group
as a control. Surface markers for mesenchymal stem cells were analyzed by flow cytometry after
expansion on different substrates. Redifferentiation potential to chondrogenesis evaluated by
biochemistry, histochemistry and immunohistochemistry, real-time PCR was consistently
enhanced in both NECMs expanded NPCs but not in both young and old SECMs expanded cells.
In conclusion, both human SDSC and NPC deposited DECMs can rejuvenate NPCs from
herniated IVD with higher proliferative potential. But redifferentiation potential of NPCs can only
be enhanced by NPC-derived NECMs. The development of an autologous disc cell-based
minimally invasive therapeutic approach is beneficial toward physiological reconstruction of a
biologically functional disc in a clinical setting.
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INTRODUCTION
Approximately 80% of the adult population is affected by low back pain; this condition has a
1

massive economic impact due to both health care costs and loss of productivity. Although the
causes of low back pain are complicated and not fully understood, an important underlying cause
is commonly believed to be degeneration of the intervertebral disc (IVD).

2;3

The IVD consists of

two components: the gelatinous nucleus pulposus (NP) at the center of the disc surrounded by
4

the annulus fibrosus, a more highly organized ring composed mainly of type-I collagen. The
extracellular matrix (ECM) of the NP is up to 80% hydrated as a result of large amounts of the
5

aggregating proteoglycan aggrecan. This proteoglycan is enmeshed in a randomly oriented
6

network of type-II collagen fibers. IVD degeneration is reported to begin in the NP with a
progressive decrease in proteoglycan content, leading to loss of hydrogel properties of the NP.

7

Clinical treatments of IVD disease include various noninvasive and invasive therapies, but are
limited to symptomatic relief.
Cell transplantation is a suitable and promising approach for IVD regeneration. Although human
NP cells (NPCs) share matrix-producing properties with chondrocytes, recent studies have shown
8

that there are indeed phenotypic differences. Stem cells seem to be another candidate for cell
transplantation; however, the lack of a definitive cell marker to distinguish NPCs from other cells
has made clinical application more difficult and less realistic. Animal studies
clinical trial (Euro Disc Randomized Trial)

11

9-11

and an early

have indicated that autologous disc cell

transplantation (ADCT) is technically feasible and biologically relevant to repairing disc damage
and retarding disc degeneration. However, one concern of critics of ADCT is that cells isolated
from degenerative discs may lack the potential of healthy counterparts.

12

In addition, the

preparation of NPCs for reimplantation is problematic because autologous transplantation
requires more cells than can be harvested from a small biopsy. During in vitro expansion,
however, like articular chondrocytes, NPCs undergo a characteristic process of dedifferentiation,
marked by a loss of type-II collagen expression and the induction of type-I collagen
expression.

13;14

With low cellular yields and low proliferative activity of NPCs in monolayer culture,

further enhancement of the biologic and metabolic viability of NPCs is desirable.
In order to make clinical application a reality, in vitro expansion cultures are expected to yield
large amounts of high-quality cells in a short period of time. Moreover, these expanded NPCs
should preferably express or at least be able to reexpress their NPC phenotype (redifferentiation
capacity) in order to produce a functional ECM. Thus, expanded cell amount and redifferentiation
capacity are two important parameters in disc regeneration. Our recent finding has shown that
decellularized extracellular matrix (DECM) deposited by porcine synovium-derived stem cells
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(SDSCs) can serve as a three-dimensional cell expansion system for SDSC proliferation while
enhancing chondrogenic potential.

15

Such an in vitro three dimensional microenvironment

benefits porcine NPCs by allowing them to expand more efficiently while maintaining their
differentiation phenotypes.

16;17

Our recent study also suggests that human fetal SDSC-derived

DECM can rejuvenate adult SDSC by decreasing replicative senescence, evidenced by
enhancing adult SDSC expansion and chondrogenic differentiation capacity.

18

Despite the fact that we demonstrated that DECM expansion could overcome porcine NPC
replicative senescence, there has been no study investigating whether DECM deposited by
human SDSCs or NPCs can rejuvenate NPCs from middle-aged patients’ herniated IVD and
whether SDSCs or NPCs from young donor is superior to adult donor for depositing the matrix.
This is an important issue to be addressed because most NPCs that need expansion are from
middle-aged patients, at which herniated discs often occur. In this study, we aim to investigate
whether DECM deposited by human SDSC or NPCs from fetal donors can serve as a tissuespecific high-quality microenvironment for ex vivo expansion of human NPCs from middle-aged
patients while maintaining NPC differentiation phenotype and re-differentiation potential. The
development of an autologous disc cell-based minimally invasive therapeutic approach would
greatly benefit physiological reconstruction of a biologically functional disc in a clinical setting.
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MATERIALS AND METHODS
DECM preparation
Human fetal source nucleus pulposus cells (NPCs) and synovium-derived stem cells (SDSCs)
were obtained from Scien-Cell™, Research Laboratories (Carlsbad, CA) and adult SDSCs
(ASDSC) were obtained from Asterand (North America Laboratories, Detroit, MI). Adult NPC from
herniated discs were collected from lumbar spine (L1-L5) of patients (age 30 – 50 years old)
following Institutional Review Board approval and donor consent. Both cell types were used to
prepare DECMs, termed SECM and NECM, respectively, as described previously.

18

Both DECMs

from fetal and adult donors were termed FE and AE. Briefly, plastic flasks (PL) were precoated
with 0.2% gelatin (Sigma, St. Louis, MO) at 37 °C for 1 h and seeded with passage 3 NPCs at
2

6000 cells per cm . After cells reached 90% confluence, 250 mM of L-ascorbic acid phosphate
(Wako Chemicals USA Inc., Richmond, VA) was added for 10 days. The deposited ECMs were
incubated with 0.5% Triton X-100 containing 20 mM ammonium hydroxide at 37 °C for 5 min to
remove the cells; they were stored at 4 °C in phosphate-buffered saline (PBS) containing 100
U/mL penicillin, 100 mg/mL streptomycin, and 0.25 mg/mL fungizone until use.
Cell counting and morphology
2

PL expanded passage 2 NPCs were plated at 3000 cells per cm on both FE, AE, or PL for two
passages with growth medium containing alpha-minimum essential medium (αMEM), 10% fetal
bovine serum (FBS), 100 U/mL penicillin, 100 µg/mL streptomycin, and 0.25 µg/mL fungizone.
2

Cell number was counted in 175 cm flasks (n = 6) using a hemocytometer for both passages and
cell morphology was photographed.
Proliferation index
-6

Before cell expansion, passage 2 NPCs were labeled with CellVue® Claret (Sigma) at 2 × 10 M
for 5 min according to the manufacturer’s protocol. After eight days, expanded cells were
collected and measured using a BD FACS Calibur™ flow cytometer (dual laser) (BD Biosciences,
San Jose, CA). Twenty thousand events of each sample were collected using CellQuest Pro
software (BD Biosciences) and cell proliferation index was analyzed by ModFit LT™ version 3.1
(Verity Software House, Topsham, ME).
Histological analysis
The pellets (n=3) will be fixed in 4% paraformaldehyde, dehydrated in a gradient ethanol series,
cleared with xylene, and embedded in paraffin blocks. 5-µm sections will be histochemically
stained with Alcian blue (Sigma, St. Louis, MO). For immunohistochemical analysis, the sections
will be immunolabeled with primary antibodies against collagen I (Sigma), collagen II [II-II6B3,
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Developmental Studies Hybridoma Bank (DSHB), Iowa City, IA], and collagen X (Sigma),
respectively. A secondary antibody of biotinylated horse anti-mouse IgG (Vector, Burlingame, CA)
will be incubated on the sections for 30 min. Immunoactivity will be detected using Vectastain
ABC reagent (Vector) with 3,3’-diaminobenzidine (DAB, 0.05%) and hydrogen peroxide (H2O2,
0.015%) as a substrate. Hematoxylin (Vector) served as a counterstain.
Biochemical analyses
o

Representative pellets (n=6) will be digested for 6 h at 60 C with 125 µg/mL papain in PBE buffer
(100 mmol/L phosphate, 10 mmol/L EDTA, pH 6.5) containing 10 mmol/L cysteine, by using 100
µL enzyme per sample. To quantify cell density, the amount of DNA in the papain digests will be
measured using the Quant-iT™. PicoGreen® dsDNA Assay kit (Invitrogen) with a CytoFluor®
Series 4000 (Applied Biosystems). GAG will be measured using dimethylmethylene blue dye and
a Spectronic™ BioMate™ 3 Spectrophotometer (Thermo Scientific, Milford, MA) with bovine
chondroitin sulfate as a standard.
Flow cytometric analysis
The following antibodies will be used: stage specific embryonic antigen-4 (SSEA-4), CD29
(BioLegend), CD90 (BD Pharmingen), and CD105 (GeneTex Inc., San Antonio, TX). As isotype
controls, IgG1 and IgG2a (Beckman Coulter, Fullerton, CA) along with IgG3 (BD Pharmingen) will
be used. The secondary antibody will use FITC-conjugated goat anti-mouse Ig (Abcam). 0.2 ×
6

10 cells will be incubated on ice in cold PBS containing 5% FBS and 1% NaN3 (Sigma) for 30
min. After incubation, primary antibodies will be added and the cells will be incubated for 60 min
at room temperature in the dark. After washing with cold PBS, cells will be incubated with the
secondary antibody for 30 min in the dark. Finally, the cells will be fixed in 400 µL of PBS with 1%
paraformaldehyde. The cells will be analyzed on a BD dual laser FACSCalibur (BD Biosciences)
using the CellQuest Pro (BD Biosciences) software package.
TaqMan real-time PCR
For studies of quantitative gene expression, the total RNA samples from representative pellets
(n=6) and reverse transcript (RT) will be prepared according to RT-PCR protocol. Chondrogenic
marker genes [SRY (sex determining region Y)-box 9 (SOX9) (Assay ID Hs00165814_m1),
aggrecan (ACAN) (Assay ID AIQJAP5), and type II collagen (COL2A1) (Assay ID
Hs00156568_m1)] were customized by Applied Biosystems as part of their Custom TaqMan®
Gene Expression Assays. Eukaryotic 18S RNA (Assay ID Hs99999901_s1 ABI) is carried out as
the endogenous control gene. Real-time PCR will be performed with iCycler iQ™ Multi Color RTPCR Detection System (Bio-Rad Laboratories, Hercules, CA). The cycle parameters are 50°C for
2 min, hot start at 95°C for 10 min followed by 40 cycles of denaturation at 95°C for 15 seconds,
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and annealing and extension at 60°C for 1 min. The cycle threshold (Ct) values for 18S RNA and
that of samples will be measured and calculated by computer software (Perkin-Elmer, Wellesley,
MA). Relative transcript levels will be calculated as χ = 2

-ΔΔCt

, in which ΔΔCt = ΔE - ΔC, ΔE = Ctexp -

Ct18s, and ΔC = Ctct1 - Ct18s.
Statistical analysis
ManneWhitney U test was used for pairwise comparison. All statistical analyses were performed
with SPSS 13.0 statistical software (SPSS Inc., Chicago, IL). ρ values less than 0.05 were
considered statistically significant.
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RESULTS
Both SDSC and NPC deposited DECMs enhanced NPC proliferation
Both fetal and adult SDSCs and NPCs were used to deposit DECMs (SECM and NECM). To
evaluate proliferative effect exerted by fetal and adult SECMs or NECM, human adult NPCs were
respectively seeded on three different substrates: PL, FE or AE (PL, FNPE or ANPE). Cell
morphology showed that NPCs expanded on PL was sporadic and randomly clustered; in
contrast, NPCs grown on both DECMs exhibited a glistening look and spindle-like shape (Figure
7.1A and 7.2A). For SECM groups, cell expansion on FE yielded the highest cell number followed
by AE with PL having the lowest cell number (Figure 7.1B). Proliferation index data was also
consistent with the cell counting (Figure 7.1C). For NECM groups, highest cell number was
observed in ANPE instead of FNPE (Figure 7.2B). ANPE expansion yielded a 1.8-fold increase
and FNPE expansion yielded a 1.2-fold increase in proliferation index compared with PL
expansion (Figure 7.2C).
Our flow cytometry data showed that MSC surface markers, CD29 and CD90, were downregulated slightly in percentage but heavily at the median fluorescence intensity (MFI) in both
DECMs expanded NPCs despite an up-regulation in MFI for CD105 in FNPE from NPCs (Figure
7.3A and 7.3B).
NPC redifferentiation capacity enhanced by NPC- but not SDSC-derived DECM
To determine the influence of DECM expansion on NPC redifferentiation potential, expanded
NPC were induced for chondrogenic differentiation for up to 21 days. After 10 or 21-day
incubation, pellets were evaluated using histology, immunostaining and biochemistry analysis.
As shown in Figure 7.4A, for SECM pretreatment groups, compared to pellets from PL, AE and
FE expanded pellets were smaller in size though pellets from FE is slightly larger than pellets
from AE at both day 10 and day 21. Biochemistry data and stronger staining for sulfated GAGs
and collagen II also showed highest chondrogenesis in PL expanded NPC pellets (Figure 7.5A).
Intriguingly, for NECM groups, pellets from PL were smallest in size at both time points while
those from FNPE were the largest (Figure 7.4B); the FNPE pellets also contained the highest
GAGs content analyzed by biochemistry (Figure 7.5B). The enhanced DNA content in FNPE and
ANPE pellets was also shown at both day 10 and day 21. The chondrogenic index (ratio of GAG
to DNA content) of FNPE pellets is almost 2-fold of PL pellets. Stronger staining for sulfated
GAGs by Alcian Blue and immunostaining for collagen II also showed the same trend, which was
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that PL expansion down-regulated while DECM expansion upregulated chondrogenesis in NPCs
with FNPE being the highest (Figure 7.4B).
Down-regulation of hypertrophic, catabolic and senescent markers in NPC-derived DECM
rejuvenated pellets
Our real-time PCR data also suggested that expression of hypertrophic markers (COLX, RUNX2,
ALPL, MMP13) was up-regulated in SECM pretreated NPCs, while down-regulated in NECM
expanded NPCs compared to their own respective PL control. Similarly, the catabolic matrix
genes that associated with inflammatory (COX2, MMP3, ADAMTS4, ADAMTS5, TIMP1) were
also down-regulated in NECM expanded NPCs but up-regulated in SECM pretreated NPCs. The
senescence marker genes (CASP3, P53, SIRT1, BMI1) also showed similar trend (Figure 7.6).
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DISCUSSION
Low back pain is often related to intervertebral disc (IVD) degeneration and herniation that results
from a progressive loss of proteoglycans and water content in the nucleus pulposus (NP).
Autologous disc cell-based therapy is a promising approach for IVD regeneration. Unfortunately,
the quantity and quality of the autologous herniated NP cells (NPCs) is limited and compromised.
The current in vitro expansion of NPCs is insufficient. Our previous studies have shown the
rejuvenation of porcine NPCs by SDSC-deposited SECM, which significantly enhanced NPC
proliferation and redifferentiation into chondrocyte like cells.

16;17

In this study, for the first time, we

have shown that human NPCs could be rejuvenated by its own deposited matrix, especially the
young matrix. Although the proliferative potentials of human NPCs can be rejuvenated by both
SDSC- and NPC-deposited DECMs, the NPC-deposited NECM is superior to SDSC-derived
DECM in enhancing the redifferentiated chondrogenic potentials in herniated NPCs.
In this study, the NP tissue that we collected from patients was the part of the herniated disc,
which could be the degenerated NP tissue. There have been only few studies evaluated the
quality of these NPCs. Up-regulated senescence associated markers as well as decreased
telomere length and loss of replicative potential have been shown in degenerated human IVD
or with progressing age.

22

19-21

Hegewald et al. observed significant signs of dedifferentiation and

degeneration as well as very limited regenerative potential for cells harvested from herniated disc
tissue of patients aged around 45-year old.

23

Ciapetti et al. suggested that the tissue in the

degenerated disc is disorganized and the paucity of cells out of cluster/chondron association
make the IVD-derived cells an unreliable source for disc regeneration.

24

Oppositely, degenerated

porcine NPC had been shown to have a higher colony-forming rate and a higher proliferation rate
though the differentiation towards chondrogenic lineage is lower than the healthy NPC in vitro.

25

Degenerated human NPC also exhibited regenerative potentials when treated with TGFβ3 and
dexamethasone by Abbott et al..

26

Our characterization of the proliferative and chondrogenic

potential evaluation also supported that adequate proliferation and redifferentiation potentials
were possessed in human NPCs from herniated disc. This provided a precious opportunity for
application of autologous NPCs in future patients.
We also observed the expression of MSC surface marker in NPCs from herniated disc and their
significantly

enhanced

potentials

to

be

rejuvenated

towards

more

proliferative

and

redifferentiation especially after the NPC-derived NECM expansion. It is plausible that these
NPCs possess mesenchymal stem cell (MSC) like stemness. However, it is still debatable
whether NP tissue, especially the degenerated NP tissue contains MSCs. A potential stem cell
niche was proposed in the IVD in four different species.
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27

Blanco et al. suggested that MSCs

existed in human degenerated NP and exhibited similar properties except the adipogenic
potential as bone marrow-derived stem cells that came from the same subjects.

28

Although

further investigation is needed before we reach a conclusion, the further promoted the yield of cell
number and proteoglycan synthesis in NPCs during redifferentiation especially by the young
NECM matrix suggested that the three-dimensional DECM could serve as an ex vivo expansion
system or “niche” for rejuvenating these NPCs from herniated disc.
Interestingly, the rejuvenated NPC redifferentiated pellets showed lower expression of
hypertrophic, catabolic and senescent marker genes. The altered NPCs feature behavior during
IVD degeneration include increased hypertrophic differentiation,
and decreased anabolic metabolism
as TGFβ1,

35

30-33

29

increased catabolic metabolism

34

and induced cell death. Addition of growth factors such

TGFβ3 and dexamethasone,

36

IGF-1 and BMP-7,

37;38

have been shown to increase

the expression of proteoglycans and collagens in degenerated NPCs in vitro. However, the
confirmation of the effect of these growth factors treatment in vivo and detailed dose-dependent
study as well as long-term safety study in large animal model are still higly anticipated as
suggested by Masuda et al..

39

Our data indicated that the three-dimensional DECMs, especially

young matrix could serve as expansion system for providing larger quantity of high quality NPCs
without administration of exogenous growth factors.
The application of acellularized NPC derived matrix for rejuvenating NPC is promising. The
unique combination, quantity and organization of ECM components give rise to the tissue-specific
structure and function. This is nowhere more evident than in this study that no attempt to emulate
native ECM is better than the native ECM itself. Similarly, Mercuri et al. also showed that acellular
porcine NP hydrogel could serve as scaffold for promoting NP regeneration when combined with
human adipose-derived stem cells.

40;41

Also NPC-derived acellular matrix facilitated the bone

marrow-derived MSC differentiation towards NPC-like lineages.

42

Our previous study also

showed that DECM deposited by porcine NPC also benefited SDSC viability and guided its
differentiation to NP lineage.

17

As a tissue-specific DECM, it serves as a scaffold for rejuvenating

herniated NPCs, especially the fetal NPC-derived young matrix.
Our previous studies indicated that porcine NPCs can be rejuvenated by porcine SDSCdeposited DECM towards more proliferative and chondrogenic potential.

16,17

In this study, we did

not observed the enhanced chondrogenesis in redifferentiated potential in NPCs. One of the
possible explanations is the difference between porcine NPCs and human NPCs. Laminin is
found to be highly expressed in immature NP tissue. Chen et al. suggested that with age, this
unique laminin decreased both in porcine and human NPCs.

43

The immunostaining of 3-month

old porcine and 2-year old human showed some positive staining of laminin, but none were
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observed in 24-month old porcine and 35-year old human. As laminin is an essential component
of

basement

membrane

surrounding

the

notochord

during

notochord

formation

and

differentiation, the presence of laminin and receptors is unique to NP tissue of IVD. Also a soft
(<720 pa) and laminin containing ECM substrate has been proved to promote the immature NPC
morphology, cell-cell interactions, and proteoglycan synthesis.
SDSC deposited SECMs suggested that laminin is missing.

44

18

Our recent proteomic data of

Based on above evidence, we

highly suspected that the absence of laminin in SECMs is probably responsible for the
unidentified enhancement of chondrogenesis in NPCs. The further investigation is ongoing.
Our next step is to perform the microarray analysis of gene expression changes in three NPCs
that expanded on different substrates and proteomics of both young and old NECMs. The
identification of significantly changed genes could suggest important signaling pathways that
manipulate the rejuvenation of NPCs by the NECMs. The critical component within the NECMs
could be identified by proteomics data and facilitate future applications of biomaterials in NP
tissue engineering and regeneration. Our purpose is to determine specific genes involved in
DECM reprogramming and/or rejuvenation so as to find specific signal transduction pathways.
Elucidating the underlying mechanism will help commercialize this technology in the near future,
which could make clinical application of large-scale expansion of high-quality NP cells from
degenerated disc patients a reality.
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FIGURE LEGENDS
Figure 7.1 (A) Cell morphology of passage 2 NPC during expansion on plastic flasks (PL) or fetal
and adult SDSC derived DECM (SECM) (FE and AE) for two passages. Cell number was
counted (B) and proliferation index was analyzed by flow cytometry (C).
Figure 7.2 (A) Cell morphology of passage 2 NPC during expansion on plastic flasks (PL) or fetal
and adult NPC derived DECM (NECM) (FNPE and ANPE) for two passages. Cell number was
counted (B) and proliferation index was analyzed by flow cytometry (C).
Figure 7.3 Mesenchymal stem cell surface markers (CD29, CD90 and CD105) were analyzed by
flow cytometry after expansion on three different subtrates from both SECM (A) and NECM (B).
Figure 7.4 Histology and immunostaining analysis of SECM (A) or NECM (B) pre-expanded
NPCs pellets after 10 or 21 days chondrogenic induction. Gross appearance of the pellets, alcian
blue staining for sulfated GAGs and immunostaining collagen II were displayed at both time
points.
Figure 7.5 Biochemistry analysis for GAGs and DNA content in SECMs expanded NPCs (A) or
NECMs expanded NPCs (B) were measured at day 0, 10 and 21. DNA content of NPC pellets
changes was normalized by the content of pellets at day 0. Chondrogenic index (the ratio of GAG
to DNA) indicated the degree of chondrogenic differentiation of NPCs.
Figure 7.6 Real-time PCR to examine the hypertrophic (COLX, RUNX2, ALPL, MMP13, VEGFA),
catabolic metaboism (COX2, MMP3, ADAMTS4, ADAMTS5, TIMP1) and senescence (CASP3,
P16, P21, P53, SIRT1, BMI1) gene markers was tested in SECM expanded NPC pellets (A) and
NECM expanded NPC pellets (B).
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CHAPTER

8:GENERAL

DISCUSSION

The objectives of this dissertation were to investigate the effect of conventional methods and the
novel DECM expansion system on SDSCs for facilitating chondrogenesis and explore the
potential cell sources of DECM; to characterize the rejuvenating effect of fetal SDSC deposited
young DECM on adult SDSCs and its potential mechanisms; to apply the young DECM
expansion system to the rejuvenation of primary NPCs from herniated human discs. The longterm goal is to develop an efficient ex vivo expansion system with proliferation and chondrogenic
potential rejuvenating capacities, which can provide a large quantity of high quality cells for
cartilage engineering. The central hypothesis is that DECM deposited by human primary cells or
stem cells can serve as an excellent ex vivo expansion system for cartilage regeneration. Due to
the shortage of autologous chondrocytes, it is critical to identify a tissue-specific stem cell for
chondrogenesis from various sources. The DECM based ex vivo stem cell expansion system has
shown promising potential in maintaining stemness and facilitating chondrogenesis but it could be
optimized. Understanding of the rejuvenation mechanism of DECM has moved forward through
biophysical and biochemical analysis. The involvement of signaling pathways and potential
epigenetic mechanisms are also subjected to scrutiny.

8.1 Synovium Derived Stem Cells are a Tissue-Specific Stem Cell for Chondrogenesis

	
  
Adult stem cells are undifferentiated cells found among differentiated cells in a tissue or organ
that can renew themselves and can differentiate to yield some or all of the major specialized cell
types of the tissue or organ. The search for adult stem cells began in the 1950s, when
researchers first discovered two populations in bone marrow. One population is the hematopoietic
stem cells and the other is bone marrow stromal stem cells [also called BMSCs]. The MSC is
known to be able to give rise to a variety of cell types, among them osteocytes, chondrocytes,
adipocytes, and other kinds of connective tissue cells. A wide variety of MSCs have been isolated
from a number of different tissues and organs, suggesting that the homeostatic maintenance of
most tissues is capable of regeneration and repair and is ultimately mediated by such tissuespecific stem cells. The tissue-specific stem cell is derived from a known tissue type and can
respond to organ-specific signals when recruited to that organ; in other words, the differentiation
potential reflects the local cell population.

1;2

Recently, SDSCs have been proposed as tissue-specific stem cells for chondrogenesis for the
following reasons. First, synovium and cartilage share an adjacent anatomical location. The
synovium is a fluid-filled cavity that surrounds joint cartilage and tendons and facilitates smooth
movement of joints. Unsurprisingly, chondrocytes and SDSCs share a similar gene expression
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3

profile. SDSCs, like chondrocytes, have been shown to accumulate type II collagen and express
the gene for proteoglycan 4, but do not accumulate large amounts of type X collagen.

4;5

Although

type X collagen is a marker of hypertrophy, it is sometimes expressed by deep-zone
chondrocytes. Also, the cells of the synovium and articular cartilage develop from the same pool
of precusor cells and remain in close relationship into adulthood.

6-8

Second, synovium can serve

as a stem cell niche/microenvironment for stem cells to reside and functions in conjunction with
9

nurturing cells to retain pluripotency, prevent apoptosis, and inhibit excessive cell replication. A
recent study from Kurth et al. demonstrated that a slow-cycling, MSC-like cell population existed
in murine knee joints, which spread out through synovium, in both the intimal layer and subintimal
layer.

10

Upon injury, the synovium and cartilage function together in the absence of medical

intervention, further demonstrating the tissue-specific capacity of SDSCs. Third, our recent study
also showed porcine SDSC-derived DECM can provide a three-dimensional environment for
promoting proliferation and chondrogenic potential without a concomitant increase in
adipogenesis and osteogenesis.

11

In Chapter 3, addition of FGF-2 during cell expansion

promoted not only SDSC chondrogenic potential but also hypertrophic marker expression.
However, expansion on DECM deposited by SDSCs could enhance chondrogenic potential
without increase of hypertrophy. As shown in Chapter 4, the tissue-specificity of SDSC could be
further enhanced by DECMs as demonstrated by increased chondrogenic but not osteogenic and
adipogenic potentials. Interestingly, in Chapter 6 we discovered that young DECM derived from
fetal SDSC rejuvenated adult SDSCs with higher proliferation and chondrogenic and adipogenic
but not osteogenic potential. The most feasible explanation is that fewer tissue-specific signals
were provided by young DECM than adult DECM. Also SDSCs have been reported to possess
superior chondrogenic and adipogenic potentials rather than osteogenic potential.

12

8.2 Reconstruction and Optimization of Decellularized Stem Cell Matrix Based Ex Vivo
Expansion System for Cartilage Degeneration

	
  
A stem cell niche is a specific site in adult tissues where stem cells reside and undergo selfrenewal and differentiation by producing large numbers of progeny. Ever since the concept of
“niche” was proposed by Schofield in 1978 to describe the physiologically limited
microenvironment of bone marrow in which the hematopoietic stem cells reside,
hypothesis has been supported by a variety of co-culture experiments in vitro.

14-17

13

the niche

Structurally, the

niche is formed by supporting cells that provide a microenvironment for stem cells and the signals
emanating from the supporting cells.

18-20

However, it still remains a major challenge to accurately

define the precise cellular components and anatomical structure of the niche.

95

The ECM comprises a scaffold of collagens and other structural proteins that are interlaced with
proteoglycans which, together, control the local mechanical environment and contribute to the
“stem cell niche” microenvironment through their own signaling moieties and their ability to bind
growth factors, cytokines, enzymes, and other diffusible molecules. Compared to traditional 2D
culture, culturing stem cells in 3D environments provides another dimension for external
mechanical inputs and for cell adhesion, which dramatically affects integrin ligation, cell
contraction, and associated intracellular signaling.

21;22

Furthermore, the 3D environment might be

necessary to model morphogenetic and remodeling events that occur over larger-length scales.
The mechanisms by which nanotopographic cues derived from ECM influence stem cell
proliferation and differentiation are not well investigated yet but appear to involve changes in
cytoskeletal organization and structure, potentially in response to the geometry and size of the
underlying features of the ECM. That is, changes in the feature size of the substrate may
influence the clustering of integrins and other cell adhesion molecules, thus altering the number
and distribution of focal adhesions. The composition and function of adhesions characterized in
3D matrices derived from tissues or cell culture were demonstrated to be different from focal and
fibrillar adhesions characterized on 2D substrates in their content of α5β1 and α β3 integrins,
ν

paxillin, other cytoskeletal components, and tyrosine phosphorylation of FAK.

23

Relative to 2D

substrates, 3D matrix interactions also display enhanced cell biological activities and narrowed
integrin usage. Similarly, in recent years, the importance of ECM has been recognized due to the
application of decellularized tissue matrix in organ or tissue regeneration.

24-30

Partially, it is

because of the highly conservative nature of ECM components between species. Different from
the above studies, we deposited ECM using stem cells and decellularized it for reconstructing this
ex vivo microenvironment for cartilage engineering due to its demand of a large quantity of high
quality cells. Our first success came from the porcine SDSC deposited DECM, which enhanced
the proliferation and chondrogenic potential when applied as an expansion system compared to
traditional expansion on plastic flask for porcine SDSC.

11

Human SDSC (both fetal and adult

SDSC) deposited DECM also exhibited the same effect as shown in Chapter 4, Chapter 5 and
Chapter 6. The investigation of the DECMs deposited by adipose and urine derived stem cells
and dermal fibroblasts in Chapter 4 also showed that, despite the differences in these DECMs, all
were able to enhance the self-renewal and chondrogenic potential compared to the 2D culture. It
not only demonstrated the advantage of 3D DECMs over 2D plastic culture in facilitating ex vivo
expansion but also suggested that there are common core components among all these DECMs.
The exploration of these similarities in future studies would benefit the development of an ex vivo
expansion system for cartilage engineering.
Communication within the niche is essential for the maintenance of proper stem cell function and
for determining the rate of stem cell self-renewal. Soluble factors may act locally or may diffuse

96

throughout the niche to direct stem cell fate decisions. Studies indicate that supporting cells,
which are located adjacent to stem cells, secrete soluble factors that are required for maintaining
stem cell identity and for specifying stem cell self-renewal.

31-33

Soluble factors, such as growth

factors and cytokines, are important for the initiation and control of stem cell differentiation. A
wide variety of soluble growth factors, such as FGF-2,
factor, and hepatocyte growth factor,

36

34

TGF-β,

35

vascular endothelial growth

bind to a component of ECM, which greatly slows their

diffusion and therefore serves to fine-tune their local concentrations and gradients.
binding can create locally higher concentrations of autocrine growth factors,
amounts of the factor to signal more effectively.

38

37

35;36

Matrix

allowing smaller

In this dissertation, we also investigated the

influence of soluble growth factor, FGF-2, on SDSC stemness in Chapter 3. We showed that
addition of FGF-2 during cell expansion significantly increased SDSC proliferation and
chondrogenic potential. The combination of DECM with FGF-2 further enhanced the proliferation
and chondrogenic potential in recellularized SDSCs, suggesting a synergistic effect between
them. However, unlike DECM, the addition of FGF-2 also significantly increased the expression of
hypertrophic markers (type X collagen).
The physiological condition, including oxygen tension, is an important component of the stem cell
microenvironment and has been shown to play a role in regulating both embryonic and adult stem
cells.

Low

oxygen

tensions

(hypoxia)

maintain

undifferentiated

states

of

embryonic,

hematopoietic, mesenchymal, and neural stem cell phenotypes and also influence proliferation
and cell-fate commitment. Despite the presence of a decreased osteogenic and chondrogenic
potential when induced to differentiate in hypoxic conditions,

39

adipose stem cells exhibited

increased chondrocytic markers when expanded in hypoxic conditions and differentiated in
normoxic cultures.

40

The effect of hypoxia in committing adipose stem cells to chondrocytes is

thought to be mediated by hypoxia-inducible transcription factor (HIF)-1α. Inhibition of HIF-1α
leads to decreased chondrogenic potential, normal osteogenic potential, and enhanced
adipogenic potential.

41

The role of hypoxia and HIF-1α in cell differentiation is tissue-specific,

because HIF-1α maintains the stem cells in an undifferentiated state, inhibits differentiation of
mesenchymal cells into osteoblasts, adipocytes, and myocytes, and stimulates differentiation into
chondrocytes.

42-45

These data support the role of oxygen tension as an important factor in the

determination of cell fate and maintenance of stemness in adipose and bone marrow derived
MSCs. In Chapter 3, application of low oxygen level (5%) in combination with FGF-2 or DECM
during expansion significantly promoted proliferation with strong chondrogenic potential,
suggesting the maintenance of stemness by hypoxia. One limitation of this study is that
expression of HIF-1α was not analyzed. In Chapter 5, we also investigated the influence of
hypoxia during pellet culture for chondrogenesis. Our data showed that low oxygen level
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increased the pellet size, GAG content, and chondrogenic marker expression after a 14 day
induction. Thus, the low oxygen level in pellet culture for chondrogenesis is established.

8.3 Biophysical and Biochemical Explanations of Decelluarized Extracellular Matrix

	
  
Another key challenge in stem cell research is to learn how to direct the differentiation of stem
cells toward specific fates. Other than the components of the ECM, a variety of cues including
biophysical factors, such as the stiffness of ECM and extrinsic mechanical factors as well as cell
shape changes, are also capable of influencing stem cell proliferation, self-maintenance, and
differentiation toward specific cell phenotypes. Recently, the elasticity of the matrix
microenvironment was identified as regulating stem cell fate. By changing the stiffness of the
substrate, human MSCs could be directed along neuronal, muscle, or bone lineages.

46

Since

then, substrate stiffness has been applied to modulate the proliferation and differentiation of
embryonic stem cells

47;48

as well as certain types of adult MSCs.

49;50

The Ras superfamily,

especially the Rho subfamily members that are well known to regulate the cytoskeleton, cell
growth, and transcription, is reported to be involved in substrate stiffness sensing.

51

Rho-

stimulated contractility drives stress fiber and focal adhesion formation and the up-regulation of αsmooth muscle actin correlates with contractility on a rigid substrate.
Rho kinase (ROCK) also mediate substrate rigidity-regulated Ca
the physiological functions of human MSCs.

54

2+

52;53

RhoA and downstream

oscillation, which determines

Rac1 is another Rho family protein that can be

activated by myosin inhibition, which also has provided evidence for the critical role of contractility
in substrate sensing.

55;56

Understanding has increased about how underlying matrix stiffness can

guide stem cells toward a specific developmental lineage,

46;57

but matrix stiffness alone is likely to

46

In order to understand how DECM

be insufficient to achieve complete terminal differentiation.

exhibits influence on recellularized cells, we measured the elasticity of different DECMs and of
cells expanded on different substrates in Chapter 4 and Chapter 6. Not surprisingly, all the DECM
expanded cells exhibited a lower elasticity compared to plastic flask expanded cells. The
maintained or enhanced stemness in the DECM expanded cells could be due to its elasticity
mimicking the in vivo niche. Additionally, the lower elasticity of fetal SDSC DECM compared to
adult SDSC DECM also resulted in a lower elasticity in recellularized adult SDSCs in Chapter 6,
which could explain the enhanced rejuvenating effect by young DECM. In Chapter 4, we also
compared the differences of elasticity in four different DECMs and cells expanded on them. As
expected, SDSCs expanded on all DECMs exhibited lower elasticity than cells expanded on
plastic flasks. However, the elasticity does not match the enhanced chondrogenic potential in
cells, which confirmed that matrix stiffness is not sufficient to determine lineage differentiation.
Alternatively, matrix stiffness could be an underlying mediator of growth factors, such as TGFβdriven processes, regulating the equilibrium between storage and release of a host of matrix-
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bound growth factors.

58

Although matrix stiffness is not the most effective at driving a specific

lineage differentiation, it is an important determinant and co-factor for directing cell differentiation
induced by soluble biochemical factors. Stem cells need to integrate microenvironmental cues
from both soluble biochemical factors and ECM to regulate differentiation.
In this dissertation, we also employed scanning electron microscopy to observe the morphology
of cells and the substrates (plastic flasks or DECMs) and interactions between them in Chapter 4
and Chapter 6. The most striking difference is between the cells expanded on plastic flasks and
DECMs. The well-spread and enlarged morphology accompanied with proliferation arrest
signified the development of senescence. The less spread and spindle shaped cells expanded on
DECMs showed a higher proliferation rate and chondrogenic potential in the later stage. Cell
shape is defined within the niche by the constraints imposed by the surrounding ECM on cells
during development and adulthood.

59;60

Alterations in adhesive interactions and crosstalk

between the ECM and the cells work to define each other. Evidence suggests that physical
control of cell shape alone can act as a potent regulator of cell signaling and lineage
differentiation.

61

As suggested in a recent review, a thorough understanding of the physical

properties of ECM could facilitate the development of biomaterials to display and deliver stem cell
regulatory signals in a precise and near-physiological fashion, and serve as a powerful artificial
microenvironment in which to study and instruct stem cell fate both in vitro and in vivo.

62

ECM is primarily composed of various collagens, laminins, and glycoproteins serving as
substrates for a myriad of adhesion molecules including integrins, cadherins, and discoidin
domain receptors. Cell-matrix interaction-induced signaling constitutes a critical determinant of
cell behavior, making ECM composition a key factor in the stem cell niche. In Chapter 6, we
applied proteomics to analyze the components of SDSC DECM from young and old donors. We
identified interesting discrepancies in the composition of these matrices, such as young matrix
contains more fibrillin-2, clusterin, and tenascin C and old matrix possesses more biglycan,
decorin, dermatoponin, elastin, periostin, thrombospondin-1, and TGF-β1. Existing literature has
shown that the young matrix contains proteins involved in cell proliferation while the old matrix
possesses components that prefer cell differentiation and apoptosis. One of the future directions
to investigate the mechanism is to focus on a specific protein that may influence the cells the
most. Identification of the critical protein would benefit the development of biomaterials for
cartilage engineering. Interestingly, we found no laminin in young or old matrix. We also
confirmed our proteomics data with immunofluorescence staining. Full characterization of DECM
using biophysical and biochemical analysis will offer great opportunities to biomaterials
technologies, which can be designed to act as carriers for local delivery of stem cells, supporting
cells, or molecular niche cues.
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8.4 Signaling Pathways Involved in the Rejuvenating Effect of Decellularized Extracellular
Matrix

	
  
The rejuvenating effect of DECM was mainly manifested in maintaining and promoting stemness
of recellularized cells. MAPK and Wnt signaling pathways are two key pathways involved in cell
proliferation and chondrogenic potential. As a major family of ECM receptors that transmit
information from the matrix to the cells, integrins play a role as key mediators for cell proliferation.
Integrin-mediated cell adhesion is required for cell motility and affects cell proliferation.

63;64

Ligands present in ECM, such as vitronectin, fibronectin, laminin, and collagen, are recognized by
specific integrins, such as integrin α5β1 for fibronectin.

65

Integrin-ECM interaction can activate

signaling cascades, such as ERK1/2, MAPK, PI3-K, and AKT.

66;67

It is agreed that sustained ERK

activation requires cooperative signaling between receptor tyrosine kinases and integrins.

64

The

induction of cyclin D1 mRNA has most frequently been attributed to the activation of ERKs.

68

However, only a sustained ERK signal is not sufficient to induce cyclin D1 protein. PI3-K is also
required for the expression and stability of cyclin D1.

69;70

in addition, FAK is an important

regulator of cyclin D1. Overexpression of wild-type and dominant negative FAK cDNAs showed
that integrin-dependent phosphorylation of FAK plays an important role in phosphorylation of ERK
and induction of cyclin D1.

71

The Wnt/β-catenin pathway is related to stem-cell self-renewal and proliferation. Maruyama et al.
found that, besides directly regulating renewal and proliferation, activation of β-catenin also alters
the lineage commitment of MSCs to differentiate into chondrocytes through cooperating with FGF
receptor 1 and balancing between BMP and FGF signaling pathways.

72

Since Wnt signaling is

also involved in inhibiting adipogenesis of MSCs through β-catenin dependent and independent
pathways,

73

tumor necrosis factor-alpha (the activator of the NF-κB pathway) inhibits

adipogenesis by the β-catenin/TCF4-dependent pathway.

74

Interactions between NF-κB and β-

catenin/TCF pathways also play a part in regulating MSC proliferation and differentiation.

75

However, balance among signaling pathways is more important in regulating MSCs through
lineage differentiation, as well as maintaining stemness. Coordination between Wnt signals and
other secreted signals contributes to the regulation of stem cell self-renewal in tissue
microenvironments.

76

Wnt signals are not only involved in ECM-mediated enhancement of stem

cell proliferation, but also contribute to retaining or promoting differentiation potential. Czyz and
Wobus reported evidence that the interaction of stem cells with ECM via integrins determines the
expression of the signaling molecules BMP-4 and Wnt-1, resulting in the activation of the
mesodermal and neuroectodermal lineage, respectively.

100

77

Defective Wnt signaling, however,

affects ECM synthesis, possibly being responsible for the etiology of the segmental premature
aging disease Hutchinson-Gilford Progeria because mice exhibit skeletal defects and apoptosis in
major blood vessels proximal to the heart.

78

This study provided insights into the role of Wnt

signaling and ECM in aging.
Wnt signaling plays an important role in chondrocyte maturation. Wnt inhibitors were reported to
promote chondrogenic differentiation of human MSCs.

79

Moreover, Wnt signaling may play a

“dual” role in chondrogenesis, depending on the specific Wnt ligand responsible for the signaling
and the development stage when Wnt is engaged. During chondrogenesis in the chicken limb,
Wnt5a delays the maturation of chondrocytes while Wnt4 accelerates the process.

80

Like Wnt5,

Wnt7a also induces a chondro-inhibitory effect, which involves the MAPK pathway and activator
protein-1 transcriptional activity.

81

Wnt14, another member of the Wnt family, is expressed in the

chondrogenic region and has been reported to arrest and even reverse chondrogenic
differentiation.

82

β-catenin, the central player in canonical Wnt signaling, is required during the

early differentiation and late-stage maturation of chondrocytes, but the canonical pathway inhibits
the progression of chondrocyte differentiation. Constitutively active β-catenin can prevent chicken
chondrocytes from differentiation by down-regulating Sox9 and type II collagen;

83

meanwhile,

mice with elevated β-catenin activity resulting from secreted frizzled-related protein deficiency
exhibit accelerated chondrocyte maturation.

84

To the best of our knowledge, there has been no study investigating MAPK and Wnt signaling in
3D DECM expanded cells and followed condensation and chondrogenesis. In Chapter 6, we
found that MAPK (especially ERK, JNK, and p38) and Wnt signaling were actively involved in
young ECM-mediated adult cell expansion and chondrogenic differentiation. The down-regulation
of p-ERK in young ECM expanded adult SDSCs indicated a decrease in cell senescence. The
increase of p-ERK in cell condensation and decrease in 10-day chondrogenic induction could be
explained by the dual role of p-ERK in promoting chondrogenesis in the early stage and inhibiting
it in the later stage. Our data also showed that the canonical Wnt3a signal is downregulated in
ECM treated adult SDSCs and remained at a comparable level during chondrogenesis with
plastic expanded adult SDSCs. In contrast, Wnt5a and Wnt11, the non-canonical signals, were
dramatically up-regulated in ECM treated adult SDSCs, especially in the young ECM group. The
same trend was observed in chondrogenic induced pellets as well.
Two tumor-suppressor proteins, p53 and pRB, are the central activating pathway of senescence.
Senescence stimuli activate p53, which then induces pRB related senescence by activating p21,
the transcriptional target of p53. This senescence is reversible by the subsequent inactivation of
p53.

85

The p53-p21-pRB pathway has also been demonstrated as playing a more important role

in senescent nucleus pulposus chondrocytes in vivo.

101

86

In addition, the p53/p21 pathway is

activated by excessive activation of Wnt/β-catenin signaling, which leads to MSC senescence as
well.

87

The induction of caveolin 1 up-regulates p53 and p21 and down-regulates pRB. Caveolin

overexpression also activates the p38 MAPK pathway, suggesting that both of these pathways
are involved in mediating chondrocyte senescence.

88

Caveolin 1 overexpression has been shown

to be responsible for loss of adipogenic differentiation abilities in senescent human MSCs.

89

Consistently, a decreased level of p21 and caveolin 1 expression was observed in low-density
seeding SDSC along with the retained the stemness in Chapter 2. Low-density seeding of SDSCs
also expressed lower levels of p-ERK and p-JNK but a higher level of p38 MAPK expression.

8.5 Decellularized Stem Cell Matrix: A Potential In Vitro Model of Epigenetic Application for
Cartilage Regeneration

	
  
Decellularized tissue matrix has proven to be beneficial in regenerative medicine;

90

it serves as a

biological scaffold for selective cell types allowing increased proliferation. The characterization of
decellularized cartilage ECM suggested that it is not only a complex 3D structure full of
biochemical

signals,

but

also

a

mechanotransduction

device.

91

This

attribute

makes

decellularized cartilage ECM a perfect candidate for cartilage tissue engineering. Encouraging
preliminary animal and clinical data have been reported.

92-94

More interestingly, DECM deposited

by human MSCs (DSCM) could be used as an in vitro expansion system.

95

DSCM promoted cell

attachment, spreading, migration, proliferation, and the maintenance of responses to
differentiation signals.

96

The rejuvenating effect of DSCM has been observed in not only adult

stem cells such as SDSCs (Chapter 3, 4, and 6)

97-99

and BMSCs

(Chapter 5) and primary cells such as articular chondrocyte
(Chapter 7).

103;104

101;102

100

but also fetal SDSCs

and nucleus pulposus cells

In this dissertation, we also found that DSCM deposited by fetal SDSCs

provided a robust rejuvenating effect in promoting adult SDSC proliferation and chondrogenic
capacities in Chapter 6.

105

The increased proliferative and chondrogenic potentials may possibly

provide large quantities of high quality cells in an autologous implantation strategy, which has
been encouraged by a recent minipig study in which DSCM-expanded SDSCs were injected
intraarticularly to treat partial-thickness cartilage defects.

106

Other than the mechanisms mentioned above, the connections of environmental cues to
chromatin and associated signaling factors that are involved in early epigenetic regulation of
cartilage regeneration have also been proposed. Several potentially related environmental factors
including aging, growth factors, hypoxia, inflammatory factors, mechanics, and oxidative stress
that may serve as epigenators (a signal that emanates in the cellular environment and initiates an
intracellular pathway that triggers expression of the epigenetic phenotype) in cartilage
regeneration have been proposed.

107

The rejuvenation effect of DSCM is supported by its

102

excellent ability in managing environmental factors. DSCM deposited by fetal SDSCs aided in the
protection of expanded cells from senescence in Chapter 5.

108

DSCM expanded SDSCs showed

robust resistance to hydrogen peroxide-induced oxidative stress.

99

Our unpublished data

suggested that DSCM expanded SDSCs exhibited an up-regulated ability to resist IL-1 β mediated inflammation. The proteomics data in Chapter 6 showed that DSCM is also rich in
growth factors and acts as a reservoir for the needs and demands of the cell.

105

The addition of

hypoxia and FGF-2 in the DSCM expansion system improved expanded SDSC proliferative and
chondrogenic potentials in Chapter 3.

98

The presence of hypoxia alone also enhanced the

rejuvenating effect of the DECM on nucleus pulposus cells.

103

While the mechanisms involved in DSCM rejuvenation remain unclear, Choi et al. showed that
the restoration of senescent human diploid fibroblasts by matrix was regulated by epigenetic
mechanisms; both Ku and SIRT1 were induced during restoration and were required for
senescent cells to return to a youthful phenotype.

109

Our microarray data also showed that both

miR-140 and miR-145 were dramatically down-regulated during cell expansion and up-regulated
during chondrogenic differentiation in DSCM pretreated SDSCs accompanied with enhanced
proliferative and chondrogenic potentials, suggesting a pivotal role of miR-140 and miR-145 in
DSCM mediated SDSC rejuvenation mechanisms (unpublished data). In response to
environmental stimuli, miR-140 targeted multiple genes to play different roles during
chondrogenic differentiation, endochondral bone formation, and osteoarthritis pathogenesis, as
summarized by Hong and Reddi.

110

Interestingly, miR-140 has been reported to target chemokine

(CXC motif) ligand 12 (CXCL12) and ADAMTS-5 in equine cord blood-derived MSCs;

111

its

overexpression protected cartilage from antigen-induced arthritis and maintained cartilage
homeostasis in a knockout mouse model.

112

It also stimulated in vitro chondrogenesis by up-

regulating SOX9 and ACAN in human MSCs.

113

SOX9 has been suggested as a downstream

target gene of miR-145 or miR-449a, which directly or indirectly represses SOX9 and cartilage
matrix gene expression in human primary chondrocytes, BMSCs, and a murine embryonic
mesenchymal cell line C3H10T1/2.

114-116

In conclusion, we demonstrated that decellularized stem cell matrix is superior to conventional
methods and provides a better microenvironment for ex vivo expansion of SDSCs while
maintaining its stemness. Decellularized matrix derived from young stem cells could rejuvenate
adult stem cells toward proliferation and chondrogenesis. This novel expansion system could also
be applied to restore the proliferative and redifferentiation potentials in herniated nucleus
pulposus cells as well.
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